Transcutaneous bilirubin screening for hyperbilirubinemia in African newborns by Okwundu, Charles I.
Transcutaneous bilirubin screening for hyperbilirubinemia 
in African newborns 
by 
Charles I. Okwundu  
Dissertation presented for the degree of Doctor of Philosophy (PhD) in Epidemiology at the Faculty of 
Medicine and Health Sciences, Stellenbosch University. 
Supervisors 
Prof. Charles Wiysonge. MD, PhD 
Prof. Johan Smith. MBchB, PhD 
April 2019
1 
Declaration 
By submitting this thesis electronically, I declare that the entirety of the work contained therein is my 
own, original work, that I am the sole author thereof (save to the extent explicitly otherwise stated), 
that reproduction and publication thereof by Stellenbosch University will not infringe any third party 
rights and that I have not previously in its entirety or in part submitted it for obtaining any 
qualification. 
This dissertation includes 5 original papers of unpublished manuscripts and 2 original published 
systematic review protocols. The development and writing of the papers (published and unpublished) 
were the principal responsibility of myself and, for each of the cases where this is not the case, a 
declaration is included in the dissertation indicating the nature and extent of the contributions of co-
authors. 
Date: April 2019 
Signature:  C. Okwundu 
Copyright © 2019 Stellenbosch University
All rights reserved
Stellenbosch University  https://scholar.sun.ac.za
2 
Abstract 
Background 
In many parts of the world, including African countries, apparently healthy newborns are usually 
discharged home early. Serum bilirubin levels usually peaks on postnatal days 3 to 5, by when many 
newborns have already been discharged home. Severe neonatal hyperbilirubinemia constitutes an 
important cause of neonatal mortality and morbidity in Africa. There is a need for ways of identifying 
newborns at risk of severe jaundice before hospital discharge especially in developing countries with 
poor health systems and inadequate follow-up procedures after discharge from hospital.  
Objectives 
The objective of this combination of studies is to provide evidence for the use of transcutaneous 
bilirubin (TcB) screening in a population of indigenous African newborns.  
Methods 
We summarized the available evidence on the accuracy and effectiveness of TcB screening in two 
Cochrane systematic reviews. In the first systematic review, we summarized the evidence on the 
effectiveness of TcB screening in newborns. The second review summarized the evidence on the 
accuracy of TcB measurement compared to total serum bilirubin (TsB) measurement. We also 
conducted research on the effects of TcB screening and on the accuracy of the TcB measurement in 
a population of South African newborns  
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Results 
For our first systematic review, we did not identify any randomized controlled trial that assessed the 
effect of TcB screening on readmission for jaundice or on the incidence of severe hyperbilirubinemia 
in newborns. Findings from included observational studies from North America suggest that universal 
pre-discharge TcB screening in newborns reduces readmission for hyperbilirubinemia and also 
reduces the incidence of severe hyperbilirubinemia.  
We conducted a randomized controlled trial of TcB screening in an indigenous population of African 
newborns from South Africa. Findings from our trial confirmed that TcB screening reliably identified 
newborns at risk of severe hyperbilirubinemia and led to a 75% reduction in the readmission rate for 
hyperbilirubinemia and up to 73% decrease in the incidence of severe hyperbilirubinemia. However, 
the effect of TcB screening on kernicterus and bilirubin induced neurology dysfunction is not known.  
Findings from our second systematic review of accuracy of TcB measurement compared to TsB 
measurement in the laboratory, suggest a significant correlation coefficient of up to 0.98 between 
these two measurements. However, there are mixed findings from the included studies on the effect 
of various factors including: gestational age, race, postnatal age, TsB concentration, on the 
correlation. Also, there are limited studies in indigenous African newborns.  
Our cross-sectional study on the accuracy of the TcB measurement in a population of South African 
newborns showed a good correlation between TcB measurement and TsB measured in the laboratory.  
Conclusion 
The TcB tool can be used to reliably estimate TsB in African newborns and can help identify 
newborns who need phototherapy before hospital discharge. We recommend that every newborn 
should be assessed for hyperbilirubinemia using objective means of measuring or estimating serum 
bilirubin measurement such as the TcB or TsB before discharge from hospital. This could go a long 
way in reducing hyperbilirubinemia related readmissions and incidence of severe hyperbilirubinemia. 
Pre-discharge TcB screening in newborns can therefore be used to identify newborns in need of 
phototherapy or those who are at risk of readmission for hyperbilirubinemia after discharge.  
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Abstrak 
Agtergrond 
In baie dele van die wêreld, insluitende Afrikalande, word oënskynlike gesonde pasgebore babas 
vroeg uit die hospitaal ontslaan. Serum bilirubienvlakke bereik gewoonlik ‘n hoogtepunt drie tot vyf 
dae na geboorte, teen die tyd wanneer baie babas alreeds ontslaan en by die huis is. Ernstige 
hiperbilirubinemie onder pasgeborenes is ‘n belangrike oorsaak van neonatale sterftes en morbiditeit 
in Afrika. Daar is behoefte aan maniere om pasgebore babas wat ‘n risiko vir ernstige geelsug het te 
identifiseer nog voordat hul uit die hospitaal ontslaan word, veral in ontwikkelende lande met swak 
gesondheidstelsels en onvoldoende opvolgprosedures na hospitaalontslag. 
Doelwitte 
Die doelwit van hierdie kombinasie van studies is om navorsingsbewyse te verskaf vir die gebruik 
van bilirubien (“TcB”) sifting deur skandering van die vel, in ‘n bevolking van inheemse pasgebore 
babas in Afrika.  
Metodes 
Ons het die beskikbare navorsingsbewyse met betrekking tot die akkuraatheid en effektiwiteit van 
TcB sifting opgesom in twee Cochrane stelselmatige oorsigte. In die eerste stelselmatige oorsig het 
ons die navorsingsbewyse rakende die effektiwiteit van TcB sifting in pasgeborenes opgesom. In die 
tweede oorsig het ons die navorsingsbewys rakende die akkuraatheid van TcB metings vergelyk met 
die totale serum bilirubien (“TsB”) meting. Ons het ook navorsing gedoen rakende die effek van TcB 
sifting asook die akkuraatheid van die TcB meting in ‘n bevolking van Suid-Afrikaanse pasgeborenes.  
Resultate 
Vir ons eerste stelselmatige oorsig het ons nie enige ewekansige steekproewe geïdentifiseer wat die 
effek van heropname in die hospitaal vir hiperbilirubinemie ondersoek het nie, of wat die insidensie 
van pasgeborenes met ernstige hiperbilirubinemie wat TcB sifting ondergaan het, ondersoek het nie. 
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Bevindinge van ingesluite waarnemingstudies van Noord-Amerika suggereer dat universele TcB 
sifting in pasgeborenes voor hospitaalontslag die heropname vir hiperbilirubinemie, asook die 
insidensie van ernstige hiperbilirubinemie, verlaag. Ons het ‘n ewekansige gekontroleerde proef 
uitgevoer van TcB sifting in ‘n inheemse Suid-Afrikaanse bevolking van pasgebore babas. 
Bevindings van ons proef het bevestig dat TcB sifting van pasgebore babas wat ‘n risiko het vir 
ernstige hiperbilirubinemie betroubaar is, en tot ‘n 75% afname in die heropnamekoers vir 
hiperbiliruminemie gelei het, asook tot en met ‘n 73% afname in die insidensie van 
hiperbilirubinemie. Die effek van TcB sifting op kernikterus en bilirubien-geïnduseerde neurologie 
is egter nie bekend nie. Bevindings van ons tweede stelselmatige oorsig oor die akkuraatheid van die 
TcB meting teenoor die TsB meting in die laboratorium suggereer ‘n beduidende korrelasie van tot 
0.98 tussen hierdie twee metings. Die ingesluite studies het egter gemengde bevindinge getoon in 
terme van faktore soos swangerskapsouderdom, ras, postnatale ouderdom en TsB konsentrasie wat 
die effek op korrelasie kan beïnvloed. Daar is ook ‘n beperkte aantal studies oor inheemse 
pasgeborenes in Afrika. Ons deursnitstudie oor die TcB meting se akkuraatheid in ‘n Suid-Afrikaanse 
bevolking van pasgebore babas het ‘n goeie korrelasie getoon tussen TcB meting en TsB meting in 
die laboratorium.  
Gevolgtrekkings 
Die TcB hulpmiddel is betroubaar en kan gebruik word om TsB in pasgebore babas in Afrika te skat. 
Dit kan ook pasgeborenes identifiseer wat fototerapie voor hospitaalontslag benodig. Ons beveel aan 
dat elke pasgebore baba getoets moet word vir hiperbilirubinemie deur middel van ‘n objektiewe 
meting of skatting van serum bilirubien, byvorbeeld TcB of TsB. Dit kan hiperbilirubinemie-
verwante hertoelatings in hospitale en die insidensie van ernstige hiperbilirubinemie verlaag. TcB 
sifting in pasgeborenes voor ontslag uit die hospital kan dus gebruik word om babas te identifiseer 
wat fototerapie benodig, of wat ‘n risiko het vir heropname vir hiperbilirubinemie na hospitaalontslag. 
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Definitions 
Acute bilirubin encephalopathy: A clinical syndrome, in the presence of severe 
hyperbilirubinemia, of lethargy, hypotonia and poor suck, which may progress to hypertonia with a 
high-pitched cry and fever, and eventually to seizures and coma. 
Extreme hyperbilirubinemia: A total serum bilirubin concentration greater than ≥428 μmol/L at 
any time during the first 28 days of life. 
Kernicterus: The pathological finding of deep-yellow staining of neurons and neuronal necrosis of 
the basal ganglia and brainstem nuclei. 
Neonate: An infant from birth to 28 days of age. 
Neonatal jaundice: Yellow discoloration of the skin of a neonate. 
Preterm Neonate: Neonate delivered before 37 completed weeks of gestation. 
Severe hyperbilirubinemia: a total serum bilirubin (TsB) concentration greater than 340 µmol/L at 
any time during the first 28 days of life. 
Transcutaneous Bilirubin: Bilirubin level determined by transcutaneous bilirubinometer. 
TcB screening for hyperbilirubinemia:  The measurement of bilirubin levels in the skin with the 
use of a transcutaneous bilirubinometer to identify apparently healthy newborns at risk for 
hyperbilirubinemia. 
Total Serum Bilirubin: Bilirubin level determined by performing a blood test 
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Chapter 1 
Introduction and scope of work 
Neonatal jaundice is one of the most common clinical signs encountered among newborns and occurs 
in approximately two thirds of all newborns in the first week after birth. Jaundice results from 
bilirubin deposition in the skin and mucous membranes. For most newborns, this is a benign condition 
and does not require any form of treatment. However, up to 5 percent of newborns will develop severe 
hyperbilirubinemia requiring medical intervention. If  left untreated, extreme levels of bilirubin can 
be toxic to the brain of the newborn and cause neurological impairment [1]. Bilirubin results primarily 
from the breakdown of red blood cells in the reticuloendothelial system. Bilirubin is transported to 
the liver where it is conjugated to a water-soluble product that is easily excreted. Immaturity of the 
liver enzyme system in the newborn is the main factor placing them at risk of developing jaundice 
[2].   
Hyperbilirubinemia is a major cause of readmission in the neonatal period [1,3–5]. Peak serum 
bilirubin levels usually occur on postnatal days 3 to 5, when many infants have already been 
discharged from the hospital. This places the infant at increased risk of severe hyperbilirubinemia due 
to delayed treatment and unduly burdens the family. In some cases, babies could have levels that can 
lead to acute bilirubin encephalopathy (ABE) or subsequent brain damage. In many resource-limited 
countries, severe or clinically signiﬁcant neonatal hyperbilirubinemia is not only a leading cause for 
hospital readmission in the ﬁrst week of life, but also constitutes an important cause of neonatal 
morbidity and mortality [6]. For example, in Nigeria, neonatal hyperbilirubinemia is the most 
common neonatal emergency, contributing 29% and 23% to 36% of morbidity and mortality, 
respectively, among newborns referred to the emergency [7,8]. Similarly, a study in Egypt found that 
severe neonatal hyperbilirubinemia accounted for 33% of total admission diagnoses to the outborn 
neonatal intensive care unit often with signs of ABE [9].  In Kenya, hyperbilirubinemia is the third-
leading cause of both newborn admissions and deaths [10].   
Why is severe neonatal hyperbilirubinemia still a problem in resource poor countries? 
• In most resource-constrained settings, newborns are discharged early from nurseries without 
continued medical supervision or follow-up in the first week of life [9].   
• Severe hyperbilirubinemia is often unpredictable and treatment is usually delayed [9]. 
• The main burden of preterm births remains in developing countries [11,12].  The greatest 
etiological factor for preterm births worldwide is infection, mainly due to bacterial infection, 
malaria and HIV [12]. Late preterm infants (born between 34 and 36 week gestation) are at 
increased risk due to extreme hepatic immaturity and feeding difficulties [13,14]. 
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• There are no objective screening strategies to identify newborns who are at high risk of 
extreme hyperbilirubinemia in many resource-limited settings. 
• Many mothers are often unregistered with inadequate prenatal care; thus, maternal blood type 
and newborn risk of hemolytic disease is usually not known.  
• There is a high prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency in some 
settings and screening for G6PD is not available and not routinely done [15]. 
• Facilities for total serum bilirubin measurements are often not available in many resource-
constrained settings. 
In addition to the problems listed above, the logistics of services required by the American Academy 
of Pediatrics (AAP) Guideline may not be relevant for bilirubin testing or follow-up of all neonates 
based on the postnatal age at discharge. The guideline also requires sufficiently-trained healthcare 
personnel. Paucity of resources and healthcare personnel to follow-up all newborns could be 
alleviated by selective follow-up of high-risk newborns that could be identified through a good 
screening strategy. 
The clinical evaluation of hyperbilirubinemia involves visual assessment of jaundice. However, this 
method can be affected by skin color (especially in dark skin babies) and does not provide a 
quantification of the total serum bilirubin (TsB) level. Current more objective methods of assessing 
hyperbilirubinemia include the use of total serum bilirubin measurement from blood sampling and 
non-invasive methods like the transcutaneous bilirubin (TcB) measurement with a handheld 
bilirubinometer. TcB measurement is a non-invasive method for estimating TsB level and helps to 
reduce the risk of anaemia and trauma associated with blood sampling for TsB measurement. 
Transcutaneous bilirubinometry works by directing light into the skin and measuring the intensity of 
the wavelength of light that is returned. The measurement is usually taken by gently pressing the 
meter against the sternum or forehead. TcB measurement provides an immediate (within a minute) 
result of bilirubin level. Using this point-of-care device saves time compared to measuring a total 
serum bilirubin and may reduce costs associated with measuring bilirubin in newborns. There are a 
few TcB devices available in the market including the Bilicheck (SpectRx, Inc, Norcross [GA], US), 
JM 103 (Draeger Medical Systems Inc, Telford, US) and JM 105 devices (Draeger Medical Systems 
Inc, Telford, US). TcB screening for hyperbilirubinemia could lead to a reduction in the number of 
newborns with severe hyperbilirubinemia and a reduction in the number readmitted to the hospital 
with the diagnosis of hyperbilirubinemia through early detection. TcB screening for 
hyperbilirubinemia is the measurement of bilirubin levels in the skin with the use of a non-invasive 
device with the aim of identifying apparently healthy newborns at risk for hyperbilirubinemia.  
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If hyperbilirubinemia is identified early, effective interventions such as phototherapy can be initiated 
early to reduce the risk of ABE from very high serum bilirubin levels. 
Our systematic search for relevant studies identified some observational studies that have evaluated 
the use of TcB screening in newborns [16–18]. However, as also noted by Sharma, there is no 
randomized controlled study evaluating the effects of TcB screening on readmission rate and 
development of severe hyperbilirubinemia [19]. The AAP recommends the use of either pre-discharge 
TsB or TcB measurements as appropriate screening options for identifying infants at risk for neonatal 
hyperbilirubinemia [20]. In contrast, according to the U.S. Preventive Services Task Force (USPSTF), 
"there is insufficient evidence to make a recommendation on screening infants for 
hyperbilirubinemia"[21]. Also, The National Institute for Health and Care Excellence (NICE) 
recommends “not to perform a bilirubin measurement in babies who are not visibly jaundiced” and 
advises visual inspection in all babies [22–25]. There are thus conflicting recommendations on the 
usefulness of pre-discharge bilirubin screening in newborns. There is currently no guideline in South 
Africa on the use of any objective method to screen newborns for hyperbilirubinemia before hospital 
discharge. In South Africa, apparently healthy newborns from well-baby nurseries are discharged 
home without any form of objective screening for hyperbilirubinemia, apart from visual inspection. 
However, visual inspection has been shown to be unreliable in the assessment of jaundice in 
newborns, especially those with dark skin. Visual assessment for jaundice can lead to an 
overestimation of risk, leading to unnecessary laboratory tests.  Visual assessment can also lead to an 
underestimation of risk, which could result in a failure or delayed identification of babies needing 
treatment. A recent study (unpublished study) in newborns delivered at Tygerberg Hospital, in Cape 
Town, South Africa showed that up to 7% of newborns are readmitted to hospital within the first 
week of life because of jaundice requiring phototherapy or exchange transfusion [Ndayasiba 2015].  
We have a unique opportunity to evaluate the effects of TcB for jaundice in a South African 
population of newborns and also provide evidence from a randomized controlled trial. We compared 
TcB screening for risk of severe hyperbilirubinemia with visual inspection for jaundice before 
hospital discharge. If shown to be useful in identifying newborns with severe hyperbilirubinemia, 
timely initiation of phototherapy could reduce the incidence of extreme hyperbilirubinemia and its 
potential neurotoxic consequences, such as kernicterus. Screening could also help to prevent 
inappropriate discharge of newborns who require treatment for hyperbilirubinemia in the initial birth 
hospitalization period.  
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Objectives 
1. To summarise the available evidence on the effect of TcB screening in newborns on 
readmission for hyperbilirubinemia, incidence of severe hyperbilirubinemia and kernicterus. 
2. To provide evidence from a randomized controlled trial in an indigenous population of 
African newborns on the effect of TcB screening for severe hyperbilirubinemia compared to 
the visual inspection for jaundice before hospital discharge. 
3. To summarise the available evidence on the accuracy of TcB measurement compared to TsB 
measurement in the laborary in newborns from different populations and settings.  
4. To provide evidence from an indigenous population of African newborns on the accuracy of 
TcB measurement compared to TsB measurement.  
Research questions:  
a. What is the impact of TcB screening for hyperbilirubinemia before discharge on the rate of 
severe hyperbilirubinemia and readmission for phototherapy?  
b. Can TcB screening in African newborns reduce the hyperbilirubinemia related readmissions 
and incidence of severe hyperbilirubinemia? 
c. Can TcB measurement be used to reliably estimate TsB measurement in newborns from 
different populations and settings? 
d. Can TcB measurement be used to reliably estimate TsB measurement in an indigenous 
population of African newborns? 
To answer these questions, we have carried out: 
1. A Cochrane Systematic review on the effectiveness of screening for hyperbilirubinemia in 
newborns. 
2. A randomized controlled trial on the use of the TcB in a population of South African 
newborns. 
3. A Cochrane Systematic review on the test accuracy of TcB measurement compared to TsB 
measurement in newborns.  
4. A cross-sectional test accuracy study of TcB measurement in a population of South African 
newborns.  
All the above listed studies have been presented in the different sections of the dissertation as listed 
in the table 1 below.  
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Table 1. Overview of chapters included in thesis. 
 
Chapter 1 Short introduction, problem statement and rational for the project. 
Chapter 2 A Cochrane systematic review summarising the evidence on TcB screening 
in newborns. 
Chapter 3 A randomized controlled trial of pre-discharge TcB screening in a 
population of South African newborns.  
Chapter 4 A case study highlighting the importance of TcB screening in African 
newborns. 
Chapter 5 A Cochrane systematic review summarizing the evidence on the accuracy 
of TcB measurement compared to TsB measurement in the laboratory. 
Chapter 6 A cross-sectional study on the accuracy of the TcB measurement (using the 
JM 105 device) compared to TcB measurement in a population of South 
African newborns. 
Chapter 7 A short conclusion summarizing the findings from the different chapters 
and implications for practice and future research.   
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Abstract  
Background  
The American Academy of Pediatrics recommends universal transcutaneous bilirubin (TcB) or total 
serum bilirubin (TsB) screening in all newborns before hospital discharge. This practice has been 
implemented in the United States and Canada and has been the standard of care in these settings for 
many years. However, the US Preventive Task Force concluded that there is no robust evidence that 
universal bilirubin screening is beneficial in reducing the incidence of important outcomes such as 
bilirubin induced neurologic dysfunction or kernicterus. In this review, we aimed to evaluate the 
impact of TcB screening on various outcomes including bilirubin induced neurologic dysfunction and 
kernicterus.  
Objectives  
We evaluated the effects of TcB screening on readmission for jaundice and other secondary 
outcomes like incidence of severe hyperbilirubinemia. 
Search methods  
We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register 
of Controlled Trials (CENTRAL 2017, Issue 1), MEDLINE via PubMed (1966 to 27 February 2017), 
EMBASE (1980 to 27 February 2017), and CINAHL (1982 to 27 February 2017). An updated search 
was conducted in August 2018. We also searched clinical trials databases, conference proceedings, 
and the reference lists of retrieved articles for randomized controlled trials and quasi-randomized 
trials. 
Selection criteria  
We aimed to include any randomized controlled trial or prospective cohort study with control arm 
that evaluated the use of TcB screening for risk of hyperbilirubinemia in newborns before hospital 
discharge. Also, the studies need to have reported important outcomes such as incidence of 
readmission for hyperbilirubinemia, incidence of severe hyperbilirubinemia, bilirubin 
encephalopathy and kernicterus.  
Data collection and analysis  
Two authors independently screened through the titles and abstracts from the search output to identify 
any relevant study. There was no study identified that met our inclusion criteria.  
The answer to the question of whether TcB screening can help to reduce readmission rate for jaundice 
and reduce the rate of severe hyperbilirubinemia can be best provided by a well-designed randomized 
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controlled trial (RCT). However, findings from our literature search did not identify any published 
RCT that evaluated this question. The current available evidence is from observational studies. Also, 
TcB or TsB screening is already standard of care in many developed countries and it will not be 
ethically feasible to conduct any randomized controlled studies in these settings. There might be an 
opportunity to evaluate the impact of TcB screening in an RCT in other settings where screening for 
hyperbilirubinemia before hospital discharge is not standard of care. At most any RCT evaluating the 
use of TcB or TsB screening in newborns might be able to evaluate surrogate outcomes such as 
readmission for jaundice and incidence of severe hyperbilirubinemia. Also, the impact of TcB or TsB 
screening on bilirubin encephalopathy or kernicterus might never be known because this will require 
a very large sample size including thousands of newborns because of the low incidence of kernicterus. 
A well designed randomized controlled trial is needed to evaluate the impact of TcB or TsB screening 
in newborns before hospital discharge. 
Main results  
We identified four observational studies and did not identify any randomized controlled trial.  
Authors' conclusions  
Evidence of low quality from observational studies suggest that TcB screening is associated with 
decreased hospital readmission rate for jaundice and decrease in the incidence of severe 
hyperbilirubinemia. 
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Plain language summary  
Transcutaneous screening for hyperbilirubinemia in neonates: A Cochrane Systematic Review 
Jaundice refers to yellowish discoloration of the skin and the white of the eye. It occurs because of 
an increase in a pigment in the blood called bilirubin. When bilirubin levels in the blood increases, it 
gets deposited in the skin and eyes and cause them to become yellow. Jaundice is a very common 
condition in newborns and affects up to 60 to 80% of newborns. In most cases, the condition is benign 
and does not require any treatment. However, in some instances, the newborns would require 
treatment in the form of phototherapy or exchange blood transfusion. Also, very high levels of 
bilirubin in the blood can find its way into the brain and cause damage to the newborn's brain resulting 
in permanent neurologic damage such as cerebral palsy. Early identification of jaundice is important 
to help prevent the potential adverse consequences. In this review we evaluated the use of a 
noninvasive transcutaneous device on readmission for jaundice and reduction in the incidence of 
severe hyperbilirubinemia. We did not identify any studies that met our inclusion criteria. However, 
evidence from a few observational studies suggest that TcB screening of newborns before hospital 
discharge is associated with a reduction in hospital readmission rate and results in a decrease in the 
incidence of severe hyperbilirubinemia. Further, well-designed studies are needed to confirm these 
findings from the two observational studies before widespread implementation of universal bilirubin 
screening. 
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Background  
Description of the condition  
Hyperbilirubinemia is a term used to describe elevated levels of bilirubin in the blood. In newborns, 
hyperbilirubinemia becomes clinically apparent as jaundice, a yellow coloration of the skin and the 
sclera, at total serum bilirubin (TsB) levels > 5 mg/dl (Porter 2002). Hyperbilirubinemia is very 
common in both term and preterm newborn infants (occurring in around 60% of newborns) and results 
from a predisposition to produce bilirubin and the newborn's limited ability to excrete it (Lauer 2011). 
Jaundice or hyperbilirubinemia is the most common cause of hospital readmission in the neonatal 
period (Soskolne 1996; Maisels 1998; Escobar 2005). Most cases of newborn jaundice are mild and 
self-limited. However, in rare cases, infants can have very high levels of bilirubin that can lead to 
bilirubin encephalopathy and kernicterus (Newman 2006). Acute bilirubin encephalopathy is a 
clinical syndrome, in the presence of severe hyperbilirubinemia, of lethargy, hypotonia and poor suck, 
which may progress to hypertonia with a high-pitched cry and fever, and eventually to seizures and 
coma. Kernicterus refers to the pathological finding of deep-yellow staining of neurons and neuronal 
necrosis of the basal ganglia and brainstem nuclei. 
The threshold concentration of bilirubin and/or the duration of hyperbilirubinemia responsible for 
causing kernicterus injury in newborn infants is not known (Dennery 2004). Low concentrations of 
bilirubin may have some antioxidant benefits, suggesting that bilirubin should not be eliminated. 
Studies from developed countries estimate the incidence of kernicterus to range from about 0.4 to 2 
per 100,000 (Sgro 2006; Manning 2007; Burke 2009). However, studies from developing countries 
suggest that the incidence may be much higher (Nair 2003; Owa 2009).  
The acute phase signs of kernicterus are poor feeding, lethargy, high-pitched cry, hypertonia or 
hypotonia, opisthotonos and seizures. The chronic manifestations include athetoid cerebral palsy, 
motor delay, gaze palsy, dental dysplasia, mental retardation and sensorineural hearing loss (AAP 
2004). Current treatments for hyperbilirubinemia include phototherapy and exchange transfusion 
(usually reserved for severe cases of hyperbilirubinemia) (NICE 2010). 
Description of the intervention  
Transcutaneous bilirubin (TcB) measurement devices are used for the rapid and noninvasive 
measurement of bilirubin levels in the skin. Transcutaneous bilirubinometry works by directing light 
into the skin of the neonate and measuring the intensity of the specific wavelength of light returned. 
The measurement is usually taken by gently pressing the meter against the sternum. Findings from 
many studies suggest that the accuracy and precision of TcB measurements correlate with standard 
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laboratory TsB (Rubaltelli 2001; Engle 2002; Maisels 2004; Slusher 2004; Jangaard 2006). Other 
studies suggest that TcB measurements do not correlate with TsB measurements in preterm newborns 
(Knupfer 2001; Karoly 2004). TcB screening involves the measurement of bilirubin in every newborn 
in whom clinical jaundice is not present or observed, prior to discharge. 
How the intervention might work  
The practice of early discharge (< 72 hours of age) of healthy term newborns is growing worldwide. 
Because peak serum bilirubin levels usually occur on postnatal day three to five, an effective means 
of screening for the onset of hyperbilirubinemia could enhance the safety of the early discharge of 
newborns. 
The clinical evaluation of hyperbilirubinemia involves the visual assessment of jaundice. However, 
this method can be affected by the newborn's skin color and does not provide a quantification of the 
TsB level. Current, more-objective methods of assessing hyperbilirubinemia include the use of TsB 
measurements from blood sampling and noninvasive methods, such as TcB measurement with a 
handheld bilirubinometer. To aid in identifying newborns with a significant risk of 
hyperbilirubinemia and its consequences, TcB and other screening strategies for hyperbilirubinemia 
prior to the discharge of newborns have been advocated (Bhutani 1999; Alpay 2000; Newman 2000; 
Stevenson 2001). TcB screening for hyperbilirubinemia is used to identify newborns with 
bilirubin levels greater than the 75th percentile for age in hours and to track those with rapid rates 
of bilirubin rise (> 0.2 mg/dl per hour). Bhutani 1999 proposed an on-the-hour-specific bilirubin 
nomogram as an approach to pre-discharge screening for hyperbilirubinemia. However, Fay 2009 
have highlighted multiple methodologic flaws in the methods used to create the hour-specific total 
bilirubin nomogram. 
TcB screening for hyperbilirubinemia, the characterization of bilirubin levels by risk, with selective 
follow up of at-risk infants and timely intervention in infants at risk of hyperbilirubinemia, could lead 
to a reduction in the number of newborns with severe hyperbilirubinemia and a reduction in the 
number of newborns readmitted to the hospital for phototherapy or exchange transfusion. If 
hyperbilirubinemia is identified early, effective interventions such as phototherapy can be initiated to 
reduce the risk of bilirubin encephalopathy. However, TcB screening could also lead to unnecessary 
readmissions, prolonged hospitalization, excess laboratory tests and increased costs. 
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Why it is important to do this review  
The American Academy of Pediatrics (AAP) and the Canadian Pediatric Society (CPS) both 
recommend the use of either pre-discharge TsB or TcB measurements as appropriate screening 
options for identifying infants at risk of neonatal hyperbilirubinemia (AAP 2004; CPS 2007). In 
contrast, however, according to the US Preventive Services Task Force, "there is insufficient evidence 
to make a recommendation on screening infants for hyperbilirubinemia to prevent chronic bilirubin 
encephalopathy" (USPSTF 2009). There is conflicting evidence for, and recommendations on, the 
usefulness of pre-discharge bilirubin screening in newborns. Without proof of efficacy, universal 
screening of newborns for hyperbilirubinemia can result in the waste of healthcare resources and the 
unnecessary testing of many newborns. 
We aim to evaluate all the relevant available evidence to assess the effects of TcB screening for 
hyperbilirubinemia in newborn infants before discharge from hospital. 
Objectives  
To evaluate to the effects of TcB screening for hyperbilirubinemia to prevent the readmission of 
neonates for phototherapy. 
Methods  
Criteria for considering studies for this review  
Types of studies  
We will include randomized controlled trials, quasi-randomized controlled trials, cluster randomized 
trials and other prospective study designs (e.g. cohort studies). 
We excluded the following types of studies: 
• Retrospectives cohort studies and all studies without any control. 
• Studies that assessed the agreement or accuracy of TcB measurement compared to TsB 
measurement 
• Studies that evaluated the predictive ability of TcB screening and the percentile bilirubin 
nomogram for subsequent hyperbilirubinemia 
Types of participants  
• Well newborns, of gestational age 35 weeks or more and weighing 1800 g or more, being 
discharged from the newborn nursery (in the first week of life) 
We will not include infants admitted to, or being discharged from, the neonatal intensive care unit. 
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Types of interventions  
1. TcB screening (alone or combined with any other method, e.g. visual assessment) compared 
to no screening or visual inspection for hyperbilirubinemia before discharge from hospital 
2. TcB screening versus TsB screening before discharge from hospital 
3. Closer follow up or home nursing visits based on TcB screening results versus post-discharge 
follow up or treatment decisions based on visual inspection 
Types of outcome measures  
Primary outcomes  
• Readmission for phototherapy or home phototherapy for hyperbilirubinemia 
• Exchange transfusion 
Secondary outcomes  
• Phototherapy before hospital discharge 
• Peak bilirubin levels 
• Acute bilirubin encephalopathy 
• Chronic bilirubin encephalopathy 
• Hearing loss 
• Length of stay (days) 
• Cost of care 
Search methods for identification of studies  
We used the standard search strategy of the Cochrane Neonatal Review Group to identify all relevant 
studies regardless of language or publication status (published, unpublished, in press and in progress). 
Electronic searches  
We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see the Cochrane 
Neonatal search strategy for specialized register). 
We conducted a comprehensive search including: Cochrane Central Register of Controlled Trials 
(CENTRAL 2017, Issue 1) in The Cochrane Library; MEDLINE via PubMed (1966 to 27 February 
2017); EMBASE (1980 to 27 February 2017); and CINAHL (1982 to 27 February 2017) using the 
following search terms: (transcutaneous OR screening) AND (hyperbilirubinaemia OR 
hyperbilirubinemia OR jaundice), plus database-specific limiters for RCTs and neonates (see 
Appendix 1 for the full search strategies for each database). We did not apply language restrictions. 
We searched clinical trials registries for ongoing or recently completed trials (clinicaltrials.gov; the 
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World Health Organization’s International Trials Registry and Platform 
www.whoint/ictrp/search/en/, and the ISRCTN Registry). 
Searching other resources  
We contacted experts and organizations or manufacturers of bilirubinometers for information on any 
relevant study. We scanned through the reference lists of all relevant studies. We searched conference 
and symposia proceedings of the Perinatal Society of Australia and New Zealand and the Paediatric 
Academic Societies (American Pediatric Society, Society for Pediatric Research and European 
Society for Paediatric Research).  
Data collection and analysis  
We used the standard methods of the Cochrane Neonatal Review Group. 
Selection of studies  
The first two review authors independently scanned through the titles and abstracts of the search 
output to identify potentially eligible studies. Discrepancies were resolved through discussion. We 
obtained full text articles of all selected abstracts to formally assess eligibility using the prespeciﬁed 
eligibility criteria. We summarized the reasons for exclusion of any potentially eligible study in the 
‘Characteristics of excluded studies’ table.
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Data extraction and management  
We designed a data extraction form for the extraction of data. Two review authors independently 
extracted data from all included studies using the data extraction form. We resolved discrepancies 
through discussion. We entered data into the latest version of Review Manager (RevMan 2014) and 
checked them for accuracy. 
Study information to be extracted includes: 
• study details: citation, start and end dates, location and study design; 
• participant details: study population eligibility (inclusion and exclusion) criteria, gestational 
age, sex, sample size and attrition rate; 
• details about the interventions: type of TcB meter used, and any other method used for 
screening for hyperbilirubinemia 
• outcome details: readmission rates for phototherapy, exchange transfusion, acute bilirubin 
encephalopathy, chronic bilirubin encephalopathy and adverse effects. 
For each dichotomous outcome, we aimed to extract information on the number of participants 
experiencing the event and the number of participants randomized to each treatment group. For each 
continuous outcome we planned to extract the means or geometric means and standard deviations (or 
information to estimate the standard deviations) for each treatment group, together with the numbers 
of participants in each group. We planned to extract medians and ranges if these are reported in place 
of means and standard deviations. 
Assessment of risk of bias in included studies  
We planned to assess the risk of bias (low, high, or unclear) of all included trials using the Cochrane 
‘Risk of bias’ tool (Higgins 2011) for the following domains: 
• Sequence generation (selection bias) 
• Allocation concealment (selection bias) 
• Blinding of participants and personnel (performance bias) 
• Blinding of outcome assessment (detection bias) 
• Incomplete outcome data (attrition bias) 
• Selective reporting (reporting bias) 
• Any other bias 
Any disagreements were resolved by discussion or by a third assessor.  
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Measures of treatment effect  
We planned to present results for dichotomous outcomes as summary risk ratios (RRs) with 95% 
confidence intervals (CIs) and absolute risk differences with 95% CIs. Also, we planned to present 
continuous outcomes using the mean difference (MD), if outcomes are measured using the same scale 
in trials or using the standardized mean difference when the outcome is measured using different 
scales. We planned to present the summary effect measures with 95% CIs. If the RR is statistically 
significant, the number needed to treat to for an additional beneficial outcome or an additional 
harmful outcome were to be calculated. 
Unit of analysis issues  
We will note the unit of analysis at the level of randomization (individual or group) and analyze the 
data accordingly. We will include cluster randomized trials in the analyses along with individually 
randomized trials. For cluster randomized trials, we will adjust the sample sizes using the methods 
described in the Cochrane Handbook for Systematic Reviews of Interventions, Section 16.3.4 or 
16.3.6 (Higgins 2011) using an estimate of the intra-cluster correlation coefficient (ICC) derived from 
the trial (if possible) or from another source. 
Dealing with missing data  
We planned to contact authors if there are missing or unclear data. We also planned to note levels of 
attrition in each of the included studies. For all outcomes we planned to carry out an intention-to-treat 
analysis. For outcomes in which the results have been pooled in meta-analysis, we planned to explore 
the impact of including studies with significant loss to follow up in the overall assessment of treatment 
effect by using sensitivity analyses. 
Assessment of heterogeneity  
We planned to assess statistical heterogeneity by visually inspecting the forest plots to detect 
overlapping CIs, applying the Chi2 test (P value < 0.10 considered statistically significant) and also 
using the I2 statistic, where an I2 of less than 25% will be considered as unimportant, 25% to 49% will 
be considered to suggest low heterogeneity, 50% to 74% will be considered to suggest moderate 
heterogeneity, and 75% or greater will be considered to indicate high heterogeneity. 
Assessment of reporting biases  
If we have 10 or more studies, we planned to explore the likelihood of reporting bias or publication 
bias for each outcome using funnel plots. 
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Data synthesis  
Quality of evidence 
We planned to use the GRADE approach, as outlined in the GRADE Handbook (Schünemann 2013), 
to assess the quality of evidence for the following (clinically relevant) outcomes.  
Two authors were to independently assess the quality of the evidence for each of the outcomes above. 
We considered evidence from randomized controlled trials as high quality but downgraded the 
evidence one level for serious (or two levels for very serious) limitations based upon the following: 
design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and 
presence of publication bias. We planned to use the GRADEpro GDT Guideline Development Tool 
to create a ‘Summary of findings’ table to report the quality of the evidence. 
The GRADE approach results in an assessment of the quality of a body of evidence in one of four 
grades: 
1. High: We are very confident that the true effect lies close to that of the estimate of the effect. 
2. Moderate: We are moderately confident in the effect estimate: the true effect is likely to be 
close to the estimate of the effect, but there is a possibility that it is substantially different. 
3. Low: Our confidence in the effect estimate is limited: the true effect may be substantially 
different from the estimate of the effect. 
4. Very low: We have very little confidence in the effect estimate: the true effect is likely to be 
substantially different from the estimate of effect. 
Subgroup analysis and investigation of heterogeneity  
We planned to carry out subgroup analyses based on gestation age (preterm versus term newborns); 
the presence of jaundice (versus no jaundice) in newborns; birth weight (<2500 g versus > 2500 g); 
and the presence of any comorbid conditions (e.g. hemolytic disease or other conditions known to 
exacerbate jaundice); mode of delivery (spontaneous vertex delivery or delivery by caesarean 
section).  
Sensitivity analysis  
Depending on the number of included studies, we planned to conduct sensitivity analyses on the 
robustness of the methods used regarding allocation concealment and losses to follow up in the 
analysis, and we will report the impact of the sensitivity analyses on the quantitative results from 
the meta-analysis. 
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Results  
Description of studies  
In this review we planned to include randomized controlled trials, quasi-randomized controlled trials, 
cluster randomized trials and other prospective study designs (e.g. cohort studies). 
We identified 113 studies after deduplication of studies from the different databases in our original 
search in August 2017 and updated search in August 2018 did not yield any new studies. We did not 
identify any studies that met our inclusion criteria. A few observational studies that evaluated the use 
of either TcB or TsB screening are summarized in the table 1 below. 
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Table 1.1: Summary of observational studies that evaluated the use of TcB screening.  
Study ID Country Period Type of study Setting and participants Sample size Outcomes 
Darling 
2014 
Canada  July 2007 
to June 
2010  
 
This was a 
before and 
after study.  
Canada. 
This study was 
conducted in 42 
hospitals across 
Ontario, Canada.  
 
The study included a 
total of 534,103 infants 
>35 weeks gestation.  
In this study, universal bilirubin 
screening did not find any change 
in jaundice related readmissions. 
However, there was an increase in 
phototherapy during 
hospitalization at birth (RR, 1.32; 
95% CI, 1.09– 1.59) and a 
decrease in jaundice related 
emergency department visits (RR, 
0.79; 95% CI, 0.64–0.96) but no 
statistically significant difference 
in phototherapy after discharge. 
Eggert 
2006 
USA March 
2001 to 
Dec 2002 
&  
Jan 2003 to 
Dec 2004  
 
This was a 
retrospective 
cohort 
study. 
 
This study was 
conducted in 18 
hospitals in the US.  
 
A total of 101,272 
newborns of > 35-week 
gestational age, 52483 after 
implementing pre-discharge 
bilirubin screening program 
compared with 48789 
delivered before (total 101 
272) >35-week gestational 
age.  
The study demonstrated a 
reduction in the proportion of 
newborns with bilirubin level 
>25mg/dl from 1 in 1572 to 1 in 
4037 (p<0.005). The rate of 
readmission for 
hyperbilirubinemia was decreased 
from 0.55% to 0.43% after 
implementation of bilirubin 
screening (p<0.005) 
Kuzniewicz 
2009 
USA Jan 1995 to 
June 2007. 
This was a 
retrospective 
cohort 
study. 
This study was 
conducted in 11 
hospitals in the US 
A total of 38,182 born > 
35-week gestational age 
born in 9 hospitals after 
implementation of 
Universal bilirubin screening was 
associated with a significantly 
lower incidence of severe 
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Bilirubin 
screening 
was with 
either TcB 
or TsB. 
universal bilirubin 
screening with 319 904 
born before implementation 
of the screening.  
hyperbilirubinemia but also with 
increased phototherapy use. 
Mah 2010 USA May 2004 
to Dec 
2008  
 
This was a 
prospective 
cohort 
study. 
This study was 
conducted in 116 
hospitals in the USA. 
 
A total of 129345 births 
before implementation of 
universal bilirubin 
screening and 899472 after 
the implementation.  
There was a 65% reduction in 
proportion of infants with TsB 
>30mg/dl. The rate of 
phototherapy use increased from 
4.4% in 2004 to 5.1% in 2008. 
Petersen 
2005 
USA August 
2002 to 
March 
2003 
(before 
TcB) and 
from May 
2003 to 
December  
2003 (after 
TcB) 
This was a 
retrospective 
cohort 
study.  
This study was 
conducted in a single 
hospital in the USA.  
 
A total of 6933 healthy 
newborns were included.  
There was a significant decrease 
in number of readmissions for 
hyperbilirubinemia per 1000 
newborns per month from 4.5 to 
1.8 (Wilcoxon rank sums two 
sample test, p=0.044). There was 
no significant difference in the 
blood sampling for TsB, length of 
hospital stay and duration of 
phototherapy prior to discharge.  
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Results of the search  
Included studies  
There was no study that met our inclusion criteria.  
Excluded studies  
We excluded many potentially eligible studies. Most of the studies on TcB screening evaluated the 
predictive ability on subsequent hyperbilirubinemia. Other studies were retrospective and did not 
provide any prospective data even though the authors reported on relevant outcomes. See table of 
excluded studies.  
Risk of bias in included studies  
We did not identify any studies that met our inclusion criteria.  
Allocation (selection bias)  
There was no study that met our inclusion criteria. 
Blinding (performance bias and detection bias)  
There was no study that met our inclusion criteria. 
Incomplete outcome data (attrition bias)  
There was no study that met our inclusion criteria. 
Selective reporting (reporting bias)  
There was no study that met our inclusion criteria. 
Other potential sources of bias  
Effects of interventions  
Primary outcomes 
• Readmission for phototherapy or home phototherapy for hyperbilirubinemia 
No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening.  
• Exchange transfusion 
No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening. 
Secondary outcomes 
• Phototherapy before hospital discharge 
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No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening. 
• Peak bilirubin levels 
No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening. 
• Acute bilirubin encephalopathy 
No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening. 
• Chronic bilirubin encephalopathy 
No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening. 
• Hearing loss 
No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening. 
• Length of stay (days) 
No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening. 
• Cost of care 
No RCT or prospective cohort study has evaluated this outcome with the use of TcB screening. 
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Discussion  
The AAP recommends universal pre-discharge TcB or TsB screening in all newborns for identifying 
infants at risk for neonatal hyperbilirubinemia AAP 2004. However, the U.S. Preventive Services 
Task Force USPSTF, "there is insufficient evidence to make a recommendation on screening infants 
for hyperbilirubinemia" USPSTF 2009. This systematic review aimed to evaluate the impact of TcB 
screening in newborns on the outcomes of readmission for hyperbilirubinemia, rates of exchange 
transfusion, acute and chronic bilirubin encephalopathy amongst other outcomes. We conducted a 
comprehensive search of all relevant databases to identify potentially eligible studies. Our search for 
relevant studies did not identify any randomized controlled trial or any other prospective study with 
control arm that evaluated the use of TcB screening in newborns. Similarly, the systematic review by 
Bhardwaj, did not identify any randomized controlled study evaluating the effects of TcB screening 
on readmission rate and development of severe hyperbilirubinemia Bhardwaj 2017. We identified a 
few observational studies that evaluated the use of TcB screening in newborns. We did not identify 
any studies of TcB for jaundice in African newborns with varying skin pigmentation. This systematic 
review did not identify any evidence from randomized controlled trials for the use of TcB screening 
newborns. However, a few observational studies from the US and Canada have demonstrated that 
universal TcB or TsB reduced jaundice readmissions and led to a reduction in the incidence of severe 
hyperbilirubinemia Alkalay 2010; Darling 2014; Eggert 2006; Kuzniewicz 2009; Mah 2010; Petersen 
2005; Wainer 2012. These findings are yet to be confirmed in any randomized controlled trials. All 
these studies reported on surrogate outcomes and non-reported on the incidence of bilirubin induced 
neurologic dysfunction of kernicterus. 
Summary of main results  
A limited number of observational studies have evaluated the effects of pre-discharge TcB screening 
on readmission for jaundice and incidence of severe hyperbilirubinemia. We did not identify any 
randomized controlled trial or any prospective study with control arm that met our inclusion criteria. 
Findings from these observational studies suggest that TcB screening could lead to reduction in 
jaundice related readmissions and reduction in the incidence of severe hyperbilirubinemia. There is 
currently no randomized controlled trial that has evaluated the use of universal TcB screening for 
hyperbilirubinemia in newborns.  
Overall completeness and applicability of evidence  
We conducted a comprehensive search of the literature. We are confident that all the currently 
available evidence has been summarized in this review.  
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Quality of the evidence  
The evidence presented in this review is evidence from observational studies. We did not identify any 
completed randomized controlled trial that evaluated the impact of TcB screening on jaundice 
readmission, severe hyperbilirubinemia and bilirubin encephalopathy. Low quality evidence suggest 
that TcB screening is associated with decreased hospital readmission rate for jaundice and decrease 
in the incidence of severe hyperbilirubinemia.  
Potential biases in the review process  
We conducted a comprehensive search in attempt to identify all relevant studies. Two authors 
independently screening studies for eligibility and did data extraction from the included studies. 
Agreements and disagreements with other studies or reviews  
A previous review by concluded that the effects of screening on the rates of bilirubin encephalopathy 
are unknown and that screening is not associated with any favorable clinical outcomes.  
Authors' conclusions  
Implications for practice  
Low quality evidence suggests a beneficial effect of transcutaneous bilirubin screening. The use of 
TcB or TsB screening is already implemented and currently standard of care in the USA and Canada. 
The use of TcB screening in newborns is not associated with any harm. Therefore, depending on 
availability of the resources and TcB meters, clinicians caring for newborns can consider 
implementing this practice which shows some promising benefit.  
Implications for research  
The answer to the question of whether TcB screening can help to reduce readmission rate for jaundice 
and reduce the rate of severe hyperbilirubinemia can be best provided by a well-designed randomized 
controlled trial. However, findings from our literature search did not identify any published RCT that 
evaluated this question. The current available evidence is from observational studies. Also, TcB or 
TsB screening is already standard of care in many developed countries and it will not be ethically 
feasible to conduct any randomized controlled studies in these settings. There might be an opportunity 
to evaluate the impact of TcB screening in an RCT in other settings where bilirubin screening is not 
standard of care. At most any RCT evaluating the use of TcB or TsB screening in newborns might be 
able to evaluate surrogate outcomes such as readmission for jaundice and incidence of severe 
hyperbilirubinemia. Also, the impact of TcB or TsB screening on bilirubin encephalopathy or 
kernicterus might never be known because this will require a very large sample size including 
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thousands of newborns because of the low incidence of kernicterus. A well designed randomized 
controlled trial is needed to evaluate the impact of TcB or TsB screening in newborns before hospital 
discharge. 
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Differences between protocol and review  
Characteristics of excluded studies  
Alkalay 2010  
Reason for exclusion This study used a historical cohort as control.  
Allen 2010  
Reason for exclusion This study evaluated the impact of TcB measurement on blood sampling 
for TsB. No outcome relevant to this review was reported 
Alpay 2000  
Reason for exclusion This study evaluated the value of first-day bilirubin measurement in 
predicting the development of significant hyperbilirubinemia in healthy 
term newborns. No outcome relevant to this review was reported. 
Bhutani 1999  
Reason for exclusion The study evaluated the use of a TcB nomogram for prediction of 
subsequent hyperbilirubinemia. No outcome relevant to this review was 
assessed. 
Bhutani 2000  
Reason for exclusion The study evaluated the accuracy of TcB measurement and the use of a 
TcB nomogram for prediction of subsequent hyperbilirubinemia. No 
outcome relevant to this review was assessed. 
Bhutani 2013  
Reason for exclusion Uncontrolled cohort study. The authors used TsB and clinical risk factor 
to predict hyperbilirubinemia 
Dalal 2009  
Reason for exclusion The study evaluated the use of a TcB nomogram for prediction of 
subsequent hyperbilirubinemia. No outcome relevant to this review was 
assessed. 
Darling 2014  
Reason for exclusion This was a population based retrospective cohort study.  
De Luca 2008  
Reason for exclusion This study compared the accuracy of two different TcB devices compared 
to TsB measurement. No outcome relevant to this review was reported. 
 
De Luca 2008a  
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Reason for exclusion This study evaluated the use of visual inspection and TcB measurement 
for detection of hyperbilirubinemia. No outcome relevant to this review 
was reported. 
Eggert 2006  
Reason for exclusion This was a retrospective cohort study. Also, in this study, the authors 
evaluated both the use of TsB and TcB screening in the same population 
Hartshorn 2010  
Reason for exclusion This was a retrospective before-and-after study 
Ho 2006  
Reason for exclusion This was a diagnostic test accuracy study comparing TcB measurement 
and TsB. 
Kaplan 2008  
Reason for exclusion No outcomes relevant to this review were reported 
Karon 2008  
Reason for exclusion The study evaluated the use of a TcB nomogram for prediction of 
subsequent hyperbilirubinemia. No outcome relevant to this review was 
assessed. 
Kurokawa 2016  
Reason for exclusion This was a diagnostic test accuracy study comparing TcB and TsB 
measurement in very low birth weight infants. 
Kuzniewicz 2009  
Reason for exclusion This was a retrospective cohort study 
Lodha 2000  
Reason for exclusion This was a diagnostic test accuracy study comparing TcB measurement 
and TsB. 
Mah 2010  
Reason for exclusion This was a before and after study.  
Maisels 2009  
Reason for exclusion The study evaluated the use of a TcB nomogram and clinical risk factors 
for prediction of subsequent hyperbilirubinemia. No outcome relevant to 
this review was assessed. 
Mishra 2009  
Reason for exclusion  
Mishra 2010  
Reason for exclusion The study evaluated the use of a TcB nomogram for prediction of 
subsequent hyperbilirubinemia. No outcome relevant to this review was 
assessed. 
Morgan 2015  
Reason for exclusion This was a before and after study.  
Petersen 2005  
Reason for exclusion This was a retrospective study 
Romagnoli 2012  
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Reason for exclusion This study evaluated the use of TcB and TsB measurement for prediction 
of subsequent hyperbilirubinemia. No outcome relevant to this review was 
assessed. 
Sanpavat 2005  
Reason for exclusion The study evaluated the use of a TcB nomogram for prediction of 
subsequent hyperbilirubinemia. No outcome relevant to this review was 
assessed. 
Seidman 1999  
Reason for exclusion This study evaluated a model for predicting neonatal jaundice based on 
several risk factors. No outcome relevant to this review was reported. 
Szabo 2004  
Reason for exclusion This study evaluated the use of the Kramer scale for the assessment of 
hyperbilirubinemia. No outcome relevant to this review was reported. 
van den 2016  
Reason for exclusion This study visual inspection for jaundice and TcB measurement for 
hyperbilirubinemia. No outcome relevant to this review was reported. 
Varvarigou 2009  
Reason for exclusion The study evaluated the use of a TcB nomogram for prediction of 
subsequent hyperbilirubinemia. No outcome relevant to this review was 
assessed. 
Wainer 2012  
Reason for exclusion This study used a historical cohort as control group.  
Wickremasinghe 2012  
Reason for exclusion This was a retrospective study. 
Yu 2011  
Reason for exclusion The study evaluated the use of a TcB nomogram for prediction of 
subsequent hyperbilirubinemia. No outcome relevant to this review was 
assessed. 
Yu 2014  
Reason for exclusion There was no control group in this study.  
Footnotes 
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Summary: We evaluated the impact on jaundice related readmissions and incidence of severe 
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newborns.  
What’s known on This Subject: Transcutaneous bilirubin (TcB) measurement seem to correlate 
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America suggest that universal TcB or TsB screening reduces readmission for jaundice, incidence of 
severe hyperbilirubinemia and predicts need for phototherapy.
Stellenbosch University  https://scholar.sun.ac.za
58 
 
What This Study Adds: Our study provides evidence from indigenous African newborns with 
varying skin pigmentation on the impact of pre-discharge TcB screening on jaundice related 
readmissions.  To our knowledge this is the first randomized controlled trial that has evaluated the 
effect of pre-discharge TcB screening in newborns before hospital discharge. 
Contributors’ Statements: 
Charles Okwundu conceptualized and designed the study, designed the data collection tools, 
coordinated and supervised data collection at the study site, drafted the initial manuscript, and 
approved the final manuscript as submitted.  
Vinod Bhutani, Charles Wiysonge and Johan Smith provided input into the methods and content 
knowledge, critically reviewed the manuscript, and approved the final manuscript as submitted. 
Tonya Esterhuizen conducted the statistical analysis, reviewed the manuscript, and approved the 
final manuscript as submitted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
59 
 
Abstract 
Background 
South African, healthy term newborns are usually discharged less than 72 hours after delivery. If 
hyperbilirubinemia is not identified early, discharged babies remain at risk for severe 
hyperbilirubinemia, an important cause of readmission, neonatal mortality and morbidity. Use of 
transcutaneous bilirubin (TcB) screening before hospital discharge has been controversial especially 
among babies with varying skin pigmentation.  
Objective 
We tested the clinical benefits of TcB screening of healthy newborns before discharge for the 
outcomes of readmission for jaundice and severe hyperbilirubinemia in a randomized controlled 
trial.  
Methods 
This was a randomized controlled trial. We compared pre-discharge TcB with visual assessment 
(alone) for jaundice in apparently healthy newborns at a public tertiary hospital in Cape Town, South 
Africa.  
Results  
Of the 1858 infants, 63% were black, 35% of mixed race and 1% white. There was a significant 
reduction in the rate of readmission for jaundice (RR 0.25, 95% CI 0.14 to 0.46. p<0.0001) and in the 
incidence of severe hyperbilirubinemia (RR 0.27, 95% CI 0.08- 0.97. p= 0.05) with the use of TcB 
screening compared to visual inspection.  
Conclusion 
Pre-discharge TcB screening is superior in identifying newborns at risk of severe hyperbilirubinemia 
compared to visual inspection. We recommend that every newborn regardless of skin pigmentation 
should receive objective bilirubin screening before hospital discharge. Universal bilirubin screening 
in newborns could potentially reduce hyperbilirubinemia related morbidity and mortality.  
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Background 
Hyperbilirubinemia is the most common reason for readmission of newborns in the first week after 
birth [1,2]. Neonatal jaundice is usually benign and does not require any intervention in most 
instances. However, up to 10% of term newborns (≥37 week gestational age) will develop severe 
hyperbilirubinemia that require treatment, usually in the form of phototherapy and possibly exchange 
blood transfusion [30]. “Severe hyperbilirubinemia” is defined as a total serum bilirubin (TsB) 
concentration greater than 340 umol/l (20 mg/dl), and “critical hyperbilirubinemia” as a TsB 
concentration greater than 425 umol/l (25 mg/dl) at any time during the first 28 days of life for late 
preterm (between 34 and 37 weeks gestational age) and term newborns[4]. Failure to identify 
newborns at risk of developing severe hyperbilirubinemia can lead to severe post-icteric neurologic 
consequences, including athetoid cerebral palsy and a variety of life-long manifestations of 
kernicterus [5,6]. 
In many settings, term newborns are discharged from hospitals within 1–2 days after delivery, before 
hyperbilirubinemia usually becomes clinically evident. Peak serum bilirubin levels usually occur on 
postnatal days 3 to 5, when many newborns have already been discharged. The inability to identify 
and manage at-risk infants prior to hospital discharge in a timely manner has been cited as the major 
root cause of adverse outcomes of hyperbilirubinemia [7 ,8].  
The burden of severe hyperbilirubinemia continues to be high in low- and middle-income countries 
(LMICs). In many LMICs, severe or clinically signiﬁcant neonatal hyperbilirubinemia is not only a 
leading cause for hospital readmission in the ﬁrst week of life, but also constitutes an important cause 
of neonatal mortality and morbidity [9-11]. A report on the global burden of hyperbilirubinemia 
suggests that sub-Saharan Africa and South Asia are the leading contributors to an estimated 1.1 
million babies who develop severe hyperbilirubinemia worldwide every year [12]. In some cases, 
babies could have levels that can lead to subsequent brain damage from kernicterus [12-16].  
Studies from countries in Africa suggest that kernicterus is still a leading cause of cerebral palsy [13-
15,17,18]. In South Africa, a retrospective study of exchange transfusion for hyperbilirubinemia in 
newborns over a period of 5 years showed that six out of 26 (23.0%) babies requiring exchange 
transfusion had signs of kernicterus [19]. Findings from various observational studies conducted in 
North America suggest that universal bilirubin screening in newborns before discharge reduces 
readmission rate for jaundice and incidence of severe hyperbilirubinemia [20-23]. However, these 
findings have not been confirmed in any randomized controlled trial [24]. Furthermore, there is no 
universal consensus on the routine screening for jaundice of all newborns either using non-invasive 
transcutaneous bilirubin (TcB) or total serum bilirubin (TsB) measurement [25-29]. 
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The current South African guideline on the management of jaundice in the newborn does not make 
any recommendation on universal screening of all newborns with either TcB or TsB before hospital 
discharge [30]. Similarly, in other African countries, there are no guidelines on universal screening 
of all newborns for risk of hyperbilirubinemia. In many LMICs, newborns are assessed for jaundice 
by visual inspection and serum bilirubin is measured only in newborns who look jaundiced and in 
some cases in newborns of rhesus D antigen (Rh-D) negative mothers [31]. 
In this randomized controlled trial (RCT), we compared the use of a transcutaneous device to visual 
inspection to screen for hyperbilirubinemia before hospital discharge in apparently healthy term and 
late preterm newborns (≥35 week gestational age). 
Objective: 
To evaluate the impact of TcB screening before hospital discharge as compared to visual inspection 
for jaundice, on readmission for hyperbilirubinemia and the incidence of severe hyperbilirubinemia 
in a South African population of newborns. 
Methods 
Study Design and setting   
This was a randomized, controlled, unblinded trial that evaluated the effect of TcB screening in term 
newborns before hospital discharge. This study was conducted at the well-baby nurseries at 
Tygerberg Hospital, Cape Town, South Africa. Tygerberg Hospital is the biggest tertiary healthcare 
institution in the Western Cape Province and has 308 pediatric beds, with approximately 7500 
deliveries per annum. According to the current policy, well babies born at ≥ 35 weeks gestation and 
birth weight ≥ 1800 grams (g) are discharged home after 6 hours for vaginal deliveries and 48 hours 
for Caesarean sections.  
We obtained approval from the Health Research Ethics Committee of the Faculty of Medicine and 
Health Sciences, Stellenbosch University. Informed consent was obtained from the mother for each 
infant. 
Study Procedures 
We screened all infants at the time of discharge for potential eligibility into the study using the 
predetermined inclusion and exclusion criteria. Those who were ≤ 72 hours of life, with a gestational 
age of at least of 35 weeks and birth weight of at least 1800g were eligible for participation. The 
gestational age was determined by antenatal ultrasound scan, last menstrual period or postnatal foot 
length measured with a plastic Vernier’s caliper for infants whose mothers were un-booked and did 
not have any prenatal dating scan [32]. 
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Randomization and blinding 
Infants who met all inclusion criteria were randomly assigned to either TcB screening for 
hyperbilirubinemia or visual inspection for jaundice. A random allocation sequence was generated 
using a computer random sequence generator. Allocation assignments were recorded on sequentially 
numbered sheets of papers and placed in sealed opaque envelopes, maintained in a secure location 
and accessible only by the Principal Investigator. The envelopes were opened sequentially for 
assignment by the research assistant after informed consent was obtained and the infants allocated to 
the group assigned in the envelope.  The study group allocation was not blinded as it is not possible 
to blind clinicians or parents to the type of screening provided due to the obvious nature of the 
intervention. The outcome assessors and statistician were blinded to the group allocation.  
Interventions: 
TcB screening group: 
In this group we measured TcB levels once using the JM 105 Jaundice Meter (Drager Medical UK 
Ltd. Hemel, Hempstead) a portable, handheld, non-invasive TcB measuring device at the time of 
enrollment [33].  An average of 3 readings was plotted on Bhutani’s hour-specific nomogram (Figure 
1) to determine the risk zone for hyperbilirubinemia. Infants in this group were classified into high-
risk, high-intermediate, low-intermediate risk and low-risk groups. For all newborns in the high-risk 
zone, we obtained a TsB. The need for phototherapy was determined based on the TsB measurement. 
Infants who met the threshold for phototherapy were kept in hospital for phototherapy. Babies in the 
high-intermediate, low-intermediate risk and low-risk groups were asked to follow up at a primary 
healthcare center closest to their home at 24, 48 and 72 hours, respectively, after discharge home. We 
did not assess the timeliness of follow-up after discharge or assess the proportion of babies who went 
for follow-up. 
Visual inspection group: 
Babies in this group were managed routinely according to the current standard of care. The 
infants were assessed for jaundice visually for the presence of tissue yellowness by blanching the skin 
over the glabella and sternum. The infants were assessed by the admitting physician at the time of 
enrollment. Venous blood sample for TsB measurement was only collected in infants who were 
clinically jaundiced or in infants of Rh-D negative mothers according to the hospital protocol. The 
need for phototherapy was determined based on the TsB result. Babies whose TsB value met the 
threshold for phototherapy according to the South African phototherapy guideline were kept for 
phototherapy before discharge home [30]. Babies who did not meet threshold for phototherapy and 
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who were not visibly jaundiced at the time of discharge were managed routinely. The mothers were 
asked to return with their newborns for follow-up assessments at the primary healthcare facility 
closest to their home within 2 days of hospital discharge. 
Sample Size 
We did not find any published study that assessed the rate of readmission for hyperbilirubinemia in 
South African newborns. Therefore, we assumed a baseline readmission rate for phototherapy of 
4.8% from the literature and an unpublished local study at Tygerberg Hospital, Cape Town on 
newborn readmission for hyperbilirubinemia [34-37]. We estimated that a minimum of 1858 
participants would give us 80% power to detect a 50% reduction in the rate of readmission with the 
use of TcB screening at 5% level of significance. The baseline readmission rate was estimated from 
a study we conducted the previous year at Tygerberg Hospital on the rate of readmission for neonatal 
hyperbilirubinemia after discharge. The readmission rate in the study was estimated to be about 4.8%. 
Study Outcomes 
The primary end point was readmission for jaundice that required phototherapy or exchange 
transfusion. For the primary outcome, we compared the proportion of readmissions for 
hyperbilirubinemia, requiring phototherapy or exchange transfusion, in the TcB to the visual 
inspection group. For every infant that was readmitted, we ascertained whether the infant met the 
threshold for either phototherapy or exchange transfusion according to the South African 
phototherapy guideline based on the TsB result at the time of readmission [30].  
The secondary end points were: phototherapy before hospital discharge, incidence of severe 
hyperbilirubinemia, critical hyperbilirubinemia or exchange transfusions and duration of hospital stay 
for those that were readmitted. The rate of phototherapy pre-discharge was measured during the birth 
hospitalization. Other outcomes (readmission for phototherapy, incidence of severe 
hyperbilirubinemia and duration of hospital stay) were determined electronically through the database 
and also by obtaining the infants’ files and the electronic patient record transcripts from the hospital 
or primary healthcare Centre where the baby was readmitted. We obtained all TsB values during the 
first month of life for newborns who were readmitted. For each readmission, we confirmed the name 
of the hospital or primary healthcare centre where the baby was readmitted, length of hospital stay, 
treatment received (phototherapy or exchange transfusion) and highest TsB level during the 
readmission period. 
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Statistical Analysis 
We collected study data using paper-based data collection forms and then transferred to the Redcap 
database. Statistical analyses was done with the use of STATA 14 statistical software (StataCorp. 
2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). 
We performed an intention to treat analysis. Differences according to the group allocation for 
continuous variables were tested with the use of unpaired t-tests with equal variances and Wilcoxon 
rank-sum tests. The Pearson chi-square test was used to test for differences between the two groups 
for categorical variables. Fisher’s exact test was used to compare the rate of phototherapy before 
hospital discharge, readmission for hyperbilirubinemia and incidence of severe hyperbilirubinemia. 
Effect sizes were reported as relative risks (RR) with 95% confidence intervals (CIs). We also 
adjusted for any plausible baseline confounding variable (e.g. history of jaundice in a previous 
sibling) by performing Mantel-Haentzel stratification.  
Results 
Subject recruitment and follow-up 
We enrolled a cohort of 1858 late preterm and term infants born between August 2015 and October 
2016. We approached a total of 1910 mothers and their infants for participation. Two mothers 
declined participation and 50 were excluded because they did not meet our inclusion criteria (Figure 
2). A total of 929 infants were enrolled to each arm. All infants were screened according to the study 
arm to which they were allocated. 
Participant characteristics 
The baseline characteristics and demographics of enrolled infants and their mothers are shown in 
Table 1. There were no significant differences between the TcB screening arm and the visual 
inspection arm, except for the history of jaundice in a previous sibling which was significantly higher 
in the TcB group.  
Outcome measures 
Readmission for jaundice 
There were a total of 65 jaundice-related readmissions (3.5%). We obtained the TsB results for these 
infants to determine if they met the threshold for phototherapy on readmission. We could not obtain 
the TsB results of 5 (3 in the visual inspection arm and 2 in the TcB arm) infants who were readmitted 
after discharge and could not determine the appropriateness of their readmission.  
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Thirteen out of 929 (1.4%) infants were readmitted in the TcB arm compared to 52 out of 929 (5.6%) 
infants in the visual inspection arm (RR 0.25, 95% CI 0.14 to 0.46. p<0.0001). Number needed to 
treat (NNT) = 24, 95% CI 17 to 40]. Among all readmitted infants, there were 12 appropriate 
readmissions in the TcB group and 48 appropriate readmissions in the visual inspection group. Since 
there was a randomization imbalance in the groups regarding a previous baby with jaundice, 
adjustment was done by stratified analysis. The Mantel-Haentzel adjusted RR was 0.25 with 95% CI 
0.14 to 0.46, indicating that after adjustment for having a previous baby with jaundice, there was still 
a significantly protective effect of TcB screening on readmission for jaundice.  
Phototherapy before discharge  
The rate of phototherapy before hospital discharge was significantly higher in the TcB group 
compared to the visual inspections group. A total of 48 (5.2%) infants received phototherapy before 
hospital discharge compared to 18 (1.9%) in the visual inspection group (RR 2.66, 95% CI 1.56 to 
4.54, p=0.0002). In the TcB arm, 83 (9%) of babies had predischarge TcB values in the high-risk 
zone (≥ 95th percentile); of these, 39 (47%) had TsB levels at which phototherapy was recommended 
according the South African phototherapy guideline. A total of 131 (14%), 173 (19%) and 542 (58%) 
of infants had pre-discharge TcB measurements in the high-intermediate, low-intermediate and low 
risk zones, respectively.  
Incidence of severe hyperbilirubinemia: 
A total of 14 (0.75%) infants had severe hyperbilirubinemia at the time of readmission, 3 infants in 
the TcB arm and 11 in the visual inspection arm. The rate of severe hyperbilirubinemia was 
significantly lower with the use of TcB screening (RR 0.27, 95% CI 0.08 to 0.970. p= 0.05).  
Rate of Exchange transfusion 
Among those who were readmitted, all the infants in the TcB group required phototherapy and none 
met the threshold for exchange transfusion. Two infants who were readmitted in the visual inspection 
group required exchange transfusions. This difference was not statistically significant.   
Bilirubin induced neurologic dysfunction 
One infant in the visual inspection was identified that had clinical signs that could suggest bilirubin 
induced neurologic dysfunction. The baby was born at 36-week gestational age with a birth weight 
of 2440g, discharged home at 72 hours after delivery, and readmitted 2 weeks later for prolonged 
neonatal jaundice. On readmission, the baby was noted to have lost about 18% of the birth weight 
and had a high-pitched cry and a TsB of 459 mmol/l. No magnetic resonance imaging of the brain 
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was done and the long-term neurologic outcome for this infant is unknown. There was no documented 
case of infants showing neurologic dysfunction in TcB arm.  
TsB before discharge 
A total of 87 (9%) infants required TsB before discharge in the TcB group compared to 70 (7.5%) 
infants in the visual inspection group (RR 1.24, 95% CI 0.91 to 1.68, p=0.156). The difference was 
not statistically significant. 
Duration of hospital stay 
The median duration of hospital stay during the readmission period was similar in both groups. 
Median duration of hospital stay in the visual inspection group was 3 [interquartile range (IQR) 2-4] 
days compared to 3 (IQR 2-3) days in the TcB group. The Wilcoxon rank-sum (Mann-Whitney) test 
did not demonstrate any statistically significant difference between arms (p = 0.216) 
Discussion 
In this RCT involving indigenous African newborns recruited from a tertiary hospital in South Africa, 
we provide evidence for the effect of pre-discharge TcB screening on readmission for jaundice and 
incidence of severe hyperbilirubinemia. To our knowledge, this RCT is the first to evaluate the impact 
of TcB screening in an African population of newborns. We demonstrated that TcB screening for 
hyperbilirubinemia was superior in identifying apparently healthy newborns requiring phototherapy 
before hospital discharge compared to visual inspection. Earlier identification of hyperbilirubinemia 
combined with treatment with phototherapy during the initial birth hospitalization led to a reduction 
in readmission rate with the use of TcB screening. 
Unexpected readmission of a newborn after discharge from the newborn nursery is an indicator of 
inadequate assessment of the newborn’s readiness for discharge. For our study, we selected the 
readmission rate as a primary outcome. Though this index is often viewed from healthcare cost, 
epidemiological burden, societal burden of trust between healthcare provider and the family, it can 
have a direct personal disruption in the maternal and newborn experience [37-40]. 
In 2004, the American Academy of Pediatrics (AAP) recommended a patient-friendly systems 
approach that every newborn be assessed for the risk of developing severe hyperbilirubinemia, by 
using pre-discharge TsB or TcB measurements, a policy also endorsed by the Canadian Paediatric 
Society (CPS) [4,25,41]. After implementation of the AAP and CPS guideline, many studies in the 
USA and Canada have demonstrated that universal TcB or TsB reduced jaundice readmissions and 
led to a reduction in the incidence of severe hyperbilirubinemia [21-23,35,42,43]. Our study not only 
validates the finding from these studies, but also provides evidence that earlier identification of 
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hyperbilirubinemia with TcB screening and treatment with phototherapy is associated with a 
reduction in hospital readmission rate for hyperbilirubinemia and in the incidence of severe 
hyperbilirubinemia in an indigenous population of African newborns.  
Other studies from LMICs have evaluated the correlation of TcB compared to TsB measurement in 
newborns with different skin pigmentation. These studies have shown good correlation between TcB 
and TsB measurement in newborns with varying skin pigmentation. The studies have also shown that 
implementation of TcB screening is feasible in LMICs [44-52]. However, because of varying access 
to healthcare and differential risk in the polycultural community of LMICs, there are limited if any 
national policy outcome studies. Thus, we could not identify any studies from LMICs that evaluated 
the impact of TcB screening on readmission rate or incidence of severe hyperbilirubinemia. 
Our study has some important limitations. This study did not evaluate the impact of TcB screening 
on reducing the incidence of kernicterus. This would require a very large study and longer follow-up 
period. In our study, only one infant in the visual inspection arm was identified that had a clinical 
sign of probable kernicterus. Blood group type and the direct Coombs test for blood group 
incompatibility are not routinely done on all newborns in our study population. Therefore, we could 
not assess whether there was any difference in the rate of blood group incompatibility between the 
two study arms.  It was difficult to determine if the highest TsB that was recorded was prior to 
phototherapy initiation. In some facilities where the babies were readmitted, phototherapy was 
initiated before blood sample for TsB was collected. Therefore, the incidence of severe 
hyperbilirubinemia in the study population could be higher than reported in this study. Blood draw 
for TsB was also ordered at the discretion of the admitting physicians. This outcome is likely to be 
different if we limited blood sampling only to infants whose TcB value were >95th centile for their 
age. This study was conducted in a tertiary facility where some mothers were kept longer in hospital 
for other medical reasons and consequently the babies were kept longer with the mothers. This 
increased the length of stay for some babies, which could lead to a reduction in readmission because 
of the delayed discharge from the initial birth hospitalization. Therefore, the readmission rates 
reported are likely to be higher in the primary healthcare setting in South Africa where mothers 
without any complications after delivery are typically discharged within 12 hours of delivery. 
However, despite these limitations, we are confident in the findings from this study because of the 
unique design of the study compared to other non- randomized studies that have evaluated the similar 
outcomes [21-23,35,42,43]. We have provided evidence from a randomized controlled study. We 
used a proper method of randomization and allocation concealment using sealed opaque envelopes. 
Though this method of concealment of allocation is prone to deliberate tampering, the investigators 
ensured that the envelopes were only opened at the time of enrollment.  The study participants were 
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similar in the baseline characteristics. Even though the study personnel and participants were not 
blinded to the treatment allocation, the outcome assessors and statistician were blinded. Therefore, 
we are confident that reduction in hospital readmission rate and reduction in the incidence of severe 
hyperbilirubinemia was as a result of the TcB screening strategy in the treatment group.  
In conclusion, TcB screening with risk stratification using the Bhutani nomogram in newborn infants 
at risk of severe hyperbilirubinemia can help to reduce readmissions for jaundice and incidence of 
severe hyperbilirubinemia. Our study further confirms that visual inspection for jaundice is not a 
reliable way to assess for the presence or absence of hyperbilirubinemia in newborns. Universal TcB 
screening in all newborns before hospital discharge in South Africa and other African countries will 
be an important step towards reducing the burden and consequences of severe hyperbilirubinemia. 
However, the high cost of the current TcB devices could be a barrier to implementation of universal 
TcB screening in many LMICs. Each transcutaneous device cost between $4,000 and $7000 [53,53]. 
Therefore, nationally driven public-private solutions are warranted such that healthcare during the 
first week after a normal pregnancy is equitable. Industry and TcB manufacturers now have the moral 
responsibility to make over-priced transcutaneous devices safe, affordable and accessible.  
Reductions in the cost of readmission, cost of more intensive treatment and family integrity are real 
and need to be realized for all newborns worldwide. 
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Figure 1. Bhutani nomogram: Bhutani VK, Johnson L, Sivieri EM. Pediatrics. 1999;103 :6 –14 
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Figure 2: Participant study flow diagram 
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Table 1: Baseline characteristics: 
Variable TcB screening 
(N=929) 
Visual inspection 
(N=929) 
P value 
Gestational age 
(mean, SD) 
38.4 weeks (1.60) 38.3 weeks (1.60)  0.332 
< 37 weeks gestation  123 (13.2) 144 (15.5)  0.232 
≥37 weeks gestation 806 (86.8) 785 (84.5)  0.212 
Birth weight 
(mean, SD) 
3128 g (575) 3118 g (566) 0.709 
IUGR  106 (12.70) 118 (11.41) 0.393 
Male 485 (52.2) 480 (51.67) 0.816 
Race  
Black 590 (63.5) 585 (63.0) 0.320 
Mixed race 319 (34.3) 334 (36.0) 0.320 
White 15 (1.3) 8 (0.9) 0.320 
Others 3 (0.3) 2 (0.2) 0.320 
Breastfeeding 870 (93.65) 893 (96.12) 0.052 
Cephalohematoma 1 (0.11) 2 (0.22) 0.056 
Previous sibling with 
jaundice 
72 (7.75) 50 (5.38) 0.039 
Age at time of 
assessment (hours) 
31.1  31.9  0.283 
Mode of delivery  
NVD 492 (52.96) 510 (54.90) 0.287 
C/S 425 (45.75) 413 (44.46) 0.287 
Vacuum 12 (1.29) 6 (0.65) 0.287 
Mothers Rh status  
Rh negative 16 (1.72) 14 (1.51) 0.927 
Rh positive 871 (93.76) 874 (94.08) 0.927 
Unknown 42 (4.52) 41 (4.41) 0.927 
Mother’s blood group  
Group A 31 (3.34) 25 (2.69) 0.666 
AB 7 (0.75) 3 (0.32) 0.666 
B 16 (1.72) 16 (1.72) 0.666 
O 37 (3.98) 35 (3.77) 0.666 
NOTE: Data are no. (%) unless otherwise indicated. 
SD= Standard deviation. NVD= Normal vertex delivery, Rh= Rhesus 
IUGR: This was determined using the WHO published international growth standards for children younger 
than 5 years.  
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Abstract 
Neonatal jaundice is very common in the first two weeks after birth, with up to 60 percent of term 
infants manifesting jaundice. Not identifying hyperbilirubinemia requiring treatment in newborns 
prior to hospital discharge in a timely manner is a major cause of adverse outcomes of 
hyperbilirubinemia.  In many developing countries, there is no routine universal screening for 
hyperbilirubinemia using total serum bilirubin (TsB) or transcutaneous bilirubin (TcB) measurement. 
In these settings, jaundice in the newborns is assessed only by visual inspection before hospital 
discharge.  
We present the case of a black male baby who was born at term gestation and who was assessed to 
be ready for discharge from the well-baby nursery. Visual inspection revealed no evidence of 
jaundice. However, the infant was enrolled in a clinical trial on TcB screening and was identified to 
have high risk for hyperbilirubinemia on the Bhutani nomogram and met threshold for phototherapy 
as confirmed by the TsB. Based on visual inspection, this infant would have been discharged home 
inappropriately, highlighting the difficulty experienced by clinicians to assess for hyperbilirubinemia 
in dark skin infants in settings where there is no universal screening for hyperbilirubinemia in all 
newborns. The case also highlights that visual assessment for jaundice should not be relied upon to 
make assessment of hyperbilirubinemia in newborns before hospital discharge.  
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Introduction 
Jaundice is a traditional established clinical sign of hyperbilirubinemia and neonatal jaundice, mostly 
due to unconjugated hyperbilirubinemia is frequent in the first two weeks after birth, with up to 60 
percent of term and 80% of preterm infants manifesting jaundice. Serum unconjugated bilirubin levels 
peaks between ages 3 to 5 days, often in a home-setting. Thus, it is not unusual that one of the common 
reasons for hospital readmission in the first week of life is neonatal hyperbilirubinemia. The inability 
to identify and manage at-risk infants prior to hospital discharge in a timely manner has been cited as 
the major root cause of adverse outcomes of hyperbilirubinemia (1, 2).  
We present a case study of a 28-hour old infant in whom the predischarge visual assessment for 
jaundice completely underestimated and missed the presence of jaundice.   
Birth History 
The infant was born via spontaneous vaginal delivery to a 35-year-old primigravid mother at 41-week 
gestational age with a birth weight of 3.6 kg and APGAR scores were 9 and 10 at 1 and 5 minutes, 
respectively. The mother had an uneventful pregnancy and antenatal care with normal laboratory 
tests. She was Rh-D positive, her ABO blood type was unknown and her serology for syphilis and 
HIV were negative. There was no significant family medical history. After a one day (28 hours) stay 
in the well-baby nursery, he was presumably ready for discharge. Breastfeeding was appropriate at 
the time of discharge. 
Physical Examination  
On examination, the neonate was alert and active. He was afebrile with a heart rate of 140 bpm and 
respiratory rate of 48 breaths/min. He had no clinical signs of jaundice or dehydration or obvious 
infection. He had normal tone, symmetric Moro-, sucking and rooting reflexes. The anterior 
fontanelle was soft and there was no cephalohematoma. The cardiovascular, respiratory and 
abdominal examination were normal. There was no hepatosplenomegaly. The infant was assessed by 
the medical team prior to discharge. In the meantime, the mother was approached by our research 
team and she consented to enroll in an ongoing randomized transcutaneous bilirubin (TcB) screening 
trial that was evaluating the effect of pre-discharge TcB screening compared to visual inspection in 
newborn infants (3). By random allocation, the infant was allocated into the TcB screening arm.  
At this time, there was no clinical sign of jaundice (see image in Figure 1). The TcB measurement 
was 299 µmol/L taken at age 28 hours. Concurrent TsB data was available about 2 hours later and 
was 229 µmol/L. Both the TcB and TsB data plotted in high-risk zone on the Bhutani nomogram 
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(figure 2). In addition, the infant met the threshold for phototherapy (5, Figure 3). Despite receiving 
phototherapy, the baby’s TsB continued to rise and had a peak bilirubin level of 352 µmol/L on the 
third day of life and decreased to 247 µmol/L by day five of life.  
 
 
Figure 1. Baby’s photo at the time of discharge. (Photo taken with consent from the mother) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Bhutani nomogram: Bhutani VK, Johnson L, Sivieri EM. Pediatrics. 1999;103 :6 –14
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The baby was discharged home after 5 days of phototherapy and did not meet threshold criteria for 
an exchange transfusion. Investigations for a cause of the hyperbilirubinemiawas not initiated. The 
baby did not show any signs of acute bilirubin or post-icteric encephalopathy. 
 
Figure 3. Generated from bilitool.org: Based on the AAP Phototherapy Guidelines (5) 
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Discussion 
Most nurseries in developing countries discharge babies early and depend on visual assessment for 
jaundice, which has repeatedly been found wanting. Visual assessment is not adequate in identifying 
hyperbilirubinemia in newborns. This case report is one of several African babies, who were deemed 
ready for early discharge from hospital and in whom visual inspection missed the presence of 
significant jaundice, as confirmed by transcutaneous bilirubinometry and central laboratory, as part 
of a randomized controlled trial. The case again highlights the difficulty experienced by clinicians to 
diagnose jaundice in African infants. The baby would have been discharged home inappropriately, 
had he not been enrolled in the clinical study, and the outcome uncertain at best, depending on 
whether the mother would have returned to hospital around 72 hours of age.  
Severe hyperbilirubinemia continues to be the major reason for newborn readmissions in the first 
month of life. This could be as a result of early discharge and inappropriate identification of newborns 
who require phototherapy. Although kernicterus represents the worst outcome of the spectrum of 
hyperbilirubinemia in newborns, it is potentially preventable if jaundice is timeously diagnosed and 
managed. Kernicterus continues to be a cause of morbidity and mortality in many developing 
countries and resources constrained settings.  In South Africa, a retrospective study of exchange 
transfusion for hyperbilirubinemia in newborns over a period of 5 years showed that six out of 26 
(6/26; 23.0%) babies requiring exchange transfusion had signs of kernicterus (4).  
Hyperbilirubinemia may not be clinically apparent in newborns before hospital discharge, especially 
in very dark-skinned babies. This will result in inappropriate home discharge of newborns who 
require treatment for jaundice before discharge. Visual inspection for jaundice should not be relied 
on to assess hyperbilirubinemia in newborns. Objective screening assessments using risk factors and 
TcB measurement or TsB measurement can help to identify those who need treatment before 
discharge. This could help to reduce readmissions for hyperbilirubinemia and potentially eliminate 
kernicterus. Also, cheaper and more affordable point of care bilirubin testing devices will help to 
make bilirubin testing in newborns more feasible more available in resource constrained settings with 
limited access to laboratories or the current expensive TcB meters.  
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Abstract  
Background  
Jaundice is a very common condition in newborns, with up to 60% of term newborns and 80% of 
preterm newborns developing jaundice in the first week of life. Bilirubin measurement can be done 
formally by standard laboratory method which requires a blood sample to be sent to the laboratory. 
Noninvasive transcutaneous bilirubin (TcB) measurement devices are currently widely available and 
used in many settings for estimation of total serum bilirubin (TsB) levels. 
Objectives  
In this review we aimed to summarize the relevant available evidence on the accuracy of TcB 
compared to TsB measurement in newborns of various race, skin colour and settings. 
Search methods  
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2018, Issue 7), 
MEDLINE via PubMed (1966 to 22 August 2018), EMBASE (1980 to 22 August 2018), and 
CINAHL (1982 to 22 August 2018). We also searched clinical trials databases, conference 
proceedings, and the reference lists of retrieved articles for randomized controlled trials and quasi-
randomized trials. Two review authors independently examined the search output to identify studies 
and also did the data extractions. Risk of bias assessment using the QUADAS 2 tool was also done 
independently by two review authors. All disagreements were resolved by discussion or by contacting 
a third author. 
Selection criteria  
We included prospective studies that evaluated the accuracy of any TcB device compared to TsB 
measurement in the laboratory. In addition to reporting correlation coefficients comparing TcB and 
TsB, the studies have to report on other measures of accuracy such as sensitivities and specificities. 
We excluded all studies that only reported correlation coefficients.  
Data collection and analysis  
Two authors independently extracted data from the included studies using a standardized data 
extraction form. We summarized the available results narratively and where possible we combined 
study data in a meta-analysis.  
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Main results  
We included 54 studies that met our inclusion criteria. All the included studies were of acceptable 
methodological quality based on the QUADAS 2 tool. The studies compared the use of various TcB 
devices (including the Minolta Airshield JM 101, JM 102, JM 103, Bilicheck, Bilimed, Bilitest and 
JH2-1A), were conducted in different countries and settings, and included newborns of different 
gestational and postnatal age. For most of the studies, the TcB measurement was taken from the 
forehead or sternum. Almost all of the studies reported on correlation coefficients and all reported on 
some other measure of accuracy such as sensitivity and specificity. The correlation coefficients 
between TcB and TsB ranged from 0.45 to 0.987. The sensitivity and specificity of various TcB cut-
off values to detect significant hyperbilirubinemia ranged from 74% to 100% and 18% to 89% 
respectively. 
Authors' conclusions  
TcB devices reliably estimated TsB levels in term and preterm newborns and could help in reducing 
the blood sampling associated with performing TsB measurements.  
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Plain language summary  
Transcutaneous bilirubinometry versus total serum bilirubin measurement for newborns 
Jaundice is a very common problem in the newborn period and results from high levels of bilirubin 
in the blood known as hyperbilirubinemia. It is important to detect hyperbilirubinemia early in order 
to prevent adverse consequences of very high bilirubin levels such as brain damage in the newborn. 
We included studies that evaluated the use of any transcutaneous bilirubin (TcB) device compared to 
total serum bilirubin (TsB) measured in the laboratory. Findings from this review suggest that TcB 
measurement is a suitable alternative to TsB measurement in monitoring hyperbilirubinemia in 
newborn infants. This would save cost, time and invasive pricks to obtain blood from the newborn. 
TcB measurement is taken from the skin and does not require blood draw. Further studies may be 
needed to better understand the best site for TcB measurement and the reason for the difference if any 
in the measurement taken from the forehead and sternum. Also, further studies are needed to ascertain 
the impact of phototherapy on the accuracy of TcB measurement. The studies need to evaluate the 
optimal timing after phototherapy when the TcB reading can be compared to or becomes similar to 
TcB obtained in newborns without any prior exposure to phototherapy. 
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Background  
Target condition being diagnosed  
Hyperbilirubinemia is a term used to describe excess of bilirubin in the blood. In newborns, 
hyperbilirubinemia becomes clinically apparent as jaundice, a yellow coloration of the skin and sclera 
(Woodgate 2015). Hyperbilirubinemia is very common in both term and preterm newborn infants 
(occurring in about 60% of newborns) and results from a predisposition to the production of bilirubin 
and their limited ability to excrete it (Lauer 2011). Most cases of newborn jaundice are mild and 
resolve spontaneously (Srgo 2006). However, in rare cases babies can have very high levels of 
bilirubin that can lead to bilirubin encephalopathy and kernicterus (Ebbesen 2005; Srgo 2006). The 
acute phase signs of kernicterus are poor feeding, lethargy, high-pitched cry, hypertonia or hypotonia, 
opisthotonos and seizures (Johnson 2002). The chronic manifestations include athetoid cerebral 
palsy, motor delay, gaze palsy, dental dysplasia, mental retardation and sensorineural hearing loss 
(AAP 2004). Studies from developed countries estimate the incidence of kernicterus to range from 
about 0.4 to 2 per 100,000 newborns (Srgo 2006; Mannig 2007; Burke 2009). However, studies from 
developing countries suggest that the incidence may be much higher (Nair 2003; Owa 2009). 
Following guidelines issued by the American Academy of Pediatrics for the management of jaundice 
in the neonate (AAP 2004), the age-long critical cut-off value of total serum bilirubin (TsB) of 20 
mg/dL (342 µmol/L) at which therapy was required is being replaced by a plot of TsB against time 
(hours) for each baby. This is compared to the nomogram for the age of the baby and used to 
determine the line of management (Higgins 2012). Current treatments for hyperbilirubinaemia 
include phototherapy and exchange transfusion, which is usually used for severe cases of 
hyperbilirubinaemia (Woodgate 2015). 
Index test(s)  
Transcutaneous bilirubin (TcB) measurement is a non-invasive method for estimating total serum 
bilirubin (TsB) level (Dai 1997). Transcutaneous bilirubinometry works by directing light into the 
skin and measuring the intensity of the wavelength of light that is returned (Boo 2007). 
Transcutaneous bilirubinometry is based on optical spectroscopy, which relates the amount of light 
absorption by bilirubin to the concentration of bilirubin in the skin. The technology was first 
introduced in 1980 (Yamanouchi 1980). The measurement is usually taken by gently pressing the 
meter against the sternum or forehead. TcB measurement provides an immediate (less than a minute) 
result of bilirubin levels (Dai 1997). Using this point-of-care device saves time compared to 
measuring TsB and may reduce costs associated with measuring TsB in newborns (Maisels 1997). 
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However, the accuracy of TcB results may be affected by gestational age, body weight and skin color 
(Knüpfer 2001; Karen 2009). For example, TcB tends to underestimate TsB in light and medium skin 
colors and overestimates in dark skin color (Samiee-Zafarghandy 2014). There are a number of TcB 
devices currently available in the market (Grohmann 2006). 
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Clinical pathway  
Newborns are routinely monitored by nursing staff and physicians for the development of jaundice 
in the first few hours of life and before discharge from the newborn nursery. This is usually done by 
visual inspection and skin blanching to assess for yellowish discoloration. Visual estimation of 
bilirubin level is not reliable (Barrington 2012). Therefore, bilirubin level needs to be assessed 
objectively by means of a TcB or TsB measurement. In some settings, TcB or TsB measurements are 
performed on all newborns as part of routine screening before hospital discharge or as targeted 
screening based on risk factors for severe hyperbilirubinemia. Some of the risk factors include 
breastfeeding, ABO/Rhesus incompatibility, glucose-6-phosphate dehydrogenase deficiency, use of 
oxytocin during delivery, vacuum-assisted delivery, prematurity, and history of jaundice in a sibling 
(AAP 2004; Keren 2005; Bhutani 2010). TcB or TsB measurement can be done as part of universal 
screening or only if a newborn is visibly jaundiced and the value is plotted on a nomogram to assess 
the need for treatment (AAP 2004). In addition, the measurements may be taken on newborns 
undergoing phototherapy to help in deciding on when to stop treatment. The bilirubin levels are 
interpreted based on the infant's gestational age and postnatal age (AAP 2004).  
Role of index test(s)  
The TcB assay is a non-invasive method for measuring bilirubin levels and it may help to reduce the 
risk of anemia and trauma associated with blood sampling for TsB measurement (Dai 1997). TcB has 
been shown to work well in both hospital and outpatient settings; and has been shown to be better 
than visual inspection for estimation of hyperbilirubinemia (De Luca 2008; Wainer 2012). 
Additionally, the TcB measurement ensures a readily available result for immediate clinical decision-
making while reducing the chances of infections associated with all invasive procedures (Jangaard 
2006). The TcB meter can be used as a screening tool to estimate the TsB level in newborns who are 
not clinically jaundiced or as a diagnostic tool in jaundiced newborns to assess the need for treatment 
(AAP 2004). 
Alternative test(s)  
Various methods are used to determine bilirubin levels in newborns. These include visual assessment, 
direct spectrophotometric methods (requiring capillary blood) and use of an icterometer (Higgins 
2012). Visual assessments for jaundice are common in newborn nurseries and outpatient settings, 
such as physicians' offices (Harrison 1989). However, studies have shown that the severity of jaundice 
cannot be assessed through visual estimation. The icterometer is a specialized ruler marked with 
different shades of yellow used to estimate the bilirubin level when pressed against a newborn’s skin 
(Akman 2000). 
Stellenbosch University  https://scholar.sun.ac.za
94 
 
Rationale  
Bilirubin measurement is one of the most frequently performed tests in newborn infants (Donzelli 
2000; Madsen 2000). Chemical methods for TsB measurement are currently the reference standard 
for measuring bilirubin levels. However, this requires repeated blood sampling which can be painful 
to the newborn, costly and time consuming. TcB measurement has been recommended as a more 
cost-effective and less traumatic method of measuring bilirubin levels in newborns (Dai 1996). In 
order to justify routine use of TcB devices, we need to systematically review all the available evidence 
from well-designed studies on the accuracy of TcB measurements compared to TsB measurement in 
newborn infants. A clear understanding of the diagnostic test accuracy of transcutaneous 
bilirubinometry using a variety of instruments in a variety of populations (including preterm and term 
infants as well as infants with various racial backgrounds) would be invaluable for understanding the 
usefulness of TcB measurement in newborns. 
Objectives  
1. To determine the diagnostic accuracy of TcB  compared with TsB as: 
a) a diagnostic test for hyperbilirubinaemia in newborns suspected to have hyperbilirubinaemia 
on visual inspection; 
b) diagnostic test for monitoring bilirubin levels in newborns receiving treatment (e.g. 
phototherapy) for hyperbilirubinaemia. 
2) To determine whether the gestational age, postnatal age, body weight, race and site of TcB 
measurement have any influence on the accuracy of TcB measurement for hyperbilirubinaemia 
in newborns. 
Methods  
Criteria for considering studies for this review  
Types of studies  
We included diagnostic test accuracy studies comparing TcB and TsB measurement for 
hyperbilirubinemia in newborns, as follows. 
• Cross-sectional studies. 
• Cohort studies. 
We excluded all randomized controlled trials, retrospective studies, case-control studies, case reports 
and any studies in which data for true positives, true negatives, false positives and false negatives 
could not be determined or studies that only reported correlation coefficients between TcB and TsB. 
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Participants  
We included studies evaluating infants aged 0 to 29 days (including term or preterm newborns) who 
required bilirubin measurement either as a universal screening test or a test for visible jaundice or for 
monitoring therapy for hyperbilirubinemia. We included studies conducted in different patient 
settings such neonatal intensive care units, pediatric emergency units, pediatric wards and studies that 
recruited participants from home or in the communities. 
Index tests  
The index test is TcB measurement in newborns with the use of any TcB device. 
Target conditions  
The target condition is hyperbilirubinemia requiring treatment either by phototherapy or by exchange 
transfusion. 
Reference standards  
The reference standard is TsB measured in the laboratory, which requires blood sampling from the 
newborn. TsB measurement can be performed in the laboratory using various methods such as high 
performance liquid chromatography (HPLC), Diazo-based methods, or other methods such as direct 
spectrophotometric methods (Kazmierczak 2002) and capillary electrophoresis (Higgins 2012). TsB 
measurement by the HPLC method is not subject to interference from hemoglobin or lipemia. 
However, this method is costly, labor-intensive and not practical for routine use (Kazmierczak 2004). 
The Diazo-based methods are the most frequently used laboratory assays but may be affected by 
hemolysis (el-Beshbishi 2009). TsB measurement requires drawing of blood causing pain and trauma 
to the neonate. Repeated blood sampling for TsB measurement can cause anemia, especially in 
preterm neonates. Inter- and intra-laboratory variability has been reported with measurements of TsB 
(Lo 2011). 
Search methods for identification of studies  
We used the standard search strategy of the Cochrane Neonatal Review Group to identify all relevant 
studies without any language restriction. Methodological filters for diagnostic studies was not used, 
to avoid missing out on some relevant studies. We attempted to get help with translation for articles 
published in other languages but in the end did not include any of these articles if we could not get a 
translation. We recorded any article for which we could not get a translation in the section 
'Characteristics of studies awaiting classification'
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Electronic searches  
We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see the Cochrane 
Neonatal search strategy for specialized register). 
We conducted a comprehensive search including: Cochrane Central Register of Controlled Trials 
(CENTRAL 2017, Issue 7) in The Cochrane Library; MEDLINE via PubMed (1966 to 22 August 
2017); EMBASE (1980 to 22 August 2017); and CINAHL (1982 to 22 August 2018) using the 
following search terms: ((transcutaneous adj2 bilirubin) OR TcB OR bilicheck OR bilichek OR JM-
103 OR JM-105 OR bilirubinomet*) AND (((blood* or serum) adj bilirubin) OR TsB OR 
spectrophotomet*).mp AND (human not animal), plus database-specific limiters for neonates (see 
Appendix 1 for the full search strategies for each database). We did not apply language restrictions. 
We searched clinical trials registries for ongoing or recently completed trials (clinicaltrials.gov; the 
World Health Organization’s International Trials Registry and Platform 
www.whoint/ictrp/search/en/, and the ISRCTN Registry). 
Searching other resources  
We screened the reference lists of any relevant reviews from DARE and MEDION for potentially 
eligible studies. 
Data collection and analysis  
Selection of studies  
Two review authors (CO and OA) independently assessed eligible articles for inclusion from the titles 
and abstracts obtained in the initial search. We resolved any disagreement through discussion or, if 
necessary, by involving a third review author. 
Data extraction and management  
Two review authors (CO and OA) independently extracted data on study characteristics using a 
standard data extraction form. Where possible we computed 2 × 2 tables of true positives, false 
positives, true negatives and false negatives, for the index tests at the thresholds reported in the 
primary study. For each included study, we extracted information on the first author's last name and 
year of publication; study country or race; gestational age of included newborns, number of enrolled 
infants and number of paired TcB and TsB, type of TcB device and site of measurement, time interval 
between TcB and TsB measurement; prior use of phototherapy and accuracy results (including 
correlation coefficients and sensitivities and specificities). The information we extracted from each 
study is presented in Table 1.
Stellenbosch University  https://scholar.sun.ac.za
97 
 
Table 1: Summary of study characteristics and results (n=54) 
 
Study ID Ethnicity or 
Race 
Gestation & 
postnatal 
age  
Sample size 
and number 
of paired 
results 
TcB device 
and site of 
measurement 
TsB measurement 
and time interval 
Indication for 
bilirubin 
Phototherapy use Results 
Ahmed 2010 Caucasians, 
Indian and 
mixed ethnicity 
Preterm < 35 
weeks 
57 newborns 
and 183 paired 
results 
Bilicheck.  
Forehead 
Diazo method 
 
Within 30 minutes 
Clinical jaundice Both infants with and 
without prior 
phototherapy use 
r = 0.8965, P, 
Area under ROC curve 
0.8423 
Akahira-
Azuma 2013 
Mongolia, race 
not described 
Late preterm 
and term ≥ 
35 weeks 
53 newborns 
and 57 paired 
samples 
JM 103.  
Sternum and 
Forehead 
Photometric method. 
Within 3 hours 
Clinical jaundice No prior phototherapy use TcBf, r= 0.888 
TcBs, r=0.886  
 
AUC from 
0.909 at 0.987 for 
different TsB values 
(>10, >13 and >15 
mg/dL) 
Bental 2009 Mixed 
(Ashkenazi and 
Sephardic 
Ethiopian) 
Late preterm 
and term ≥ 
35 weeks 
628 newborn 
and 1091 
paired samples 
JM 103.  
Sternum and 
Forehead 
Colorimetric method. 
Within 90 minutes 
Clinical jaundice No prior phototherapy use r= 0.846 
AUC were 
0.969, 0.971 & 0.987 for 
TsB values >10, >13 and 
>15 mg/dl respectively.  
Bertini 2008 Italian/White Preterm and 
term 
newborns > 
32 weeks 
241 newborns 
and 241 paired 
samples. 
Bilitest BB 
77. 
Forehead 
Spectrophotometric 
method. Within 10 
minutes.  
Clinical jaundice No prior phototherapy use r= 0.830 
AUC were 
0.851, 0.63 & 0.939 for 
TsB values >11, >13 and 
>15 mg/dl respectively. 
Bhutani 2000 USA/ Mixed 
(white, black, 
hispanics) 
Late preterm 
and term ≥ 
35 weeks. 
 
12 to 98 
hours 
517 newborns 
and 1788 
paired samples 
Bilicheck. 
Forehead 
HPLC. Within 30 
minutes 
Clinical jaundice No prior phototherapy use r= 0.91 
white: r=0.91 
Blacks: r= 0.91 
Hispanics: r= 0.93 
Asian and others: r=0.90 
Bhutta 1991 Pakistani 
newborns, race 
not specified 
Term and 
preterm> 34 
weeks  
63 newborns 
and 100 paired 
samples 
JM 101. 
Forehead 
Photometric method 
with 2 hours 
Clinical jaundice No prior phototherapy use r= 0.66 
TcB cut-off of 17 detects 
TsB > 12.5 with 
sensitivity and specificity 
of 88 & 53% 
respectively. 
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Bilgen 1998 Turkish 
newborns, race 
not specified 
Term 
newborns ≥ 
37 weeks, 1 
to 5 days of 
life 
96 newborns 
and 96 paired 
samples 
JM 101. 
Forehead 
Direct 
spectrophotometric 
method within 30 
minutes.  
Clinical jaundice No prior phototherapy use r= 0.83 
TcB cut-off of 13 detects 
TsB > 12.9 with 
sensitivity and specificity 
of 100 & 56% 
respectively 
Boo 2007 Malay, Chinese 
and Indian 
newborns 
Term 
newborns ≥ 
37 weeks, 1 
to 5 days of 
life 
345 newborns 
and 345 paired 
samples 
Bilichek. 
Forehead and 
sternum. 
Direct 
spectrophotometric 
method within 30 
minutes. 
Clinical jaundice No prior phototherapy use TcBf, r= 0.80 
TcBs, r= 0.86 
TcBf cut-off of 250 
μmol/L, the Bilicheck 
detected TsB ≥ 300 
μmol/L with a sensitivity 
of 100% & specificity of 
39.2%, At TcBs cut-off 
of 200 μmol/L, the 
Bilicheck 
detected TsB ≥ 300 
μmol/L with a sensitivity 
of 100% and a specificity 
of 33.6%. 
Campbell 
2011 
Canada, diverse 
population 
(whites, blacks, 
Asian, Indian, 
Latino) 
Late preterm 
and term ≥ 
35 weeks 
430 newborns 
and 430 paired 
samples.  
Bilichek. 
Forehead 
Direct 
spectrophotometric 
method within 30 
minutes. 
Clinical jaundice No prior phototherapy use To detect a TsB of 
200 μmol/L, a TcB value 
of 180 μmol/L would 
provide 96% sensitivity 
and 55% specificity. 
To detect a TsB 
value of 250 μmol/L, a 
TcB of 200 μmol/L 
would provide 96% 
sensitivity 
and 57% specificity. 
Chimhini 
2018 
Zimbabwe, Black Preterm and 
term infants 
between 28 
and 42 
weeks, 0-10 
days of life  
283 newborns 
and 283 paired 
samples.  
JM 103, 
forehead and 
sternum  
Diazo within 30 
minutes. 
Clinical jaundice 
with no prior 
phototherapy 
No prior phototherapy use TcBf, r = 0.72 
TcBs, r= 0.77 
 
Christo 1988 South Indian Term and 
preterm 
newborns 
138 newborns 
and 138 paired 
samples 
JM 101, 
forehead and 
sternum and 
average of the 
two readings 
Spectrophotometric 
method within 30 
minutes. 
Infants from 
whom blood 
specimen was 
drawn for bilirubin 
or other reasons 
Infants with and without 
prior phototherapy use  
r= 0.90  
TcB cut off of 18 mg/dl 
detects TsB > 13 mg/dl 
with 95% sensitivity and 
83% specificity.  
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De Luca 
2007 
Caucasian  Preterm 
newborns, 30 
to 36 week 
gestation 
340 newborns 
and 340 paired 
results 
Bilicheck, 
forehead 
Spectrophotometric 
method within 10 
minutes. 
Universal 
screening of all 
newborns 
No prior phototherapy use r= 0.795. 
TcB cut-off values were 
111 umol/l for TsB > 171 
Amol/l (sensitivity 
100%; specificity 40%) 
and 171 umol/l 
for TsB >205 Amol/l 
(sensitivity 100%; 
specificity 72%). 
De Luca 
2008 
Italy, Caucasian  Term and 
preterm 
newborns > 
34 week 
gestation 
686 newborns 
and 686 paired 
results 
BiliMed and 
Bilicheck, 
forehead 
Spectrophotometric 
method within 15 
minutes. 
Clinical jaundice No prior phototherapy use BiliMed, r= 0.45 
Bilicheck, r= 0.75 
To identify TsB levels > 
205.2 mmol/l, BC 
cut-off values are 116.3 
mmol/l (sensitivity 99%; 
specificity 20%) 
while for BM 
they are 85.5 mmol/l 
(sensitivity 99%; 
specificity 13%)  
Donzelli 
2000 
Italy, Caucasian  Preterm 
newborns, 
24-36 weeks 
gestation 
70 newborns, 
number of 
paired samples 
not specified 
JM 102, 
sternum 
Spectrophotometric 
method within 10 
minutes. 
Clinical jaundice Both patient with prior 
and without prior 
phototherapy use 
r=0.84 
TcB index of 18 gave a 
Specificity and positive 
predictive value were 
64% and 54%, 
respectively.  
 
Engle 2002 Hispanic and 
nonhispanic 
Term and 
late preterm 
newborns ≥ 
35 week 
gestation 
304 newborns 
and 404 paired 
comparisons 
Bilichek, 
forehead 
Diazo method within 
30 minutes. 
Clinical jaundice No prior phototherapy use r= 0.84 
The authors reported 
different sensitivities and 
specificities with 6 
different cut offs for TcB 
measurement.  
Engle 2005 Hispanic Term and 
late preterm 
newborns ≥ 
35 weeks 
121 newborns 
and 121 paired 
samples. 
JM 103, 
sternum 
Diazo method within 
30 minutes. 
clinical jaundice No prior phototherapy use R=0.77 
The authors reported 
different sensitivities and 
specificities with 6 
different cut offs for TcB 
measurement. 
For TsB 
>17 mg/dl and a JM 
cutoff value of 13 mg/dl, 
sensitivity was 100%, 
specificity of 58%.  
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Fok 1986 Chinese 
newborns 
Term 
newborns ≥ 
37 week 
gestation 
259 newborns 
and 705 paired 
comparisons 
JM 101, 
Forehead and 
sternum 
Spectrophotometric 
method within one 
hour. 
Clinical jaundice Both patient with prior 
and without prior 
phototherapy use 
TcBs, r = 0.91 
TcBf, r= 0.86 
The sensitivity and 
specificity, the forehead 
TcBf index ≥ 22 has a 
sensitivity OF 100% and 
specificity 20 % to detect 
TsB   ≥ 255 μmol/l (15 
mg/dl). 
Harish 1998 North Indian 
newborns 
Term and 
preterm 
newborns > 
30 weeks.  
2 to 20 days 
145 newborns. 
Number of 
paired 
comparisons 
not mentioned. 
JM 101, 
forehead 
Not described Clinical jaundice Both patient with prior 
and without prior 
phototherapy use 
r = 0.71 
The sensitivity and 
specificity, the forehead 
TcBf index ≥ 18 has a 
sensitivity of 97.3% and 
specificity 50 % to detect 
TsB   ≥ 13 mg/dl. 
 
Hemmati 
2013 
Iranian newborns Mostly term 
and late 
preterm ≥ 35 
weeks, ≤ 35 
weeks (only 
5 patients) 
560 newborns. 
Number of 
paired 
comparisons 
not mentioned. 
Bilicheck, 
forehead 
Spectrophotometric 
and Diazo method 
Clinical jaundice No prior phototherapy use r= 0.969 
A TcB cut-off value of 
15mg/dl detected TsB 
>15 mg/dl with 
sensitivity and specificity 
of 96.6% and 99% 
respectively. 
Ho 2006 Chinese 
newborns 
Term ≥ 37 
weeks and 
preterm > 32 
weeks. 
2 to 9 days 
83 newborns 
(77 term and 6 
preterm), 
number of 
paired 
comparisons 
not reported. 
Bilicheck,  
JM 102, 
forehead & 
sternum  
Spectrophotometric 
and Diazo method 
Clinical jaundice No prior phototherapy use JM 102, TcBf, r= 0.718 
& TcBs, r= 0.814 
Bilicheck, TcBf, r= 0.757 
& TcBs, r=0.794 
 
JM 102, a cut-off point 
of 20 at the forehead and 
21 at the sternum 
produced a 
specificity of 50% and 
78%, respectively with a 
sensitivity 
of 100%. For BiliCheck, 
a cut-off point of 250 
μmol/L on the forehead 
and 260 μmol/L on the 
sternum produced a 
specificity of 61.9% and 
70.0%, respectively with 
a sensitivity of 100%. 
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Holland 2009 Race was 
recorded for 
83.8%, consisting 
of 27.1% 
Caucasian, 54.7% 
Hispanic, 16.0% 
African 
American, and 
2.2% other races 
Term and 
preterm 
newborns > 
36 weeks, 1-
5 days old 
343 newborns 
with 343 paired 
comparisons 
Bilicheck, 
forehead and 
sternum 
Diazo Indication for 
bilirubin 
measurement not 
mentioned 
No prior phototherapy use The study reported 
multiple correlation 
between TcB and TsB 
were similar for all 
laboratory methods and 
TcB measurement sites.  
 
Karolyi 2004 Caucasian Preterm 
newborns 23 
to 33 weeks 
124 newborns, 
124 paired 
comparisons 
JM 102, 
sternum 
Photometric method 
within 10 minutes 
Routine bilirubin 
measurement 
No prior phototherapy use 
or at least 6 hours after 
phototherapy use. 
R=0.68 
 TcB cut-off 
reading of 14 detected  
hyperbilirubinemia ≥ 
150umol/l with a 
sensitivity of 100%  
and a specificity of 34% 
 
Karon 2008 146 Caucasian, 
19 Asian, 9 
Hispanic, and 3 
African 
American 
Term and 
late 
newborns > 
32 weeks  
177 newborns, 
177 paired 
comparisons.  
8 to 81 hours 
Bilichek, 
forehead 
Diazo and Vitros 
method within 30 
minutes.  
Clinical jaundice No prior phototherapy R= 0.65 (Diazo) and r= 
0.66 (Vitros). TcB risk 
was in a higher risk zone 
in 128 (72.3%) of 177 
neonates compared with 
the diazo TsB, while the 
TcB was in a higher risk 
zone for 68 (51.9%) of 
131 neonates compared 
with the Vitros TsB. 
Karrar 1989 Saudi newborns Term 
newborns ≥ 
37 week 
gestation and 
4 to 10 days 
of life. 
155 newborns 
and 155 paired 
comparisons  
JM 101, 
forehead 
American optical 
bilirubinometer, 
Time interval was not 
mentioned (but 
probably within 30 
minutes) 
Clinical jaundice No prior phototherapy r= 0.817 
At a cut-off TcB index of 
21, the device had 
sensitivity of 74% and 
specificity of 90% to 
detect TsB ≥ 12.5 mg/dl 
Kaynak-
Turkmen 
2011 
Turkish 
newborns 
Term and 
preterm ≥ 30 
weeks. 
3 to 19 days 
of life. 
54 newborns 
and 54 paired 
comparisons 
Bilicheck, 
forehead 
HLPC, Diazo method, 
BR 501 
bilirubinometer 
Indication for 
bilirubin 
measurement not 
mentioned. 
No prior phototherapy There was good 
correlation between 
TcB and HPLC-bilirubin 
(B) (r=0.85). 
The cut-off limits 
providing a sensitivity of 
100% for TcB 
measurements were TcB 
≥9 mg/dl for 
HPLC-B >17 mg/dl and 
TcB ≥8 mg/dl for HPLC-
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B >15 mg/dl and HPLC-
B 
>13 mg/dl. 
Kitsommat 
2013 
Asian newborns 
(not specified) 
Term and 
late preterm 
newborns 
age 5-14 
days of life 
405 newborns 
and 455 paired 
comparisons 
Konica 
Minolta JM-
103 
Diazo method within 
30 minutes 
Clinical jaundice No prior phototherapy use 
or at least 24 hours after 
phototherapy use. 
r=0.80 
To detect a TsB level of 
≥255 μmol/L, using the 
TcB cutoff level of 204 
μmol/L 
provides a sensitivity of 
96 % with a specificity of 
58 %. 
Knupfer 2001 128 Caucasians 
and 7 Asians 
Preterm 23-
36 weeks. 2 
to 6 days of 
life. 
135 newborns 
and 400 paired 
comparisons 
Bilicheck, 
forehead 
Diazo method, time 
interval not mentioned 
Indication for 
bilirubin 
measurement not 
mentioned. 
Newborns without prior 
phototherapy and with 
phototherapy were 
included 
The sensitivity and 
specificity of TcB to 
detect TsB above 
treatment threshold were 
78.0 and 72.5 
respectively 
Kolman 2007 Hispanics Term and 
late preterm 
newborns > 
35 weeks 
gestations. 0 
to 144 hours 
of life. 
192 newborns 
and 192 paired 
comparisons 
Bilicheck, 
forehead 
Diazo within 30 
minutes.  
Universal bilirubin 
screening 
No prior phototherapy r=0.870 
A TcB level above the 
75th percentile detected 
all 
infants with a TsB level 
above the 95th percentile, 
sensitivity 100%, and 
specificity 66%. 
Laeeq 1993 Pakistani 
newborns 
Term 
newborns ≥ 
37 weeks 
105 newborns, 
number of 
paired 
comparisons 
not mentioned 
JM101, 
forehead, 
sternum and 
chest 
Diazo method within 
30 minutes. 
Indication for 
bilirubin 
measurement not 
stated 
No prior phototherapy use r=0.774 
TcB sensitivity was 90%, 
specificity 78% and 
positive predictive value 
64% at mean TsB of 9.92 
mg/dl 
Lam 2008 Chinese 
newborns 
Term and 
late preterm 
>35 weeks 
gestation 3 to 
7 days of 
life. 
113 newborns 
and 113 paired 
comparisons 
JM 103, 
forehead and 
sternum 
Spectrophotometric 
method within 5 
minutes 
Clinical jaundice No prior phototherapy use TcB cut-off of 230 
μmol/L (13.5 mg/dl) and 
298 μmol/L (17.7mg/dl) 
have 100% sensitivity 
and specificity 
respectively, to predict a 
total TsB level of higher 
than 250 μmol/L. The 
area under the curve was 
0.822. JM-103 tended to 
overestimate the TsB; the 
bias was around 14 
μmol/L. 
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Leite 2007 White (66.5%), 
mixed race 
(23.5%) and 
black (10%) 
Term and 
preterm 
newborns < 
36 weeks, 
postnatal age 
< 3 days and 
≥ 3 days 
200 newborns 
and 200 paired 
comparisons 
Bilicheck,  Spectrophotometric 
method within 30 
minutes 
Indication for 
bilirubin 
measurement not 
stated 
37.5% were on 
phototherapy and 62.5% 
had no prior phototherapy 
use.  
r= 0.92 
TcB cut-off 14 mg/dL 
had sensitivity of 88.2% 
and specificity 97.8%.   
Lin 1993 Chinese 
newborns 
Term 
newborns ≥ 
37 weeks  
305 newborns 
and 444 paired 
comparisons 
Minolta 
Airshield, 
forehead and 
sternum 
Spectrophotometric 
method within 30 
minutes 
Indication for 
bilirubin 
measurement not 
stated 
No prior phototherapy use TcBf, r= 0.82 
TcBs, r= 0.86 
The sensitivity and 
specificity of TcBf to 
detect TsB > 12.9mg/dl 
were 68% and 80 % 
respectively.  
The sensitivity and 
specificity of TcBs to 
detect TsB > 12.9mg/dl 
were 84% and 84% 
respectively. 
Maisels 1982 White newborns Term 
newborns ≥ 
37 weeks 
157 newborns 
and 292 paired 
comparisons 
JM 101, 
forehead and 
sternum 
Diazo method within 
30 minutes 
Bilirubin 
measurement was 
obtained routinely 
on all infants 
expect 11 infants 
where it was 
obtained on 
clinical grounds 
No prior phototherapy use TcBf and TcBs, r= 0.93 
The authors report 
different sensitivities and 
specificities for different 
TcB cut-offs.  
TcBf index of 24 had 
sensitivity and specificity 
of 100% and 97% 
respectively to detect 
TsB> 12.9 mg/dl. 
TcBs index of 23 had 
sensitivity and specificity 
of 100% and 96% 
respectively to detect 
TsB> 12.9mg/dl. 
Maisels 2004 White (59.2%), 
black (29.8%), 
East 
Asian (4.5%), 
Middle Eastern 
(3.8%), 
Indian/Pakistani 
(1.6%), and 1.1% 
Hispanic. 
Term and 
late preterm 
newborns 
>35 weeks 
849 newborns 
and 849 paired 
comparisons 
JM 103 and 
Bilicheck, 
forehead and 
sternum 
Not specified.  
 
Clinical jaundice No prior phototherapy use TcBf, r=0.914 
TcBs, r=0.953 
 
The areas under the ROC 
for different JM-103 
cutoff values when TsB > 
10 mg/dL, >13 mg/dL, 
and >15 mg/dL were 
0.962, 0.963, 0.975, 
respectively.  
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Maisels 2011 Mixed-race 
population ( 
primarily 
Caucasian and 
Hispanic, 
followed by 
Asian and 
African 
American 
infants) 
Term and 
late preterm 
newborns 
>35 weeks 
120 newborns 
and 120 paired 
comparisons 
JM 103, 
sternum 
Diazo within 30 
minutes 
Clinical jaundice No prior phototherapy use r=0.78 
Different sensitivities and 
specificities for different 
TcB cut of values and  
TcB cut-off of 13 
detected TsB 15 mg/dl 
with 99% sensitivity and 
44%. 
Neocleous 
2014 
White newborns Term 
newborns ≥ 
37 weeks. 24 
to 96 hours 
222 newborns 
and 368 paired 
samples. 
Bilicheck, 
forehead 
Direct 
spectrophotometric 
method within 20 
minutes 
Clinical jaundice Prior use of phototherapy 
was not mentioned 
r=0.439 
To detect a TsB value of 
205 μmol/l, a TcB value 
of 207 μmol/l would 
provide 95.4% sensitivity 
and 18.6% specificity 
(positive predictive value 
would be 79.4% and 
negative predictive value 
55.2%). Similarly, to 
detect a TsB value of 240 
μmol/l, a TcB of 265 
μmol/l would provide 
22.5% sensitivity and 
94.2% specificity 
Panburana 
2010 
Thailand 
(specific race not 
mentioned) 
Term and 
late preterm≥ 
35 weeks. 24 
to 130 hours 
74 newborns 
and 224 paired 
comparisons 
JM 103, 
forehead 
Method for TsB 
measurement was not 
reported 
Clinical jaundice  Newborns without prior 
phototherapy and with 
phototherapy were 
included 
r= 0.81 
The authors reported 
different sensitivities and 
specificities for before 
and during phototherapy 
use. 
TcB accurately predicted 
different levels of TsB 
before phototherapy use.  
Qualter 2011 Ireland (97.7% 
Caucasian) 
Term and 
late preterm≥ 
35 weeks. 18 
to 124 hours 
84 newborns 
and 84 paired 
comparisons 
Bilicheck and 
JM 103, 
forehead 
Diazo method within 
30 minutes 
Clinical jaundice No prior phototherapy use Bilicheck, r= 0.88 
JM 103, r= 0.70 
100% sensitivity was 
achieved using the 75th 
percentile on Bhutani 
nomogram 
for BiliCheck 
and the 40th 
percentile for JM 103 
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Raimondi 
2012 
Caucasian and 
black newborns. 
Term and 
late preterm≥ 
35 weeks 
289 newborns 
and 343 paired 
comparisons 
JM 103, 
Bilicheck and 
Bilimed, 
forehead 
Direct 
spectrophotometric 
method, within 20 
minutes 
Clinical jaundice Phototherapy use was not 
mentioned 
Correlations coefficients, 
r, were 0.85, 0.86 and 
0.70 for JM 103, 
Bilicheck and Bilimed 
respectively. The 
corresponding area under 
the ROC curves when 
TsB>14 mg/dl were 0.92, 
0.95 and 0.75 
respectively.  All devices 
showed tendency to 
overestimate at higher 
levels of TsB.  
Rodríguez-
Capote 2009 
Caucasian and 
non-Caucasian 
Term and 
late preterm≥ 
35 weeks 
154 newborns 
and 154 paired 
comparisons 
JM 103 and 
Bilicheck, 
forehead 
Diazo method, within 
30 minutes 
Routine bilirubin 
measurement 
No prior phototherapy use Correlations coefficients, 
r, were 0.85 and 0.86 for 
JM 103 and Bilicheck 
respectively.  
Applying the risk 
classification using the 
40th, 75th, and 95th 
percentile of the Bhutani 
nomogram a 6%, 0%, 
and 1% false negative 
rate was found for 
BiliCheck and 62%, 74% 
and 81% for the Minolta 
Air-Shields JM-103. 
Both devices showed 
tendency to 
underestimate TsB. 
Rubaltelli 
2001 
white,  
Asian, Hispanic, 
African, and 
other races. 
Term and 
preterm > 30 
weeks and 0 
to 28 days of 
life 
210 newborns, 
number of 
paired 
comparisons 
not reported 
Bilicheck, 
forehead and 
sternum 
HPLC, within 30 
minutes 
Routine bilirubin 
measurement 
No prior phototherapy use TcBf, r= 0.890 
TcBs, r=0.881 
With the use of a cutoff 
point for HPLC-B of 13 
mg/dL (222 mmol/L) and 
a cutoff of 11 mg/dL on 
the TcBf and TsB, 
similar 
sensitivity/specificity 
(93%/73% for 
TcBf, 95%/76% for TsB) 
were observed. The use 
of a cutoff point for 
HPLC-B of 17 mg/dL 
(290 mmol/L) and 14 
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mg/dL (240 mmol/L) for 
TcBf and TsB also 
produced 
Similar 
sensitivity/specificity 
(90%/87% for Bilicheck 
and 
87%/83% for TsB). 
Rylance 2014 Black African Preterm 
(mostly> 32 
weeks) and 
term 
newborns> 
37 weeks. 0 
to 14 days of 
life.  
128 newborns 
and 296 paired 
comparisons 
JM 103, 
forehead and 
sternum 
Diazo method, near 
simultaneous 
measurements with 
TcB 
Clinical jaundice Newborns without prior 
phototherapy and with 
phototherapy were 
included 
For infants not under 
phototherapy, the lowest 
TcB reading (from 
forehead or sternum) 
gave the strongest 
correlation with TsB: 
r=0.83 for term infants 
and r=0.71 for premature 
infants. For infants 
undergoing phototherapy, 
the highest TcB reading 
gave the strongest 
correlation with TsB: 
r=0.66 for term infants 
and r=0.71 for premature 
infants. 
Sajjadian 
2012 
Iranian newborns Preterm 25 
to 37 week 
gestation. 1 
to 14 days of 
life.  
126 newborns 
and 126 paired 
comparisons  
JH2-1A, 
forehead and 
sternum 
Diazo method, within 
30 minutes  
Clinical jaundice Newborns without prior 
phototherapy and with 
phototherapy were 
included 
There was significant 
correlation coefficients of 
TcBf and TsBs vs TsB 
TcB for infants under 
phototherapy (r=0.67 and 
r=0.69, P<0.001) and in 
neonates without 
phototherapy (r=0.69 and 
r=0.64. 
The authors reported 
different sensitivities and 
specificities for different 
cut-offs of TsB. 
Samanta 
2004 
The 
race/population 
was not reported 
Preterm ≥33 
week and 
Term ≥ 37 
weeks 
gestation. 1 
to 11 days of 
life. 
300 newborns 
and 300 paired 
comparisons 
Bilicheck, site 
of 
measurement 
was not 
reported 
Diazo method, near 
simultaneous 
measurements with 
TcB 
Clinical jaundice No prior phototherapy use r= 0.77 
Bilicheck identified 
significant jaundice (TsB 
above 250 mol/l) with a 
sensitivity of 91% and 
specificity of 66%.  
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Samiee-
Zafarghandy 
2014 
Multi-racial with 
different skin 
color 
Term and 
preterm ≥ 35 
weeks 
451 newborns 
and 598 pairs 
comparisons 
JM 103, 
sternum 
Direct 
spectrophotometric 
method, within 30 
minutes 
Clinical jaundice 
and during routine 
newborn screening 
No prior use of 
phototherapy for at least 
12 hours 
For light skin color. 
TcB cut-off of 145 
umol/L detected TsB > 
170 umol/L with 
sensitivity and specificity 
of 100 & 95 respectively. 
Medium skin color: TcB 
cut-off of 130 umol/L 
detected TsB > 170 
umol/L with sensitivity 
and specificity of 95.9 & 
75.1 respectively.  
Dark skin color: TcB cut-
off of 170 umol/L 
detected TsB > 170 
umol/L with sensitivity 
and specificity of 100 & 
89.3 respectively. 
 
Sampavat 
2004 
Thailand/Asian Term and 
preterm ≥ 36 
weeks 
388 newborns 
and 460 paired 
comparisons 
JM 103, 
sternum 
Direct 
spectrophotometric 
method, within 15 
minutes 
Clinical jaundice No prior use of 
phototherapy 
r=0.8 
TcB levels of more than 
8, 9, 10, and 12 mg/dl, 
which were used as cut-
off points to indicate 
blood sampling were 
chosen as demarcations 
in predicting TsB levels 
of 10, 12, 13 and 15 
mg/dl, respectively. 
The sensitivity and 
specificity for different 
TcB cut-offs ranged from 
92-96% and 50-83% 
respectively. TcB showed 
a tendency to 
underestimate TsB levels.  
Sampavat 
2005 
Thailand/Asian Term and 
preterm ≥ 36 
weeks 
134 newborns 
and 154 paired 
comparisons 
JM 103 and 
Bilicheck, 
forehead 
Direct 
spectrophotometric 
method, within 15 
minutes 
Clinical jaundice No prior use of 
phototherapy 
The correlation 
coefficients between TcB 
(JM and BC) and TsB 
were  
r 0.80 and 0.82, 
respectively. 
TcB levels of more than 
8, 9, 10, and 12 mg/dl, 
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which were used as cut-
off points to indicate 
blood sampling were 
chosen as demarcations 
in predicting TsB levels 
of 10, 12, 13 and 15 
mg/dl, respectively. 
The sensitivity of BC 
was higher, but 
specificity was lower, 
than JM in 
corresponding to 
different TsB levels, 
except at a TsB level of 
15 mg/dl when both 
instruments 
yielded 100% sensitivity. 
Sanpavat 
2007 
Thailand/Asian Preterm 
newborns < 
36 weeks 
196 newborns 
and 249 paired 
comparisons 
JM 103, 
forehead 
Direct 
spectrophotometric 
method, within 1 hour. 
Clinical jaundice No prior use of 
phototherapy 
r=0.79 
The sensitivity and 
specificity of TcB of 
different cut-off values to 
detect significant 
hyperbilirubinemia 
ranged from 53.1% to 
97.8% and 40% to 88.9% 
respectively. 
Schmidt 2009 Hispanic Preterm 
newborns ≤ 
34 weeks 
90 newborns, 
umber of 
paired 
comparisons 
not clear from 
the article. 
JM 103, 
sternum 
Diazo method within 
45 minutes 
Routine bilirubin 
measurement 
No prior use of 
phototherapy 
The correlation 
coefficient, r ranged from 
0.79 to 0.92. 
The sensitivity and 
specificity of TcB of 
different cut-off values to 
detect significant 
hyperbilirubinemia 
ranged from 88% to 
100% and 21% to 81% 
respectively. 
Schumacher 
1985 
Caucasian Newborns > 
36 weeks, 
postnatal age 
1 to 5 days.  
106 newborns 
and 106 paired 
comparisons 
JM 101, 
sternum 
Direct 
spectrophotometric 
method within 30 
minutes 
Clinical jaundice No prior use of 
phototherapy 
r = 0.74= The TcB device 
classified 
hyperbilirubinemia with 
a sensitivity of 94% and 
specificity of 77.5%. 
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Szabo 2004 White, Asian, 
Indian and 
African 
Preterm 
newborns 34 
to 36 weeks 
gestation 
69 newborns 
and 107 paired 
comparisons. 
JM 102 & 
Bilicheck, 
forehead and 
sternum.  
 
Direct 
spectrophotometric 
method, near 
simultaneous 
measurements. 
Clinical jaundice No prior use of 
phototherapy 
The correlation 
coefficients, r, for JM 
102 and Bilicheck from 
the sternum where: 0.90 
and 0.89 respectively.  
TsB > 190 umol/l can be 
detected with 95% 
sensitivity with Minolta 
JM 102 >19 units, with 
Bilicheck >145 umol/l 
over the sternum and 
>165 umol/l over the 
forehead  
Taha 1984 Saudi newborns Term 
newborns > 
37 week 
gestation. 
3 to 12 days 
68 newborns 
and 120 paired 
comparisons 
JM 101, 
forehead 
Direct 
spectrophotometric 
method, near 
simultaneous 
measurements. 
Clinical jaundice No prior use of 
phototherapy 
r=0.878 
TcB index of 22 has a 
sensitivity and specificity 
of 69% and 92% 
respectively to detect 
TsB > 12.9 mg/dl 
Wong 2002 Mostly white, 6 
non-white 
Term and 
preterm > 31 
to gestation 
64 newborns 
and 64 paired 
comparisons 
JM 102 and 
Bilicheck, 
forehead 
Photometric method, 
within 30 minutes. 
Clinical jaundice No prior use of 
phototherapy 
r= 0.94 to 0.99 
TcB with JM 105 cut-off 
> 170 umol/L detected a 
TsB > 250 umol/L with 
100% sensitivity and 
31.9% specificity. 
TcB with Bilicheck cut-
off > 150 umol/L 
detected a TsB > 250 
umol/L with 100% 
sensitivity and 21.3% 
specificity. 
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Yaser 2014 South African 
newborns 
Preterm 24 
to 34 weeks 
122 newborns 
and 122 paired 
comparisons 
JM 103, 
forehead, 
sternum and 
interscapular 
area.  
Method for TsB 
measurement was not 
reported.  
Clinical jaundice No prior use of 
phototherapy 
The correlation 
coefﬁcients for TcBf, 
TcBs and TcBi were 
0.904, 0.929 and 0.859 
respectively. 
 The interscapular site 
had the highest 
sensitivity of 94% and 
lowest false negative rate 
of 6%. 
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Assessment of methodological quality  
Two of the review authors (CO and OA) independently assessed the methodological quality of each 
included study using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool 
(Whiting 2011), which consists of four domains. We developed a rating guideline for assessment of 
the domains in order to ensure consistency. We assessed each of the four domains with respect to the 
risk of bias. Additionally, we assessed the first three domains in terms of applicability. We conducted 
a pilot test of our review-specific QUADAS-2 tool against five primary studies in order to identify 
possible areas of discrepancies between authors. We resolved discrepancies in assessments by 
consensus. The items of the QUADAS-2 tool and our scoring interpretations for each item are 
presented in Appendix 2. 
Statistical analysis and data synthesis  
We planned to perform statistical analysis according to Cochrane guidelines for diagnostic test 
accuracy (DTA) reviews (Macaskill 2010). We planned to include studies that reported on correlation 
between TcB and TsB and also reported sufficient data that allows for the construction of a 2 × 2 
table. However, during the review process we made the decision to broaden the inclusion criteria and 
include studies that did not have sufficient data for 2 × 2 table but reported on other measures of 
accuracy apart from the correlation coefficient. Studies that only reported the Pearson correlation 
coefficients to describe the relationship between TcB and TsB measurements were excluded. 
We had planned to use the 2 × 2 tables to calculate sensitivity and specificity for each study and also 
meta-analysis of sensitivities and specificities where appropriate using the bivariate model if the same 
threshold for positivity was used. According to the bivariate method we planned to calculate overall 
sensitivity and specificity and their 95% confidence intervals (CIs), based on the binomial 
distributions of the true positives and true negatives (Reitsma 2005). However, because the studies 
were very clinically heterogeneous, we presented most of the findings narratively. We were able to 
combine the results for some of the studies that evaluated the accuracy of the JM 101 device.  
Investigations of heterogeneity  
We had planned to investigate heterogeneity by visual examination of both the ROC plot of raw data 
and the forest plots of sensitivities and specificities. However, this was not done because we could 
not perform a meta-analysis. 
Sensitivity analyses  
We did not perform any sensitivity analysis because data from none of the studies was combined in 
a meta-analysis.
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Assessment of reporting bias  
We are not planning to use funnel plots to evaluate the impact of publication bias or other biases 
associated with small studies. 
Results  
Results of the search  
We identified a total of 495 studies from the various databases. After de-duplication, we screened 
315 titles and abstracts for eligibility. Of these, we obtained full text articles of 146 studies for full 
assessment. We included 54 studies that met our inclusion criteria and 91 studies were excluded for 
various reasons as described in the Characteristics of excluded studies section ( Figure 1). 
Methodological quality of included studies  
Risk of bias assessment for each included study was done using the QUADAS-2 tool. The majority 
of the studies were assessed as low risk for bias across the different domains; patient selection, index 
test, reference standard, and flow and timing (Figure 2 & Figure 3). The detailed assessment of the 
risk of bias and the judgement for each domain are described in the Characteristics of included studies. 
The majority of the included studies were assessed as low risk for bias with respect to patient 
selection, index test, reference standard, flow timing and applicability. 
Findings  
The 54 included studies have a total sample size of 12,254 newborns. The total number of paired 
comparisons of TcB and TsB could not be ascertained because in many of the studies, the number of 
paired measurements was more than the number of included participants (because some participants 
had measurements at more than one occasion) and not all the studies mentioned the number of paired 
measurements. 
The characteristics of the included studies are presented in Characteristics of included studies and 
table 1 . The studies were published between 1982 and 2018 and varied in terms of population 
characteristics/ethnicity, gestational age and postnatal age of the included infants, sample size and 
number of paired measurements of TcB and TsB, the TcB device used, site of TcB measurement, 
type of method used for TsB assay in the laboratory, time interval between TcB and TsB 
measurement, indication for measurement of bilirubin and whether the participants received 
phototherapy or not prior to measurement of TcB and TsB. 
Most of the included studies were carried out in the neonatal intensive care units or the regular well 
baby nurseries. A few of the studies were conducted in outpatient settings of emergency departments 
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(Engle 2005; Kitsommart 2013; Lam 2008; Maisels 1982). Different race groups were represented 
across the different studies. Some studies included a mixture of infants from different ethnic 
backgrounds while others focused on newborns from a specific race group. Amongst others, the 
different ethnic groups/race include: White (Bertini 2008, De Luca 2007, De Luca 2008; Donzelli 
2000; Maisels 1982; Schumacher 1985); Chinese infants (Fok 1986, Ho 2006, Lam 2008, Lin 1993); 
Indigenous African infants (Chimhini 2018; Rylance 2014); and Hispanic (Engle 2002; Kolman 
2007; Schmidt 2009). The gestational age of the newborns included also differed across the included 
studies. Most of the studies included late preterm ≥ 35-week gestational age and term newborns ≥ 37 
weeks gestational age (18 studies), while others included preterm infants < 35 weeks gestation (9 
studies), only term newborns ≥ 37 weeks gestation (8 studies), and the rest of the studies included 
newborns of any gestational age > 23 weeks.  
The postnatal age varied significantly across the studies and ranged from 0 to 29 days of life. Some 
studies did not report the postnatal age of the included participants. The sample size ranged from 57 
infants (Ahmed 2010) to 849 infants (Maisels 2004) and the number of paired measurements of TcB 
and TsB ranged from 57 (Akahira-Azuma 2013) to 1091 (Bental 2009). Some studies included 
multiple paired measurements of TcB and TsB from the same participant. The number of paired TcB 
and TsB corresponded to the number of newborns included in the study in the following studies 
(Bertini 2008; Bilgen 1998; Boo 2007; Campbell 2011; Chimhini 2018; Christo 1988; De Luca 2007; 
De Luca 2008; Holland 2009; Karolyi 2004; Karon 2008; Karrar 1989; Kaynak-Turkmen 2011; 
Kolman 2007; Lam 2008; Leite 2007; Maisels 2004; Qualter 2011; Sajjadian 2012; Schumacher 
1985). The number of paired samples not reported in Donzelli 2000; Harish 1998; Hemmati 2013; 
Ho 2006; and Rubaltelli 2001. 
The studies assessed the measurement of TcB using various TcB devices (Minolta-Air Shields JM 
101, JM 102, JM 103, Bilicheck) compared with TsB measurement in the laboratory by different 
methods (including HPLC, direct spectrophotometric, and diazo method). All the included studies 
reported on the correlation between TcB and TsB using the Pearson correlation coefficient and also 
reported on some other measure of accuracy such as sensitivity or specificity using for a specific TsB 
threshold as diagnostic for hyperbilirubinemia. Overall, there were good correlations between TcB 
and TsB in the included studies. The studies reported different sensitivity and specificity for different 
thresholds. 
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JM 101 transcutaneous device 
TcB measurement with the JM 101 jaundice meter was assessed in a number of studies (Bhutta 1991; 
Bilgen 1998; Christo 1988; Fok 1986; Harish 1998 Karrar 1989; Laeeq 1993; Maisels 1982; 
Schumacher 1985; Taha 1984). All these studies showed a significant correlation between TcB 
measured with the JM 101 device and the TsB measured in the laboratory. The Pearson correlation 
coefficient, r, ranged from 0.66 (Bhutta 1991) to 0.93 (Maisels 1982). TcB measured with the JM 101 
device also showed a high sensitivity in detecting significant hyperbilirubinemia. The studies used 
different thresholds to define hyperbilirubinemia and also different TcB cut-off values. The 
Sensitivity ranged from 74% to 100% and specificity ranged from 53 to 88%. Data table 1; Data and 
analyses. Figure 4; Figure 5. 
JM 102 transcutaneous device 
JM 102 (Donzelli 2000; Harish 1998; Ho 2006; Karolyi 2004; Lin 1993; Szabo 2004a; Wong 2002). 
All the studies reported a significant correlation between TcB measured with the JM 102 device and 
the TsB measured in the laboratory. The Pearson correlation coefficient, r, ranged from 0.68 (Karolyi 
2004) to 0.99 (Wong 2002). TcB measured with the JM 102 device also showed a high sensitivity in 
detecting significant hyperbilirubinemia. The studies used different thresholds to define 
hyperbilirubinemia and also different TcB cut-off values. The Sensitivity ranged from 68% to 100% 
and specificity ranged from 21 to 88%. 
JM 103 transcutaneous device 
The JM 103 device has been evaluated in multiple studies (Akahira-Azuma 2013; Bental 2009; 
Chimhini 2018; Engle 2005; Kitsommart 2013; Lam 2008; Maisels 2004; Maisels 2011; Panburana 
2010; Qualter 2011; Raimondi 2012; Rodriguez-Capote 2009; Rylance 2014; Samiee-Zafarghandy 
2014; Sanpavat 2004; Sanpavat 2005; Sanpavat 2007; Schmidt 2009; Yaser 2014). Findings from 
these studies showed a good correlation (with correlation coefficient, r, ranging from 0.70 to 0.95) 
between TcB measured with the JM 103 device and TsB measured in the laboratory. 
Bilicheck transcutaneous device 
The Bilicheck has been evaluated in numerous studies (Ahmed 2010; Bhutani 2000; Boo 2007; 
Campbell 2011; De Luca 2007; De Luca 2008; Engle 2002; Hemmati 2013; Ho 2006; Holland 2009; 
Karon 2008; Kaynak-Turkmen 2011; Knupfer 2001; Kolman 2007; Leite 2007; Maisels 2004; 
Neocleous 2014; Qualter 2011; Raimondi 2012; Rodriguez-Capote 2009; Rubaltelli 2001; Samanta 
2004). Findings from these studies showed a good correlation (with correlation coefficient, r, ranging 
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from 0.75 to 0.96)) between TcB measured with the Bilicheck device and TsB measured in the 
laboratory. 
Bilimed transcutaneous device 
De Luca 2008; Raimondi 2012 evaluated the use of Bilimed for TcB measurement and found a 
correlation coefficient, r of 0.45 and 0.70 respectively with TsB.  
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Factors affecting TcB measurement: 
1) Site of measurement. 
Maisel 2004 reported a better correlation between TcB and TsB when the measurement is taken from 
the sternum (r=0.953) compared to the forehead (r=0.914). Other studies also report better correlation 
when the measurement is taken from the sternum compared to the forehead (Engle 2002; Fok 1986; 
Holland 2009). In Engle 2002 among a Hispanic population, BiliCheck measurements from the 
forehead underestimated TsB, particularly when the TsB exceeded 10 mg/ dl. For neonates under 28 
weeks of age, TcB measurement over sternum with the JH2-1A device had better correlation than 
TcB over forehead (Sajjadian 2012).  
2) Race/Ethnicity 
The findings on the effect of ethnicity or skin color was mixed across the included studies. Maisels 
2004 showed a better correlation between TcB and TsB among white newborns with light or medium 
skin color compared to black newborns with dark skin color, with correlation coefficients, r or 0.95 
and 0.82 respectively. Samiee-Zafarghandy and Wainer 2009 observed that TcB underestimated TsB 
in light and medium skin color and overestimated it in dark skin color with wide limits of agreement. 
In contrast, ethnicity did not significantly affect the correlation between TcB and TsB measurements 
(Bental 2009; Bhutani 2000; Campbell 2011; Karon 2008; Rodriguez-Capote 2009). Holland 2009 
and Szabo 2004a found that TcB measurement on the forehead was affected by race with a 1.3 to 1.7 
mg/dL negative bias for non-Caucasian compared with Caucasian neonates. However, ethnicity may 
not be a surrogate for skin color (Samiee-Zafarghandy 2014). Engle 2002 and Neocleous 2014; found 
a poor correlation among Hispanic and Greek newborns respectively. This could be because their 
study included a large proportion of newborns with TsB level > 13 mg/dl. 
3) Gestational age 
The effect of gestational age on the correlation between TcB and TsB was evaluated in a number of 
studies. The correlation among preterm infants ranged from 0.68 to 0.96 (De Luca 2007; Donzelli 
2000; Sanpavat 2007; Knupfer 2001; Szabo 2004a; Rubaltelli 2001; Rylance 2014). In Knupfer 2001 
Rubaltelli 2001; Rylance 2014 found that the TcB correlation in the preterm is less compared to term 
newborns, with more overestimation of TsB in preterm newborns. However, Hemmati 2013; Karolyi 
2004; Karon 2008; Sanpavat 2004 did not find any difference with change in gestational age in 
preterm newborns. In these studies, the correlation between TcB and TsB was almost similar to that 
in term newborns. In Sanpavat 2004; Sanpavat 2005; Sanpavat 2007 it was also reported that TcB 
might tend to overestimate TsB in preterm infants and underestimate TsB in term infants. It is not 
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clear whether TcB over- or underestimates TsB in preterm infants as the included studies report 
different findings.  
4) Postnatal age 
Postnatal age is an important variable that seem to affect the correlation of TcB and TsB. There are 
also conflicting results from across the studies. Some studies report no difference in the correlation 
with advancing postnatal age while others report poorer correlation with advancing postnatal age 
(Karolyi 2004; Knupfer 2001; Knudsen 1996; Szabo 2004). The effect of postnatal age could be the 
effect of maturation and thickening of the skin (Knudsen 1996). Karon 2008 and Samanta 2004 did 
not find any effect of postnatal age on the accuracy of TcB measurement. It is important to note that 
many of the reported studies did not report the postnatal age of the included participants. 
5) Type of TcB device 
Some of the included studies evaluated the use 2 of more TcB devices (De Luca 2008; Ho 2006; 
Maisels 2004; Neocleous 2014; Raimondi 2012; Rodriguez-Capote 2009; Sanpavat 2005). De Luca 
2008 compared the use of the Bilimed device and Bilicheck with TsB. The linear regression analysis 
showed a better correlation between BiliCheck and TsB (r=0.75) than between BiliMed and TsB 
(r=0.45). Similarly, in the study by Raimondi 2012, correlation analysis using Pearson coefficients 
showed good results for Bilicheck (r = 0.86) and JM-103 (r = 0.85) but poor for BiliMed (r = 0,70) 
regardless of the skin pigmentation. In Sanpavat 2005, the correlation coefficients between TcB 
measured with the JM 103 and Bilicheck device and TsB were similar (r= 0.80 and 0.82, 
respectively). However, TcB using the JM 103 device had a tendency to underestimate TsB levels, 
and TcB using the Bilicheck device had a tendency to overestimate TsB levels (Sanpavat 2005). 
Holland 2009 found that the performance of the BiliCheck is influenced by the site of the 
measurement. Rodriguez-Capote 2009 showed that both the Bilicheck and the JM 103 device showed 
a good correlation with TsB (BiliCheck, r=0.86; JM-103, r=0.85), with both devices showing a 
tendency to underestimate the TsB. Similarly, Maisels 2004 found no difference in the performance 
of the JM 103 and Bilicheck device (Bilicheck: r = 0.973, JM: r = 0.971). Also, the study by Samanta 
2004 showed no difference between Bilicheck and JM 103 (r = 0.82 and r = 0.80, respectively). In 
contrast, in a mostly Caucasian population of newborns, Qualter 2011 found that Bilicheck was more 
accurate than JM 103 having a slightly stronger correlation with the TsB.  
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Discussion  
We conducted a comprehensive systematic review to evaluate the use of TcB measurement compared 
to TsB measurement in newborns of various gestational and postnatal age and from different ethnic 
background and race. Findings from our review supports the AAP guideline that states TcB is a 
suitable alternative to measure TsB in newborns (AAP 2004). Unlike previous reviews, we did not 
restrict our review to newborns of any particular gestational age or newborns from any specific ethnic 
background or race (Moey 2016; Nagar 2016; Nagar 2013). 
Summary of main results  
Findings from this review demonstrate that the various TcB devices have been extensively evaluated 
in newborns from different ethnic groups and settings. The findings show acceptable correlation 
between TcB measured with these devices and TsB measured in the laboratory. The JM-101 (Draeger 
Medical Systems Inc, Telford, US), JM-102 (Draeger Medical Systems Inc, Telford, US), JM 103 
(Draeger Medical Systems Inc, Telford, US) and JM 105 devices (Draeger Medical Systems Inc, 
Telford, US) and BiliChek (Bilicheck (SpectRx, Inc, Norcross [GA], US), all showed very good 
correlation coefficients when compared with the different methods for TsB measurement in the 
laboratory. However, the BiliMed in general performed quite poorly compared to other devices. TcB 
measurement also has a high sensitivity in detecting clinically significant hyperbilirubinemia in 
newborns and has been shown in the included studies to be an acceptable screening tool for 
hyperbilirubinemia in newborns.  
There are conflicting results on the effects of various variable or factors on the accuracy of the TcB 
measurement. The findings are mixed on the impact of factors such as gestational age, postnatal age, 
race or ethnic background, site of TcB measurement (e.g. forehead vs sternum), type of TcB device 
and use of phototherapy. Maisels 2006 concluded that both the BiliCheck and the JM-103 are less 
reliable in predicting TsB in more preterm infants, particularly those younger than 30 weeks’ 
gestation. Some studies suggest that TcB measurement shows better correlation in Caucasian or light 
skinned newborns compared to black newborn while other have found no effect of race or ethnic 
group on TcB measurement. Also, many studies have shown a better correlation of TcB with TsB 
when the measurement is taken from the sternum compared to the forehead. The evidence from the 
included studies is also conflicting in terms of other factors (such as gestational age, skin colour and 
type of TcB device) that could affect the accuracy of TcB measurement.  
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Strengths and weaknesses of the review  
We conducted a comprehensive search of the literature to identify all potentially eligible studies. We 
included studies of newborns from different ethnic background and race, and also newborns of 
various gestational age and race. We narrowed our inclusion criteria to exclude studies published in 
languages other than English and studies that did not report any other measure of accuracy apart from 
the correlation coefficient. Many of the included studies did not report blinding of the observers. 
However, we do not think this is likely to affect the outcome both TcB and TsB are objective 
measurement and very unlikely to be influenced by lack of blinding. 
Applicability of findings to the review question  
Authors' conclusions  
Implications for practice  
Guidelines published by both the AAP and the Canadian Pediatric Society suggest that the TCB value 
may be used as a substitute for TsB in evaluating the risk of significant neonatal hyperbilirubinemia 
in the healthy newborn (AAP 2004; CPS 2007). Currently various TcB devices are being used in 
many countries and settings. TcB method of measuring bilirubin has several advantages. It is a non-
invasive and non-painful way to measure bilirubin compared to TsB which requires blood draw 
through heel sticks or venipuncture. TcB results are obtained almost instantaneously. Though 
previous guidelines (Kazmierczak 2006) suggested that there insufficient evidence to recommend one 
device over another, more recent studies have shown advantage of some devices and better correlation 
of some of the TcB devices compared to others. For example, TcB measured with the Bilicheck and 
JM 103 device have been shown in more recent studies to have better correlation with TsB than with 
TcB measured with the Bilimed. The Bilimed device has been shown to have poor correlation with 
TsB (De Luca 2008 and Raimondi 2012). 
Implications for research  
Several studies of the JM device suggest that measurement taken from the sternum correlates better 
with TsB compared to measurement taken from the forehead (Fok 1986; Holland 2009; Maisels 2004; 
Yamauchi 1991). However, the manufacturer of the device suggests that both sternum and forehead 
can be used. Further studies may be needed to better understand the best site for TcB measurement 
and the reason for the difference if any in the measurement take from the forehead and sternum. Also, 
further studies are needed to ascertain the impact of phototherapy on the accuracy of TcB 
measurement. The studies need to evaluate the optimal timing after phototherapy when the TcB 
reading can be compared to or becomes similar to TcB obtained in newborns without any prior 
exposure to phototherapy.
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Figure 1: Study flow diagram. 
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Figure 2: Risk of bias and applicability concerns graph: review authors' 
judgements about each domain presented as percentages across included studies 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
140 
 
 
 
 
Figure 3: Risk of bias and applicability concerns summary: review authors' 
judgements about each domain for each included study
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Figure 4: (Analysis 1)  
 
Figure 5: Summary ROC Plot of 1 TcB (JM 101) 
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What’s known on This Subject: TcB measurement has been shown to correlate with TsB in 
preterm and newborns in many different settings.  
What This Study Adds: Our study provides evidence from indigenous African newborns with 
varying skin pigmentation on the accuracy of TcB measurement using the JM 105 device in a 
population of South African late preterm and term newborns.  To our knowledge at the time of 
this study there was no published studies that assessed the performance of the JM 105 
transcutaneous device in newborns.   
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Abstract 
Background:  
Transcutaneous bilirubin (TcB) measurement in newborns has been studied extensively in 
many countries and settings. However, there are no reported studies on TcB measurements 
among late preterm and term South African newborns. Also, there are currently no published 
studies that evaluated the new Draeger JM 105 transcutaneous device in newborns.  
In this study we compared the performance of the JM 105 device for measurement of TcB 
compared with total serum bilirubin (TsB) measurements in South African late preterm and 
term newborns. 
Methods:  
TcB measurements were obtained using the JM 105 TcB device from the sternum at postnatal 
age 6 to 72 hours in a population of late preterm and term South African newborns. TcB 
measurements were performed within 15 minutes of obtaining blood sample for TsB 
measurement. The Pearson correlation coefficient (r) and the Bland-Altman plot were used to 
estimate the relationship between the TcB and TsB measurement.  
Results:  
An indigenous population of 132 African newborns were enrolled. The gestational age ranged 
from 35 to 42 weeks; birth weight from 2010 to 5030 grams; and postnatal age 11 to 72 hours 
of life. The TsB ranged from 11 to 311 umol/l while the TcB ranged from 9 to 308 umol/l. 
Overall, the correlation analysis using Pearson coefficient, r, showed a good correlation with 
r= 0.902 (95% CI 0.83 to 0.98) between TcB and TsB. The Bland Altman analysis showed that 
the TsB can be overestimated by TcB measured with the JM 105 device with a bias of up to 
16.7 μmol/L with 95% limits of agreement of (1.96 x 23.5 umol/l=46.1), lower limit = -29.4; 
upper limit = 62.8).  
Conclusions:  
TcB measurement using the JM 105 transcutaneous device showed a good correlation with 
TsB measurement in an indigenous population of South African late preterm and term 
newborns and can be used as a reliable screening tool to identify hyperbilirubinemia.  
Keywords 
Hyperbilirubinemia, transcutaneous bilirubin, serum bilirubin, newborn  
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Background 
Jaundice is a very common condition in the newborn during the first week of life with up to 60 
percent of term newborns developing jaundice during the first week of life [1,2]. Jaundice is 
the discoloration of skin and sclera color to yellowish in a newborn by bilirubin [3].  
Hyperbilirubinemia can be defined as total serum bilirubin (TsB)  above the 95th percentile for 
age during the first week of life [4,5]. The types or causes of hyperbilirubinemia in the newborn 
can be classified into physiological jaundice, pathological jaundice, breastfeeding or breast 
milk jaundice [6]. In many settings, with the current practice of early discharge of newborns, 
usually within 2 days for normal vaginal deliveries and within 3 days for caesarean section 
deliveries, hyperbilirubinemia is the most common reason for readmission in the first week of 
life.  
Assessment of hyperbilirubinemia can be done by visual inspection, TsB measurement, or by 
transcutaneous bilirubin (TcB) measurement. TsB measurement in the laboratory requires 
blood draw which is painful to the newborn and results are not available immediately. TcB 
measurement is noninvasive, does not require blood draw and provides immediate result. The 
American Academy of Pediatrics (AAP) recommends the use of either a TsB or a TcB 
measurement to screen and identify newborns at risk of severe hyperbilirubinemia [7]. Visual 
assessment for hyperbilirubinemia has been shown to be inaccurate and not recommended 
[8,9].  
TcB measurement was introduced more than 30 years ago [10]. Since its first introduction, 
various transcutaneous point of care devices have been developed that can give instantaneous 
bilirubin measurements. The accuracy of various TcB devices has been extensively studied in 
many countries and settings. The accuracy of the JM 103 (Draeger Medical Systems Inc, 
Telford, US) device was studied in a population of preterm infants in South Africa [11]. 
However, there are no published studies on the reliability or accuracy of TcB measurement in 
late preterm and term South African newborns with varying skin pigmentation. Furthermore, 
there are limited studies of the new JM-105 (Draeger Medical Systems Inc, Telford, US) 
device. The Draeger JM-105 jaundice meter is portable, handheld, non-invasive TcB 
measuring device, which measures the yellowness of subcutaneous tissue by using two optical 
paths to measure the optical density difference at two wavelengths in the newborn and provides 
a visual digital measurement. The JM-105 is a modification of the JM-103 jaundice meter. The 
basic functionality, including the measuring probe, hardware, and software used to process the 
measurements, are identical to the JM-103 [12]. 
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In this study, we assessed the correlation of TcB measurement using the JM 105 TcB device 
with TsB measurement in a population of South African late preterm (≥ 35 week gestational 
age) and term newborns.  
Methods: 
Study setting and participant selection 
This study was carried out in the postnatal ward of Tygerberg Hospital, a teaching hospital in 
Cape Town, South Africa between August 2015 and October 2016. Tygerberg Hospital is a 
tertiary hospital with about 7500 deliveries per annum. The study was approved by the Health 
Research Ethics Committee of Stellenbosch University and written informed consent was 
obtained from all parents before participation. During a clinical trial on TcB screening for 
hyperbilirubinemia, we obtained TsB samples on all infants whose TcB measurement was 
>95th centile for age on the Bhutani’s nomogram [13–15]. We also simultaneously obtained 
TcB readings on all infants who required blood draw for TsB measurement based on clinical 
evidence of jaundice. We included newborn infants with gestational age ≥ 35 weeks and birth 
weight of 1800g with postnatal age 6 to 72 hours of life. Infants with previous phototherapy 
use or who were currently undergoing phototherapy were excluded.  
For each infant, the following demographic information were collected from the medical 
records: gestational age, birth weight, postnatal age at time of assessment, sex, and race.  
TcB measurement 
The TcB measurements were done with the Draeger JM 105 TcB meter by the principal 
investigator who was trained in the use of the device.  A single device was used during the 
study and the device was used according to the manufacturer’s instructions. The device was 
calibrated each day before use and was set to take the average of 3 different readings. The 
measurements were taken within 15 minutes of blood sampling for TsB. The TcB 
measurements were taken by pressing the device probe against the infants’ skin on the mid 
sternum. The bilirubinometer was cleaned with an alcohol wipe between patients. 
TsB measurement 
Venous blood samples were used to measure the TsB levels by means of Diazo method at the 
Tygerberg Hospital NHLS laboratory. After blood samples were taken, the samples were 
protected from light exposure by sending them through to the Hospital laboratory through the 
pneumatic tube system. The laboratory technicians were not aware of the TcB results.
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Data collection and analysis 
The data was collected on a paper data collection form and registered in a Database using 
Microsoft Excel 2016 and analysed using STATA 12 statistical software.  The correlation 
between TcB and TsB was assessed using the Pearson correlation coefficient. The Bland-
Altman analysis which plots the differences between two assays against the mean of the two 
compared methods was used. The bias was calculated as a mean of the differences between the 
paired TsB and TcB values [16]. A p-value of < 0.05 was considered to be statistically 
significant. 
Results: 
A total of 132 newborns were enrolled from whom 132 pairs of TcB and TsB measurements 
were obtained. The baseline characteristics of the newborns are summarized in Table 1.  TsB 
was requested on the infants for the following reasons; 82 (62%) infants were classified as 
high-risk zone of the Bhutani nomogram based on TcB screening; 46 (35%) infants had clinical 
evidence of jaundice by visual inspection; 4 (0.03%) infants had mothers who were Rh 
negative.  
The TsB levels ranged from 11 to 311 umol/l (mean 176umol/l) while the TcB readings ranged 
from 9 to 308 umol/l (193 umol/l). The linear regression correlations between TcB and TsB 
measurements are shown in Figure 1. The correlation coefficient between TcB and TsB in all 
132 participants was; r=0.907 95% CI 0.83 to 0.98, p< 0.001. The correlation between TcB 
and TsB varied between the two major race groups (Blacks and mixed race) in the study 
sample. The correlation coefficient among the blacks was 0.94 compared to 0.92 among the 
mixed race. However, this difference between the two groups was not statistically significant. 
A Bland–Altman plot of all 132 comparisons is shown in Figure 2. The average of TcB 
measured with the JM 105 device and TsB values is shown on the x-axis, and the difference is 
displayed on the y-axis. The analysis showed that the agreement between TcB and the TsB can 
be overestimated with a bias of up to 16.7 μmol/L with 95% limits of agreement of (1.96 x 
23.5 umol/l=46.1), lower limit = -29.4; upper limit = 62.8). The TcB measured by the JM 105 
device in our study showed a tendency to overestimate the TsB. The tendency for TcB to 
overestimate TsB was uniform throughout the range of bilirubin values studied. A linear 
regression analysis showed that bias was uniform and did not show any particular pattern with 
increasing or decreasing levels of TsB.  
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Table 1: Demographics of the study population (n=132) 
Gestational age, weeks (mean ± SD) 38.4 ± 1.57 
Birth weight, g (mean ± SD) 3152 ± 588 
Male sex 79 (60%) 
Race 
Blacks 69 (52%) 
Mixed race  58 (44%) 
Indians 1 (1%) 
White 4 (3%) 
Postnatal age at time of assessment, 
hours (mean ± SD). 
37.7 ± 17.6 
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Fig. 1. Graphical depiction of TsB versus TcB measurements (taken with the Draeger JM 105 
device). TsB and TcB values presented in μmol/L.  
 
 
 
 
 
Fig. 2 Bland–Altman plot depicting difference between TcB and TsB measured at sternum, 
on Y-axis against mean of TcB and TsB on X-axis.  
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Discussion  
In this study, we evaluated the use of the JM 105 device in an indigenous population of African 
newborns. All the TcB measurements in our study was taken from the sternum. A previous 
study in South Africa evaluated the use of the JM 103 device in preterm newborns less than 
35-week gestational age [11]. At the time of our study in 2015, there was no known published 
study that evaluated the use of the JM 105 jaundice device. This is the first study to our 
knowledge to assess the correlation between TcB and TsB in South African late preterm and 
term newborns. Our study demonstrated a good correlation between TcB measurement taken 
from the sternum and TsB measured in the laboratory. Similarly, other studies among 
indigenous African newborns showed good correlation between TcB and TsB measurement 
with correlation coefficient ranging from 0.77 to 0.90 [17–19].  In our study, TcB had tendency 
to overestimate TsB in almost all the measurements. Again, this finding is similar to that from 
other studies of indigenous African newborns in Malawi and Nigeria that showed that TcB 
values overestimated TsB for both premature and term infants [17,20].   
A number of studies have evaluated the correlation and accuracy between various TcB devices 
and TsB in late preterm and term newborns from diverse populations and settings [21–31]. To 
our knowledge, our study is the first to address the accuracy of the JM-105 device during the 
late first week of life in a South African population of late preterm and term newborns.  
The study by Yamana et al published in 2017 evaluated the use of JM 105 TcB device among 
Japanese newborns with measurements taken from the scaphoid fossa [32].  
Findings from other studies from different race groups have been mixed. Some studies have 
also reported a tendency for TcB to overestimate TsB [21,22,33–36]. In contrast, other studies 
have reported a tendency for TcB to underestimate TsB [23,37–40]. In our study, the Bland 
Altman analysis showed a uniform bias for all the range of TsB measurements. Similarly, 
Maisels et al did not find any significant difference between the deviations from the regression 
line when comparing lower and higher concentrations of TsB concentration [41]. 
Many factor can affect the accuracy of the TcB meter. These include race, ethinity or skin 
colour.  There has been mixed findings from other studies on the impact of race or skin colour 
on the accuracy of TcB compared with TsB measurement. Maisel et al showed a better 
correlation between TcB and TsB among white newborns with light or medium skin colour 
compared to black newborns with dark skin colour, with correlation coefficients, r or 0.95 and 
0.82 [42]. Also, other studies among Hispanic newborns found a poor correlation among 
Hispanic and Greek newborns respectively [29,43]. In contrast, race or skin did not 
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significantly affect the correlation between TcB and TsB measurements in some other reports 
[14,39,40,44,45]. In our study, the correlation between TcB and TsB was not significantly 
different in dark skinned newborns compared with that in in the mixed-race population. 
 
Our study has a few limitations. We did not compare the measurements of TcB taken from 
different sites of the body. TcB measurements were obtained by only one person, the principal 
investigator after training. In clinical practice the device will be used by different persons with 
varying level of training, this could affect the performance of the device. However, the device 
is very user-friendly and requires minimal training to use.   
This study provided evidence on the validity of the Draeger JM 105 transcutaneous 
bilirubinometer in a population of indigenous African newborns in South Africa. We have 
evidence of good correlation and reliability between TcB and TsB measurement among late 
preterm and term South African newborns. In our setting, TcB measurement may be considered 
as a screening tool for babies who require blood sampling for TsB and possible decision to 
commence phototherapy. Further studies are needed to evaluate the effect of TcB measurement 
among South African infants undergoing phototherapy and evaluate if TcB measurement can 
be used to decide when to stop phototherapy. The number of blood samples obtained for TsB 
could be reduced with the use of TcB measurement as a screening tool for newborns who might 
need phototherapy for hyperbilirubinemia.  
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Chapter 7 
Conclusion 
Hyperbilirubinemia is a common problem in the newborn period with up to 60% of term newborns 
and 80% of preterm newborns having some degree of hyperbilirubinemia. Severe hyperbilirubinemia 
with TsB exceeding 20mg/dl or extreme hyperbilirubinemia with bilirubin level > 25mg/dl puts the 
newborn at risk of adverse neurologic consequences such as kernicterus. Kernicterus is very rare in 
developed countries with adequate resources and health care infrastructure. However, in many 
resource constrained settings, kernicterus is still an important cause of morbidity and mortality in the 
newborn. 
In this project we have sought to provide evidence on the usefulness of transcutaneous bilirubin (TcB) 
screening in an African population of newborns.   
We aimed to provide answers the following questions: 
a. What is the evidence for the use of TcB screening for hyperbilirubinemia in newborns before 
discharge?  
b. What is the effect of TcB screening on readmissions for hyperbilirubinemia and on the 
incidence of severe  hyperbilirubinemia in an indigenous population of African newborns? 
c. Can TcB measurement be used to reliably estimate TsB measurment in newborns from 
different populations and settings and what factors effect the accuracy of TcB measurement? 
d. What is the accuracy of TcB measurement using the JM 105 device compared to TsB 
measurement in an indigenous population of African newborns? 
These questions have been addressed by a mix of different study designs. We started by reviewing 
the currently available evidence on the of TcB screening on readmissions for hyperbilirubinemia and 
incidence of severe hyperbilirubinemia in newborns. We conducted a comprehensive search of the 
literature to identify all relevant studies that evaluated the use of TcB screening for the 
aforementioned outcomes. We identified 5 observational studies conducted in the United States and 
Canada. We did not identify any randomized controlled trial (RCT) that evaluated the effect of TcB 
screening on readmissions for jaundice and incidence of severe hyperbilirubinemia. Findings from 
the observational studies suggest that TcB screening for hyperbilirubinemia in newborns is associated 
with reduction in hyperbilirubinemia related readmissions and incidence of severe 
hyperbilirubinemia. Currently, universal TcB or TsB screening for hyperbilirubinemia has been 
implemented in the United States and Canada following recommendations from the American 
Academy of Pediatrics and the Canadian Pediatric Society. However, universal screening for 
hyperbilirubinemia is not standard of care in many other countries, including South Africa. In these 
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settings, TcB or TsB measurements are only obtained for diagnosis of hyperbilirubinemia in 
newborns when jaundice is present.   
The answer to the question on the impact of TcB screening for hyperbilirubinemia in newborns can 
best be provided by a well-designed RCT.  However, our systematic review of TcB screening did not 
identify any RCT. Therefore, we designed and implemented an RCT to assess the impact on 
readmission and incidence of severe hyperbilirubinemia in a population of indigenous African.  To 
our knowledge, this is the first RCT that has evaluated the use of TcB screening for 
hyperbilirubinemia in newborns. We were able to demonstrate in this RCT that TcB screening in 
South African newborn infants led to a reduction in the incidence of hyperbilirubinemia related 
readmissions and the incidence of severe hyperbilirubinemia. Our findings further confirmed the 
findings from previous observational studies conducted in the United States and Canada. Our trial on 
TcB screening for hyperbilirubinemia and previous observational studies were not able to provide 
evidence on the impact of TcB screening on other clinically relevant outcomes such as kernicterus.  
The impact of universal bilirubin screening of newborns on kernicterus has not been demonstrated in 
any study. This is because of the rare incidence of kernicterus. Any randomized trial to evaluating 
this question will require recruitment of millions of newborns to be able to detect a difference. 
Therefore, a clinical trial to answer this question might never be feasible, especially in developed 
countries where universal bilirubin screening in all newborn infants before hospital discharge is 
already standard of care. We have contributed to the currently available body of evidence by 
providing the first evidence from a RCT that TcB screening in newborns can lead to a reduction in 
jaundice related readmissions and also a reduction in the incidence of severe hyperbilirubinemia in 
newborns. Furthermore, our study is the first to evaluate the impact of TcB screening in a population 
of indigenous African newborns with varying skin pigmentation.  
In this project we also conducted a Cochrane systematic review on the currently available evidence 
on the accuracy of TcB measurement compared to TcB in newborns. Our search of the literature 
identified numerous studies of TcB accuracy compared with TsB. These studies were conducted in 
many different countries and settings and included newborns of various gestational age. The included 
studies evaluated the use of various TcB devices, including the Bilicheck (SpectRx, Inc, Norcross 
[GA], US), JM 103 (Draeger Medical Systems Inc, Telford, US) and JM 105 devices (Draeger 
Medical Systems Inc, Telford, US). 
 
Finding from the review suggests that TcB devices can be used to reliably estimate TsB. However, 
many studies report the tendency of TcB to overestimate TsB. Also, many factors or variables have 
been shown to affect the accuracy of TcB measurements. These factors include; gestational age, 
postnatal age, race, skin colour or ethnicity, type of TcB device, previous exposure to phototherapy 
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and site of TcB measurement (e.g. forehead vs. sternum). The findings from the included studies on 
how these factors could affect TcB measurement are not consistent.  
Our systematic review of the literature did not find any studies evaluating the accuracy of TcB 
measurement in late preterm or term South African newborns. Also, there are very limited number of 
studies that evaluated the new Draeger JM 105 TcB device. Therefore, we conducted a cross-sectional 
study to evaluate the usefulness of the Draeger JM 105 device to estimate TcB compared to TsB 
measured in the laboratory. We recruited a total of 132 late preterm and term newborns in the study.  
Findings from the study showed a good correlation between TcB measured with the JM 105 device 
and TsB measured in the laboratory, with correlation coefficient, r, of up to 0.97. Suggesting that TcB 
measurement can reliably estimate TsB in an indigenous population of South African newborns. 
 
In summary, findings from the studies presented in this dissertation suggest that: 
• TcB measurement can be used to reliably estimate TsB in indigenous African newborns.   
• TcB screening of newborns for hyperbilirubinemia before hospital discharge can lead to a 
reduction hyperbilirubinemia related readmissions and also reduction in the incidence of 
severe hyperbilirubinemia. 
• TcB measurement can be affected by factors such as gestational age, postnatal age, skin 
colour/ethinicity and prior use of phototherapy.  
Based on these findings, we make the following recommendations:  
1. We recommend a policy and practice change to start implementation of routine screening of 
newborns for hyperbilirubinemia before hospital discharge in South Africa and other African 
countries. As recommended by the AAP, hyperbilirubinemia screening should be with the use 
of either TcB or TsB measurement before hospital discharge of apparently healthy newborns. 
2. We recommend implementation studies  to identify potential barriers to the implementation 
of TcB or TsB screening in newborns especially in resource-limited settings. 
 
3. Further studies are needed to determine the optimal timing for TcB screening for 
hyperbilirubinemia in newborns before discharge, especially in settings where newborns are 
discharged home as early as 6 hours after delivery. 
4. There is a need for studies to evaluate the cost effectivness of the various options for screening 
for hyperbilirubinemia in newborns (e.g. cost effectiveness of TcB vs TsB screening).  
5. We recommend further studies to evaluate the best methods for screening of 
hyperbilrubinemia in preterm newborns who are < 35 weeks gestation and require longer stay 
in the hospital.  
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6. Further studies are needed to further evaluate the impact of various factors such as gestational 
age, postnatal age, skin colour/ethinicity and prior phototherapy use. 
7. TcB device manufacturers now have the moral responsibility to make over-priced 
transcutaneous devices safe, affordable and accessible. If not, the high cost of the current TcB 
devices could be a barrier to implementation of universal TcB screening in many low- and 
middle-income countries.   
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Search strategy for TcB screening systematic review 
PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low 
birth weight OR VLBW OR LBW or infan* or neonat*) AND (randomized controlled trial [pt] OR 
controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR 
randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])) 
Embase: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight 
or low birth weight or VLBW or LBW or Newborn or infan* or neonat*) AND (human not animal) 
AND (randomized controlled trial or controlled clinical trial or randomized or placebo or clinical 
trials as topic or randomly or trial or clinical trial) 
CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth 
weight OR VLBW OR LBW or Newborn or infan* or neonat*) AND (randomized controlled trial 
OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR 
trial OR PT clinical trial) 
Cochrane Library: (infant or newborn or neonate or neonatal or premature or preterm or very low 
birth weight or low birth weight or VLBW or LBW) 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 
165 
Risk of bias tool  
We used the standard methods of Cochrane and Cochrane Neonatal to assess the methodological 
quality (to meet the validity criteria) of the trials. For each trial, we sought information regarding the 
method of randomization, and the blinding and reporting of all outcomes of all the infants enrolled in 
the trial. We assessed each criterion as low, high, or unclear risk. Two review authors separately 
assessed each study. We resolved any disagreement by discussion. We added this information to the 
table Characteristics of included studies. We evaluated the following issues and entered the findings 
into the risk of bias table: 
1. Sequence generation (checking for possible selection bias). Was the allocation sequence 
adequately generated? 
For each included study, we categorized the method used to generate the allocation sequence as: 
a. Low risk (any truly random process e.g. random number table; computer random number 
generator); 
b. High risk (any non-random process e.g. odd or even date of birth; hospital or clinic record 
number); 
c. Unclear risk. 
2. Allocation concealment (checking for possible selection bias). Was allocation adequately 
concealed? 
For each included study, we categorized the method used to conceal the allocation sequence as: 
a. Low risk (e.g. telephone or central randomization; consecutively numbered sealed opaque 
envelopes); 
b. High risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth); 
c. Unclear risk 
3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge 
of the allocated intervention adequately prevented during the study? 
For each included study, we categorized the methods used to blind study participants and personnel 
from knowledge of which intervention a participant received. Blinding was assessed separately for 
different outcomes or class of outcomes. We categorized the methods as: 
a. Low risk, high risk or unclear risk for participants; 
b. Low risk, high risk or unclear risk for personnel; 
4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the 
allocated intervention adequately prevented at the time of outcome assessment? 
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For each included study, we categorized the methods used to blind outcome assessment. Blinding 
was assessed separately for different outcomes or class of outcomes. We categorized the methods 
as: 
a. Low risk for outcome assessors. 
b. High risk for outcome assessors. 
c. Unclear risk for outcome assessors. 
5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, 
protocol deviations). Were incomplete outcome data adequately addressed? 
For each included study and for each outcome, we described the completeness of data including 
attrition and exclusions from the analysis. We noted whether attrition and exclusions were reported, 
the numbers included in the analysis at each stage (compared with the total randomized 
participants), reasons for attrition or exclusion where reported, and whether missing data were 
balanced across groups or were related to outcomes. Where sufficient information was reported or 
supplied by the trial authors, we re-included missing data in the analyses. We categorized the 
methods as: 
a. Low risk (< 20% missing data); 
b. High risk (≥ 20% missing data); 
c. Unclear risk. 
6. Selective reporting bias. Are reports of the study free of suggestion of selective outcome 
reporting? 
For each included study, we described how we investigated the possibility of selective outcome 
reporting bias and what we found. We assessed the methods as: 
a. Low risk (where it is clear that all of the study's pre-specified outcomes and all expected 
outcomes of interest to the review have been reported); 
b. High risk (where not all the study's pre-specified outcomes have been reported; one or more 
reported primary outcomes were not pre-specified outcomes of interest and are reported 
incompletely and so cannot be used; study fails to include results of a key outcome that would have 
been expected to have been reported); 
c. Unclear risk. 
7. Other sources of bias. Was the study apparently free of other problems that could put it at a high 
risk of bias? 
For each included study, we described any important concerns we had about other possible sources 
of bias (for example, whether there was a potential source of bias related to the specific study 
design or whether the trial was stopped early due to some data-dependent process). We assessed 
whether each study was free of other problems that could put it at risk of bias as: 
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a. Low risk; 
b. High risk; 
c. Unclear risk 
If needed, we explored the impact of the level of bias through undertaking sensitivity analyses. 
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Search strategy for TcB accuracy review. 
PubMed: 
((transcutaneous n2 bilirubin) OR TcB OR bilicheck OR bilichek OR JM-103 OR JM-105 OR 
bilirubinomet*) AND (((blood* or serum) n1 bilirubin) OR TsB OR spectrophotomet*) AND 
((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth 
weight OR VLBW OR LBW or infan* or neonat*) NOT (animals [mh] NOT humans [mh])) 
CINAHL: 
((transcutaneous N2 bilirubin) OR TcB OR bilicheck OR bilichek OR JM-103 OR JM-105 OR 
bilirubinomet*) AND (((blood* or serum) N bilirubin) OR TsB OR spectrophotomet*) AND 
(infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR 
VLBW OR LBW or Newborn or infan* or neonat*) 
Embase: 
(infant, newborn or neonat* or premature or very low birth weight or low birth weight or VLBW or 
LBW or infan*) AND ((transcutaneous adj2 bilirubin) OR TcB OR bilicheck OR bilichek OR JM-
103 OR JM-105 OR bilirubinomet*) AND (((blood* or serum) adj bilirubin) OR TsB OR 
spectrophotomet*).mp AND (human not animal) 
CRS: 
((transcutaneous NEAR2 bilirubin) OR TcB OR bilicheck OR bilichek OR JM-103 OR JM-105 OR 
bilirubinomet*) AND (((blood* or serum) NEXT bilirubin) OR TsB OR spectrophotomet*) AND 
(infant* or newborn or neonat* or premature or preterm or very low birth weight or low birth 
weight or VLBW or LBW) 
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QUADAS-2 tool 
QUADAS-2 tool: Risk of bias and applicability judgements 
Domain 1: Patient selection 
A. Risk of bias 
 
1. Was a consecutive or random sample 
of patients enrolled? 
Yes/No/Unclear 
"Yes" if it is clearly stated in the paper that a consecutive or a 
random sample of patients was enrolled. 
"No" if the patients were not recruited consecutively or the 
sample was not random. 
"Unclear" if there is insufficient information to answer "yes" or 
"no". 
2. Was a case-control design avoided? Yes/No/Unclear 
The answer will always be "yes" since the review will exclude 
case-control studies. 
3. Did the study avoid inappropriate 
exclusions? 
Yes/No/Unclear 
"Yes" if the stated inclusion and exclusion criteria are clear and 
appropriate. 
"No" if the stated inclusion and exclusion criteria include 
inappropriate subjects. 
"Unclear" if insufficient information is available to answer "yes" 
or "no". 
4. Could the selection of patients have 
introduced bias? 
RISK: Yes/No/Unclear 
"No" if questions 1 and 3 are answered "yes" (Low risk). 
"Yes" if questions 1 or 3 is answered "no" (High risk). 
"Unclear" if insufficient information is available to answer 
questions 1 or 3. 
B. Concerns regarding applicability 
 
Describe included patients (prior testing, presentation, intended use of index test and setting): 
1. Is there concern that the included 
patients do not match the review 
question? 
CONCERN: Yes/No/Unclear 
"No" when the study population represents an unselected sample 
of newborns expected to receive TcB assessment for 
hyperbilirubinaemia (Low). 
"Yes" if included patients are inherently different from those 
expected to receive TcB assessment for hyperbilirubinaemia 
(High). 
"Unclear" if there is insufficient information to make a judgement 
on the patient inclusion (Unclear). 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
A. Risk of bias 
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Describe the index test and how it was conducted and interpreted: 
1.Were the index test results interpreted 
without knowledge of the results of the 
reference standard? 
Yes/No/Unclear 
“Yes” if the paper states that the index test is interpreted by 
individual(s) who were unaware of the results of the reference 
test(s). 
“No” if the results of the index test were known by the 
individuals performing the reference test, or if the same 
individual performed both tests. 
"Unclear" if there is insufficient information to answer "yes" or 
"no". 
2. If a threshold was used, was it pre-
specified? 
Yes/No/Unclear 
"Yes" if a pre-specified positivity threshold was stated. 
"No" if a threshold was not pre-specified. 
"Unclear" if there is insufficient information to answer "yes"or 
"no". 
3. Could the conduct or interpretation of 
the index test have introduced bias? 
RISK: Low/High/Unclear 
“No” if questions 1 and 2 are answered'"yes" (Low risk). 
“Yes” if questions 1 or 2 is answered "no" (High risk). 
“Unclear if there is insufficient information available to answer 
"yes" or "no" (Unclear risk). 
B. Concerns regarding applicability 
 
Is there concern that the index test, its 
conduct, or interpretation differ from the 
review question? 
CONCERN: Low/High/Unclear 
“No” if there are no concerns based on the information available 
(Low). 
“Yes” if the index test is not TcB measurement for 
hyperbilirubinaemia in newborns or if the conduct of the test or 
its interpretation is not applicable to the review question (High). 
"Unclear" if there is insufficient information to answer "yes" or 
"no". 
Domain 3: Reference standard 
A. Risk of bias 
 
Describe the reference standard and how it was conducted and interpreted: 
1 Is the reference standard likely to 
correctly classify the target condition? 
Yes/No/Unclear 
"Yes" if the reference standard is TsB measured by one of the 
laboratory methods mentioned in this protocol. 
"No" if the above condition is not met. 
"Unclear" if there is insufficient information to answer "yes" or 
"no". 
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2 Were the reference standard results 
interpreted without knowledge of the 
results of the index test? 
Yes/No/Unclear 
"Yes" if it is stated that the individual performing/interpreting the 
results of the reference standard was kept unaware of the results 
of the index test. 
"No" if the results of the TcB measurement were known to the 
individual performing/interpreting the reference standard. 
"Unclear" if there is insufficient information to answer "yes" or 
"no". 
Could the reference standard, its 
conduct, or its interpretation have 
introduced bias? 
RISK: Low/High/Unclear 
"No" if questions 1 and 2 are answered "yes" (Low risk). 
"Yes" if question 1 or 2 is answered "no" (High risk). 
"Unclear" if there is insufficient information to answer "yes" or 
"no". 
B. Concerns regarding applicability 
 
Is there concern that the target condition 
as defined by the reference standard 
does not match the review question? 
CONCERN: Low/High/Unclear 
"No" if the target condition is hyperbilirubinaemia in newborns 
(Low). 
"Yes" if the target condition is not hyperbilirubinaemia in 
newborns or it is not clearly stated (High). 
"Unclear" if there is insufficient information available to answer 
"yes"or "no" (Unclear). 
Domain 4: Flow and timing 
A. Risk of bias 
 
Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded 
from the 2x2 table (refer to flow diagram): 
Describe the time interval and any interventions between index test(s) and reference standard: 
1.Was there an appropriate interval 
between index test(s) and reference 
standard? 
Yes/No/Unclear 
"Yes" if the time between the index test and the reference 
standard is less than 30 minutes. 
"No" if the time between the index test and the reference standard 
is longer than 30 minutes for a significant proportion of the 
patients. 
"Unclear" if insufficient information is available to answer "yes" 
or "no". 
2. Did all patients receive a reference 
standard? 
Yes/No/Unclear 
"Yes" if all the patients who received the index test received a 
reference standard. 
"No" if not all the patients who received the index test received a 
reference standard. 
"Unclear" if there is insufficient information to answer "yes" or 
"no". 
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3. Did patients receive the same 
reference standard? 
Yes/No/Unclear 
“Yes” if the same reference standard was used for all patients. 
“No” if different reference standards were used. 
“Unclear” if there is insufficient information to answer "yes" or 
"no". 
4. Were all patients included in the 
analysis? 
Yes/No/Unclear 
“Yes”if all patients were included in the analysis, or if any 
withdrawals or exclusions are adequately explained with a flow 
chart. 
“No” if withdrawals or exclusions are not explained or accounted 
for. “Unclear” there is insufficient information to answer "yes" or 
"no". 
Could the patient flow have introduced 
bias? 
RISK: Low/High/Unclear 
"No" if questions 1, 2, 3 and 4 are answered "yes" (Low risk). 
"Yes" if any of the four questions is answered "no" (High risk). 
"Unclear" if there is insufficient information to answer "yes" or 
"no" (Unclear risk). 
TcB: Transcutaneous bilirubin 
TsB: Total serum bilirubin 
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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate to the effects of transcutaneous screening for hyperbilirubinemia to prevent the readmission of neonates for phototherapy.
B A C K G R O U N D
Description of the condition
Hyperbilirubinemia is a term used to describe elevated levels of
bilirubin in the blood. In newborns, hyperbilirubinemia becomes
clinically apparent as jaundice, a yellow coloration of the skin and
the sclera, at serum bilirubin levels > 5 mg/dL (Porter 2002). Hy-
perbilirubinemia is very common in both term and preterm new-
born infants (occurring in around 60% of newborns) and results
from a predisposition to produce bilirubin and the newborn’s lim-
ited ability to excrete it (Lauer 2011). Jaundice or hyperbiliru-
binemia is the most common cause of hospital readmission in the
neonatal period (Soskolne 1996; Maisels 1998; Escobar 2005).
Most cases of newborn jaundice are mild and self limited. How-
ever, in rare cases, infants can have very high levels of bilirubin that
can lead to bilirubin encephalopathy and kernicterus (Newman
2006). The threshold concentration of bilirubin and/or the dura-
tion of hyperbilirubinemia responsible for causing kernicterus in-
jury in newborn infants is not known (Dennery 2004). Low con-
centrations of bilirubin may have some antioxidant benefits, sug-
gesting that bilirubin should not be completely eliminated. Stud-
ies from developed countries estimate the incidence of kernicterus
to range from about 0.4 to 2 per 100,000 (Sgro 2006; Manning
2007; Burke 2009). However, studies from developing countries
suggest that the incidence may be much higher (Nair 2003; Owa
2009).
The acute phase signs of kernicterus are poor feeding, lethargy,
high-pitched cry, hypertonia or hypotonia, opisthotonos and
seizures. The chronic manifestations include athetoid cerebral
palsy, motor delay, gaze palsy, dental dysplasia, mental retardation
and sensorineural hearing loss (AAP 2004). Current treatments
for hyperbilirubinemia include phototherapy and exchange trans-
fusion (usually reserved for severe cases of hyperbilirubinemia)
(NICE 2010).
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Description of the intervention
Transcutaneous bilirubin (TcB) measurement devices are used for
the rapid and noninvasive measurement of bilirubin levels in the
skin.Transcutaneous bilirubinometryworks by directing light into
the skin of the neonate and measuring the intensity of the spe-
cific wavelength of light returned. The measurement is usually
taken by gently pressing the meter against the sternum. Find-
ings from many studies suggest that the accuracy and precision
of TcB measurements are correlate with standard laboratory to-
tal serum bilirubin (TsB) (Rubaltelli 2001; Engle 2002; Maisels
2004; Slusher 2004; Jangaard 2006). Other studies suggest that
TcB measurements do not correlate with TsB measurements in
preterm newborn (Knupfer 2001; Karoly 2004). TcB screening
involves the measurement of bilirubin in every newborn in whom
clinical jaundice is not present or observed, prior to discharge.
How the intervention might work
The practice of early discharge (< 72 hours of age) of healthy term
newborns is growing worldwide. Because peak serum bilirubin
levels usually occur on postnatal days three to five, an effective
means of screening for the onset of hyperbilirubinemia could en-
hance the safety of the early discharge of newborns.
The clinical evaluation of hyperbilirubinemia involves the visual
assessment of jaundice. However, this method can be affected by
the newborn’s skin color and does not provide a quantification of
the TsB level. Current, more-objective methods of assessing hy-
perbilirubinemia include the use of TsB measurements from blood
sampling and noninvasive methods, such as TcB measurement
with a handheld bilirubinometer. To aid in identifying newborns
with a significant risk of hyperbilirubinemia and its consequences,
TcB and other screening strategies for hyperbilirubinemia prior to
the discharge of newborns have been advocated (Bhutani 1999;
Alpay 2000; Newman 2000; Stevenson 2001). Transcutaneous
screening for hyperbilirubinemia is used to identify newborns with
bilirubin levels greater than the 75th percentile for age in hours
and to track those with rapid rates of bilirubin rise (> 0.2 mg per
100 mL per hour). Bhutani 1999 proposed an on-the-hour-spe-
cific bilirubin nomogram as an approach to predischarge screen-
ing for hyperbilirubinemia. However, Fay 2009 have highlighted
multiple methodologic flaws in the methods used to create the
hour-specific total bilirubin nomogram.
Transcutaneous screening for hyperbilirubinemia, the characteri-
zation of bilirubin levels by risk, with selective follow up of at-risk
infants and timely intervention in infants at risk of hyperbiliru-
binemia, could lead to a reduction in the number of newborns
with severe hyperbilirubinemia and a reduction in the number of
newborns readmitted to the hospital for phototherapy or exchange
transfusion. If hyperbilirubinemia is identified early, effective in-
terventions such as phototherapy can be initiated to reduce the
risk bilirubin encephalopathy. However, TcB screening could also
lead to unnecessary readmissions, prolonged hospitalization, ex-
cess laboratory tests and increased costs.
Why it is important to do this review
The American Academy of Pediatrics (AAP) and the Canadian
Pediatric Society both recommend the use of either predischarge
serumbilirubin orTcBmeasurements as appropriate screening op-
tions for identifying infants at risk of neonatal hyperbilirubinemia
(AAP 2004; CPS 2007). In contrast, however, according to the
US Preventive Services Task Force, “there is insufficient evidence
to make a recommendation on screening infants for hyperbiliru-
binemia to prevent chronic bilirubin encephalopathy” (USPSTF
2009). There is conflicting evidence for, and recommendations
on, the usefulness of predischarge bilirubin screening in newborns.
Without proof of efficacy, universal screening of newborns for hy-
perbilirubinemia can result in the waste of healthcare resources
and the unnecessary testing of many newborns.
We aim to evaluate all the relevant available evidence to assess
the effects of transcutaneous screening for hyperbilirubinemia in
newborn infants before discharge from hospital.
O B J E C T I V E S
To evaluate to the effects of transcutaneous screening for hyper-
bilirubinemia to prevent the readmission of neonates for pho-
totherapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials, quasirandomized
controlled trials, cluster randomized trials and other prospective
study designs (e.g. cohort studies).
Types of participants
• Well newborns, of gestational age 35 weeks or more and
weighing 1800 g or more, being discharged from the newborn
nursery (in the first week of life)
We will not include infants admitted to, or being discharged from,
the neonatal intensive care unit.
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Types of interventions
1. TcB screening (alone or combined with any other method, e.g.
visual assessment) compared to no screening or visual inspection
for hyperbilirubinemia before discharge from hospital
2. TcB screening versus serum bilirubin screening before discharge
from hospital
3. Closer follow up or home nursing visits based on TcB screening
results versus postdischarge follow up or treatment decisions based
on visual inspection
Types of outcome measures
Primary outcomes
• Readmission for phototherapy or home phototherapy for
hyperbilirubinemia
• Exchange transfusion
Secondary outcomes
• Phototherapy before hospital discharge
• Peak bilirubin levels
• Acute bilirubin encephalopathy
• Chronic bilirubin encephalopathy
• Hearing loss
• Length of stay (days)
• Cost of care
Search methods for identification of studies
We will use the standard search strategy of the Cochrane Neona-
tal Review Group to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press and
in progress).
Electronic searches
We will search the following electronic databases: the Cochrane
Central Register of Controlled Trials (CENTRAL, The Cochrane
Library - current),MEDLINE (1950 to current), EMBASE (1980
to current) and CINAHL (1982 to current).We will searchMED-
LINE, EMBASE and CINAHL for relevant articles using the
search terms: [Infant OR Newborn (explode) [MeSH heading]
AND transcutaneous (explode) [MeSH heading] OR screening
AND [hyperbilirubinaemia OR hyperbilirubinemia OR jaundice
(explode) [MeSH heading]]. We will search clinical trial registries
for any ongoing trials (www.clinicaltrials.gov; www.controlled-
trials.com/ and www.who.int/ictrp).
Searching other resources
We will attempt to contact experts and organizations or manufac-
turers of bilirubinometers for information on any relevant study.
We will scan through the reference lists of all relevant studies. We
will search any previous reviews, including cross-references and
abstracts, and conference and symposia proceedings of the Perina-
tal Society of Australia and New Zealand and the Paediatric Aca-
demic Societies (American Pediatric Society, Society for Pediatric
Research and European Society for Paediatric Research).
Data collection and analysis
We will use the standard methods of the Cochrane Neonatal Re-
view Group.
Selection of studies
The first two review authors will independently scan through the
titles and abstracts of the search output to identify potentially el-
igible studies. Discrepancies will be resolved through discussion
or, if required, we will consult the third author. We will obtain
full text articles of all selected abstracts to formally assess eligi-
bility using the prespecied eligibility criteria. We will summarize
the reasons for exclusion of any potentially eligible study in the
‘Characteristics of excluded studies’ table.
Data extraction and management
We will design a data extraction form for the extraction of data.
Two review authors will independently extract data from all in-
cluded studies using the data extraction form. We will resolve dis-
crepancies through discussion or, if required, we will consult the
third review author. We will enter data into the latest version of
Review Manager (RevMan 2011) and check them for accuracy.
We will contact authors of the studies identified via email or tele-
phone to provide more information, if necessary.
Study information that will be extracted will include:
• study details: citation, start and end dates, location and
study design;
• participant details: study population eligibility (inclusion
and exclusion) criteria, gestational age, sex, sample size and
attrition rate;
• details about the interventions: type of transcutaneous
bilirubin meter used and any other method used for screening
for hyperbilirubinemia
• outcome details: readmission rates for phototherapy,
exchange transfusion, acute bilirubin encephalopathy, chronic
bilirubin encephalopathy and adverse effects.
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For each dichotomous outcome, we will extract information on
the number of participants experiencing the event and the num-
ber of participants randomized to each treatment group. For each
continuous outcome wewill extract themeans or geometric means
and standard deviations (or information to estimate the standard
deviations) for each treatment group, together with the numbers
of participants in each group. Medians and ranges will also be ex-
tracted if these are reported in place of means and standard devi-
ations.
Assessment of risk of bias in included studies
The first two review authors will independently assess the risk
of bias in each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreement by discussion or by consulting
the third review author.
(1) Sequence generation (checking for possible selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups. We will
assess the method as:
• adequate (any truly random process, e.g. random number
table; computer random number generator);
• inadequate (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);
• unclear (if we do not find enough information to make a
judgment).
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to
conceal the allocation sequence in sufficient detail and determine
whether intervention allocation could have been foreseen in ad-
vance of or during recruitment, or changed after assignment. We
will assess the methods as:
• adequate (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or
nonopaque envelopes; alternation; date of birth);
• unclear (if we do not find enough information to make a
judgment).
(3) Blinding (checking for possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will judge studies
to be at low risk of bias if they were blinded, or if we judge that the
lack of blinding could not have affected the results. We will assess
blinding separately for different outcomes or classes of outcomes.
We will assess the methods as:
• adequate, inadequate or unclear for participants;
• adequate, inadequate or unclear for personnel;
• adequate, inadequate or unclear for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data, including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported, the numbers included in the analysis
at each stage (compared with the total numbers of randomized
participants), reasons for attrition or exclusion where reported,
and whether missing data were balanced across groups or were
related to outcomes. Where sufficient information is reported, or
can be supplied by the trial authors, we will reinclude missing data
in the analyses that we undertake. We will assess methods as:
• adequate (where fewer than 20% of data are missing);
• inadequate (where more than 20% of the data are missing);
• unclear (if we do not find enough information to make a
judgment).
(5) Selective reporting bias
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• adequate (where it is clear that all of the study’s prespecied
outcomes and all expected outcomes of interest to the review
have been reported);
• inadequate (where not all the study’s prespecied outcomes
have been reported; one or more reported primary outcomes were
not prespecied; outcomes of interest are reported incompletely
and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear (if we do not find enough information to make a
judgment).
(6) Other sources of bias
We will describe for each included study any important concerns
we have about other possible sources of bias.Wewill assess whether
each study was free of other problems that could put it at risk of
bias as: yes, no or unclear.
Measures of treatment effect
We will present results for dichotomous outcomes as summary
risk ratios (RRs) with 95% confidence intervals (CIs) and absolute
risk differences with 95% CIs. Continuous outcomes will be pre-
sented using the mean difference (MD), if outcomes are measured
using the same scale in trials, or using the standardized mean dif-
ference when the outcome is measured using different scales. The
summary effect measures will be presented with 95% CIs. If the
RR is statistically significant, the number needed to treat to for an
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additional beneficial outcome (NNTB) or an additional harmful
outcome (NNTH) will be calculated.
Unit of analysis issues
We will note the unit of analysis at the level of randomization
(individual or group) and analyze the data accordingly. We will in-
clude cluster randomized trials in the analyses along with individ-
ually randomized trials. For cluster randomized trials, we will ad-
just the sample sizes using the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions, Section 16.3.4 or
16.3.6 (Higgins 2011) using an estimate of the intracluster corre-
lation coefficient (ICC) derived from the trial (if possible) or from
another source.
Dealing with missing data
We will attempt to contact authors if there are missing or unclear
data. We will also note levels of attrition in each of the included
studies. For all outcomes we will carry out an intention-to-treat
analysis. For outcomes in which the results have been pooled in
meta-analysis, we will explore the impact of including studies with
significant loss to follow up in the overall assessment of treatment
effect by using sensitivity analyses.
Assessment of heterogeneity
We will assess statistical heterogeneity by visually inspecting the
forest plots to detect overlapping CIs, applying the Chi2 test (P
value < 0.10 considered statistically significant) and also using
the I2 statistic, where an I2 of less than 25% will be considered
as unimportant, 25% to 49% will be considered to suggest low
heterogeneity, 50% to 74%will be considered to suggest moderate
heterogeneity, and 75% or greater will be considered to indicate
high heterogeneity.
Assessment of reporting biases
If we have 10 or more studies, we will explore the likelihood of
reporting bias or publication bias for each outcome using funnel
plots.
Data synthesis
We will analyze the data using ReviewManager 5.2.7. Where pos-
sible, we will adjust for the effect of clustering in cluster random-
ized trials and combine the results with results from individually
randomized studies in meta-analysis. We will use a random-effect
model for any meta-analyses.
Quality of evidence
The quality of evidence across each outcome measure will be as-
sessed using the GRADE approach. GRADE defines the quality
of evidence as the confidence we have in the estimate of effect for
an outcome (Atkins 2004). The quality rating across studies has
four levels: high, moderate, low or very low. Randomized trials are
categorized as high quality, but can be downgraded. Some of the
factors that would impact on the quality of evidence are the risk of
bias in included studies, the presence of unexplained heterogene-
ity or inconsistency, the imprecision of results, indirectness of the
evidence and publication bias (Balshem 2011).
Subgroup analysis and investigation of heterogeneity
We plan to carry out subgroup analyses based on gestation age
(preterm versus term newborns); the presence of jaundice (versus
no jaundice) in newborns; birth weight (<2500g versus > 2500g);
and the presence of any comorbid conditions (e.g. hemolytic dis-
ease or other conditions known to exacerbate jaundice); mode of
delivery (spontaneous vertex delivery or delivery by caesarean sec-
tion).
Sensitivity analysis
Depending on the number of included studies, we plan to con-
duct sensitivity analyses on the robustness of the methods used
regarding allocation concealment and losses to follow up in the
analysis, and we will report the impact of the sensitivity analyses
on the quantitative results from the meta-analysis.
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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
• To determine the diagnostic accuracy of TcB as:
i) a diagnostic test for hyperbilirubinaemia in newborns suspected to have hyperbilirubinaemia on visual inspection;
ii) a diagnostic test for monitoring bilirubin levels in newborns receiving treatment (e.g. phototherapy) for
hyperbilirubinaemia.
1. a diagnostic test for hyperbilirubinaemia in newborns suspected to have hyperbilirubinaemia on visual inspection;
2. a diagnostic test for monitoring bilirubin levels in newborns receiving treatment (e.g. phototherapy) for hyperbilirubinaemia.
• To determine whether the gestational age, postnatal age, body weight, race and site of TcB measurement have any influence on
the accuracy of TcB measurement for hyperbilirubinaemia in newborns.
1Transcutaneous bilirubinometry versus total serum bilirubin measurement for newborns (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stellenbosch University  https://scholar.sun.ac.za
B A C K G R O U N D
Target condition being diagnosed
Hyperbilirubinaemia is a term used to describe excess of bilirubin
in the blood. In newborns, hyperbilirubinaemia becomes clini-
cally apparent as jaundice, a yellow colouration of the skin and
sclera (Woodgate 2015). Hyperbilirubinaemia is very common
in both term and preterm newborn infants (occurring in about
60% of newborns) and results from a predisposition to the pro-
duction of bilirubin and their limited ability to excrete it (Lauer
2011). Most cases of newborn jaundice are mild and resolve spon-
taneously (Srgo 2006). However, in rare cases babies can have very
high levels of bilirubin that can lead to bilirubin encephalopathy
and kernicterus (Ebbesen 2005; Srgo 2006). The acute phase signs
of kernicterus are poor feeding, lethargy, high-pitched cry, hyper-
tonia or hypotonia, opisthotonos and seizures (Johnson 2002).
The chronic manifestations include athetoid cerebral palsy, mo-
tor delay, gaze palsy, dental dysplasia, mental retardation and sen-
sorineural hearing loss (AAP 2004). Studies from developed coun-
tries estimate the incidence of kernicterus to range from about
0.4 to 2 per 100,000 (Srgo 2006; Mannig 2007; Burke 2009).
However, studies from developing countries suggest that the in-
cidence may be much higher (Nair 2003; Owa 2009). Following
guidelines issued by the American Academy of Pediatrics for the
management of jaundice in the neonate (AAP 2004), the age-long
critical cut-off value of total serum bilirubin (TsB) of 20 mg/dL
(342 µmol/L) at which therapy was required is being replaced by
a plot of TsB against time (hours) for each baby. This is compared
to the nomogram for the age of the baby and used to determine
the line of management (Higgins 2012). Current treatments for
hyperbilirubinaemia include phototherapy and exchange transfu-
sion, which is usually used for severe cases of hyperbilirubinaemia
(Woodgate 2015).
Index test(s)
Transcutaneous bilirubin (TcB) measurement is a non-invasive
method for measuring serum bilirubin level (Dai 1997). Tran-
scutaneous bilirubinometry works by directing light into the skin
and measuring the intensity of the wavelength of light that is re-
turned (Boo 2007). Transcutaneous bilirubinometry is based on
optical spectroscopy, which relates the amount of light absorption
by bilirubin to the concentration of bilirubin in the skin. The
technology was first introduced in 1980 (Yamanouchi 1980). The
measurement is usually taken by gently pressing the meter against
the sternum or forehead. Transcutaneous bilirubin measurement
provides an immediate (less than a minute) result of bilirubin lev-
els (Dai 1997). Using this point-of-care device saves time com-
pared to measuring serum bilirubin and may reduce costs associ-
ated with measuring serum bilirubin in newborns (Maisels 1997).
However, the accuracy of TcB results may be affected by gesta-
tional age, body weight and skin colour (Knüpfer 2001; Karen
2009). For example, TcB tends to underestimate TSB in light
and medium skin colours and overestimates in dark skin colour
(Samiee-Zafarghandy 2014). There are a number of TcB devices
available, including the Bilicheck device, JM 103 and JM 105 de-
vices (Grohmann 2006).
Clinical pathway
Newborns are routinely monitored by nursing staff and physi-
cians for the development of jaundice in the first few hours of life
and before discharge from the newborn nursery. This is usually
done by visual inspection and skin blanching to assess for yel-
lowish discolouration. Visual estimation of bilirubin level is not
reliable (Barrington 2012). Therefore, bilirubin level needs to be
assessed objectively by means of a TcB or TsB measurement. In
some settings, TcB or TsB measurements are performed on all
newborns as part of routine screening before hospital discharge or
as targeted screening based on risk factors for severe hyperbiliru-
binaemia. Some of the risk factors include breastfeeding, ABO/
Rhesus incompatibility, glucose-6-phosphate dehydrogenase defi-
ciency, use of oxytocin during delivery, vacuum-assisted delivery,
prematurity, and history of jaundice in a sibling (AAP2004; Keren
2005; Bhutani 2010). TcB or TsB measurement can be done as
part of universal screening or only if a newborn is visibly jaun-
diced and the value is plotted on a nomogram to assess the need
for treatment (AAP 2004). In addition, the measurements may be
taken on newborns undergoing phototherapy to help in making
a decision on when to stop treatment. The bilirubin levels are in-
terpreted based on the infant’s gestational age and postnatal age
(AAP 2004).
Role of index test(s)
The TcB assay is a non-invasive method for measuring bilirubin
levels and it may help to reduce the risk of anaemia and trauma
associated with blood sampling for TsB measurement (Dai 1997).
TcB has been shown to work well in both hospital and outpa-
tient settings; and has been shown to be better than visual inspec-
tion for estimation of hyperbilirubinemia (De Luca 2008; Wainer
2012). Additionally, the TcB measurement ensures a readily avail-
able result for immediate clinical decision-making while reducing
the chances of infections associated with all invasive procedures
(Jangaard 2006). The TcB meter can be used as a screening tool
to estimate the serum bilirubin level in newborns who are not
clinically jaundiced or as a diagnostic tool in jaundiced newborns
to assess the need for treatment (AAP 2004).
Alternative test(s)
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Various methods are used to determine bilirubin levels in new-
borns. These include visual assessment, direct spectrophotomet-
ric methods (requiring capillary blood) and use of an icterome-
ter (Higgins 2012). Visual assessments for jaundice are common
in newborn nurseries and outpatient settings, such as physicians’
offices (Harrison 1989). However, studies have shown that the
severity of jaundice cannot be assessed through visual estimation.
The icterometer is a specialized ruler marked with different shades
of yellow used to estimate the bilirubin level when pressed against
a newborn’s skin (Akman 2000).
Rationale
Bilirubin measurement is one of the most frequently performed
tests in newborn infants (Donzelli 2000; Madsen 2000). Chemi-
cal methods for serum bilirubin measurement is currently the ref-
erence standard for measuring bilirubin levels. However, this re-
quires repeated blood sampling which can be painful to the new-
born, costly and time consuming. Transcutaneous bilirubin mea-
surement has been recommended as a more cost-effective and less
traumatic method of measuring bilirubin levels in newborns (Dai
1996). In order to justify routine use of TcB devices, we need to
systematically review all the available evidence from well-designed
studies on the accuracy of TcB measurements in newborn infants.
A clear understanding of the diagnostic test accuracy of transcu-
taneous bilirubinometry using a variety of instruments in a vari-
ety of populations (including preterm and term infants as well as
infants with various racial backgrounds) would be invaluable for
understanding the usefulness of TcB measurement in newborns.
O B J E C T I V E S
• To determine the diagnostic accuracy of TcB as:
i) a diagnostic test for hyperbilirubinaemia in newborns
suspected to have hyperbilirubinaemia on visual inspection;
ii) a diagnostic test for monitoring bilirubin levels in
newborns receiving treatment (e.g. phototherapy) for
hyperbilirubinaemia.
• To determine whether the gestational age, postnatal age,
body weight, race and site of TcB measurement have any
influence on the accuracy of TcB measurement for
hyperbilirubinaemia in newborns.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include diagnostic test accuracy studies comparing TcB
and TsB measurement for hyperbilirubinaemia in newborns, as
follows.
• Cross-sectional studies.
• Cohort studies.
Wewill exclude all randomised controlled trials, retrospective stud-
ies, case-control studies, case reports and any studies in which data
for true positives, true negatives, false positives and false negatives
cannot be determined. Retrospective studies will also be excluded.
Participants
We will include studies evaluating infants aged 0 to 29 days (in-
cluding term or preterm newborns) who require bilirubin mea-
surement either as a universal screening test or a test for visible
jaundice or for monitoring therapy for hyperbilirubinaemia. We
will include studies conducted in different patient settings such as
neonatal intensive care units, paediatric emergency units, paedi-
atric wards and studies that recruited participants from home or
in the communities.
Index tests
We will include studies that assessed the accuracy of any TcB
device in newborns.
Target conditions
The target condition is hyperbilirubinaemia requiring treatment
either by phototherapy or by exchange transfusion.
Reference standards
The reference standard is TsB measured in the laboratory, which
requires blood sampling from the newborn. TsB measurement can
be performed in the laboratory using various methods such as high
performance liquid chromatography (HPLC), Diazo-based meth-
ods, or other methods such as direct spectrophotometric methods
(Kazmierczak 2002) and capillary electrophoresis (Higgins 2012).
Total serum bilirubin measurement by the HPLC method is not
subject to interference from haemoglobin or lipaemia. However,
this method is costly, labour-intensive and not practical for rou-
tine use (Kazmierczak 2004). The Diazo-based methods are the
most frequently used laboratory assays but may be affected by
haemolysis (el-Beshbishi 2009). Total serum bilirubin measure-
ment requires drawing of blood causing pain and trauma to the
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neonate. Repeated blood sampling for TsBmeasurement can cause
anaemia, especially in preterm neonates. Inter- and intralabora-
tory variability has been reported with measurements of TsB (Lo
2011).
Search methods for identification of studies
We will use the standard search strategy of the Cochrane Neonatal
ReviewGroup to identify all relevant studies without any language
restriction. Methodological filters for diagnostic studies will not
be used, to avoid missing out on some relevant studies. We will
attempt to get translation for articles written in languages other
than English. We will record any article for which we could not
get a translation in the section ’Characteristics of studies awaiting
classification’.
Electronic searches
We will search the following databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library.
• MEDLINE Ovid (from 1966).
• Embase Ovid SP (from 1982).
• CINAHL (via EBSCOhost) (from 1982).
We will also search the following trial registries.
• ClinicalTrials.gov
• International Standard Randomised Controlled Trial
Number (ISRCTN) registry (www.isrctn.com/)
• World Health Organization (WHO) International Clinical
Trials Platform (ICTRP) Search portal (apps.who.int/
trialsearch/).
There will be no date restrictions in the search of trial registries.
Our search strategy for Embase was developed by discussion be-
tween the author team and the Cochrane Neonatal Group’s Tri-
als Search Co-ordinator (Appendix 1). We will adapt it for use in
other databases.
We will also conduct searches based on the Embase strategy to
identify other potential studies in:
• DARE (Database of Abstracts of Reviews of Effects);
• MEDION database (for Systematic Reviews of Diagnostic
Studies).
We will screen the reference lists of any relevant reviews from
DARE and MEDION for potentially eligible studies.
Searching other resources
We will examine the references lists of all included studies for
possible additional studies.
Data collection and analysis
Selection of studies
Two review authors will independently assess eligible articles for
inclusion from the titles and abstracts obtained in the initial search.
They will resolve any disagreement through discussion or, if nec-
essary, by involving a third review author.
Data extraction and management
Two review authors will independently extract data on study char-
acteristics using a standard data extraction form.We will compute
2 × 2 tables of true positives, false positives, true negatives and false
negatives, for the index tests at the thresholds reported. Where
reported, we will exclude undetermined or indefinite results from
the analyses. We will discuss differently extracted data until con-
sensus is reached. The information we will extract from each study
is presented in Table 1.
Assessment of methodological quality
Two of the authors will independently assess the methodological
quality of each included study using theQuality Assessment of Di-
agnostic Accuracy Studies-2 (QUADAS-2) tool (Whiting 2011),
which consists of four domains. We will develop a rating guideline
for assessment of the domains in order to ensure consistency. We
will assess each of the four domains with respect to the risk of
bias. Additionally, we will assess the first three domains in terms
of applicability.We will pilot our review-specific QUADAS-2 tool
against five primary studies in order to identify possible areas of
discrepancies between authors. We will make modifications to the
tool if possible, to ensure consistency.Wewill resolve discrepancies
in assessments between review authors by consensus. If this is im-
possible, wewill seek final resolution using a third-party arbitrator.
The items of the QUADAS-2 tool and our scoring interpretations
for each item are presented in Appendix 2.
Statistical analysis and data synthesis
We will perform statistical analysis according to Cochrane guide-
lines for diagnostic test accuracy (DTA) reviews (Macaskill 2010).
We will include studies reporting sufficient data that allows for
the construction of a 2 × 2 table and also studies that only re-
ported the Pearson correlation coefficients to describe the relation-
ship between TcB and TsB measurements. The data from the 2
× 2 tables will be used to calculate sensitivity and specificity for
each study and also meta-analysis of sensitivities and specificities
where appropriate using the bivariate model if the same thresh-
old for positivity was used. According to the bivariate method
we will calculate overall sensitivity and specificity and their 95%
confidence intervals (CIs), based on the binomial distributions of
the true positives and true negatives (Reitsma 2005). However,
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we anticipate that studies will use multiple thresholds, both be-
tween studies and within individual studies. If data with more
than one positive threshold is reported within a study, we will ex-
tract the relevant data and present the findings graphically for each
threshold. We will perform meta-analysis with the most common
threshold where appropriate; and fit a summary receiver operat-
ing characteristic (ROC) curve using a bivariate random-effects
model (Reitsma 2005). We will use the latest version of the Re-
view Manager (RevMan) software to graphically present coupled
forest plots, showing the pairs of sensitivity and specificity (and
their 95% CIs) of each study, for each threshold. We will also
present coupled forest plots of the Pearson correlation coefficients
across studies where relevant, to allow basic visual inspection of
individual studies only. All indefinite results will be excluded from
the analysis.
Investigations of heterogeneity
The investigation of heterogeneity will be performed through vi-
sual examination of both the ROC plot of raw data and the forest
plots of sensitivities and specificities. We will formally investigate
potential sources of heterogeneity other than threshold effect in
bivariate models if we have a sufficient number of studies. By fit-
ting the covariates in a bivariate regression model, we will investi-
gate the following sources of heterogeneity in the diagnostic per-
formance across studies: type of TcB meter; gestational age (term
versus preterm infants); race or skin colour; prior use of photother-
apy; and reference standard. We will investigate the effect of these
covariates by conducting subgroup analyses in the latest version of
the RevMan software and by including each of these factors as co-
variates in the bivariate regression model. A minimum of 10 stud-
ies will be needed per covariate included in the regression model.
Sensitivity analyses
We will perform sensitivity analyses on the different domains
scored on the QUADAS-2 tool, in order to explore the influence
of the quality of the included studies. We will perform additional
sensitivity analyses if other suitable factors are identified during
the review process and any such analysis will be reported as ’post
hoc’ in the final review.
Assessment of reporting bias
We are not planning to use funnel plots to evaluate the impact of
publication bias or other biases associated with small studies.
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A D D I T I O N A L T A B L E S
Table 1. Data from each study
[Study ID] First author, year of publication
Type of study Journal article, unpublished data
Participants Sample size
Country of study
Baseline characteristics (gestational age, postnatal age, race, body weight)
Study design Retrospective/prospective design
Sample (consecutive, random or unclear)
Study criteria Inclusion criteria
Exclusion criteria
Reference standard Name of assay/manufacturer
Name of instrument
Cut-off values
Time between reference standard performance and TcB measurement
Blinding of operator to TcB result
Index test Name of device
Cut-off values
Operator training
site of measurement (forehead, sternum)
Target condition Universal screening of newborns for hyperbilirubinaemia
Diagnostic determination of hyperbilirubinaemia in visibly jaundiced newborns
Monitoring of bilirubin in newborns on therapy for hyperbilirubinaemia
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Table 1. Data from each study (Continued)
Data Number of true positives and false positives
Number of true negatives and false negatives
Number of undetermined/uninterpretable results
Sensitivity and specificity of index test
Number of missing results for index test
Number of missing results for reference standard
Notes Source of funding (whether any author is affiliated with the manufacturer of the index test; the study was
directly funded by the manufacturer; authors reported conflicts of interests related to the manufacturer or other
funding sources)
A P P E N D I C E S
Appendix 1. Embase search strategy
Our search strategy for Embase OVID below was developed by discussion between the author team and the Cochrane Neonatal Group’s
Trials Search Co-ordinator. We will adapt it for use in other databases.
(infant, newborn or neonat* or premature or very low birth weight or low birth weight or VLBW or LBW or infan*) AND ((transcu-
taneous adj2 bilirubin) OR TcB OR bilicheck OR bilichek OR JM-103 OR JM-105 OR bilirubinomet* AND ((blood* or serum) adj
bilirubin) OR TsB OR spectrophotomet*).mp
Appendix 2. QUADAS-2 tool
QUADAS-2 tool: Risk of bias and applicability judgements
Domain 1: Patient selection Domain 1: Patient
A. Risk of bias
1.Was a consecutive or random sample of patients enrolled? Yes/No/Unclear
“Yes” if it is clearly stated in the paper that a consecutive or a
random sample of patients was enrolled
“No” if the patients were not recruited consecutively or the sample
was not random
“Unclear” if there is insufficient information to answer “yes” or
“no”
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(Continued)
2.Was a case-control design avoided? Yes/No/Unclear
The answer will always be “yes” since the review will exclude case-
control studies
3. Did the study avoid inappropriate exclusions? Yes/No/Unclear
“Yes” if the stated inclusion and exclusion criteria are clear and
appropriate
“No” if the stated inclusion and exclusion criteria include inap-
propriate subjects
“Unclear” if insufficient information is available to answer “yes”
or “no”
4.Could the selection of patients have introduced bias? RISK: Yes/No/Unclear
“No” if questions 1 and 3 are answered “yes” (Low risk).
“Yes” if questions 1 or 3 is answered “no” (High risk).
“Unclear” if insufficient information is available to answer ques-
tions 1 or 3
B. Concerns regarding applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Describe included
use of index test
1. Is there concern that the included patients do not match
the review question?
CONCERN: Yes/No/Unclear
“No” when the study population represents an unselected sample
of newborns expected to receive TcB assessment for hyperbiliru-
binaemia (Low)
“Yes” if included patients are inherently different from those ex-
pected to receive TcB assessment for hyperbilirubinaemia (High)
“Unclear” if there is insufficient information tomake a judgement
on the patient inclusion (Unclear)
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) Domain 2: Index
please complete for
A. Risk of bias
Describe the index test and how it was conducted and interpreted: Describe the index
preted:
1.· Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes/No/Unclear
“Yes” if the paper states that the index test is interpreted by indi-
vidual(s) who were unaware of the results of the reference test(s)
“No” if the results of the index test were known by the individuals
performing the reference test, or if the same individual performed
both tests
“Unclear” if there is insufficient information to answer “yes” or
“no”
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(Continued)
2. If a threshold was used, was it pre-specified? Yes/No/Unclear
“Yes” if a pre-specified positivity threshold was stated.
“No” if a threshold was not pre-specified.
“Unclear” if there is insufficient information to answer “yes”or
“no”
3.Could the conduct or interpretation of the index test have
introduced bias?
RISK: Low/High/Unclear
“No” if questions 1 and 2 are answered’“yes” (Low risk).
“Yes” if questions 1 or 2 is answered “no” (High risk).
“Unclear if there is insufficient information available to answer
“yes” or “no” (Unclear risk)
B. Concerns regarding applicability
Is there concern that the index test, its conduct, or interpre-
tation differ from the review question?
CONCERN: Low/High/Unclear
“No” if there are no concerns based on the information available
(Low)
“Yes” if the index test is not TcB measurement for hyperbilirubi-
naemia in newborns or if the conduct of the test or its interpreta-
tion is not applicable to the review question (High)
“Unclear” if there is insufficient information to answer “yes” or
“no”
Domain 3: Reference standard Domain 3: Refer
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: Describe the refer
interpreted:
1 Is the reference standard likely to correctly classify the target
condition?
Yes/No/Unclear
“Yes” if the reference standard is TsB measured by one of the
laboratory methods mentioned in this protocol
“No” if the above condition is not met.
“Unclear” if there is insufficient information to answer “yes” or
“no”
2 Were the reference standard results interpreted without
knowledge of the results of the index test?
Yes/No/Unclear
“Yes” if it is stated that the individual performing/interpreting the
results of the reference standard was kept unaware of the results
of the index test
“No” if the results of the TcB measurement were known to the
individual performing/interpreting the reference standard
“Unclear” if there is insufficient information to answer “yes” or
“no”
Could the reference standard, its conduct, or its interpretation
have introduced bias?
RISK: Low/High/Unclear
“No” if questions 1 and 2 are answered “yes” (Low risk).
“Yes” if question 1 or 2 is answered “no” (High risk).
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(Continued)
“Unclear” if there is insufficient information to answer “yes” or
“no”
B. Concerns regarding applicability
Is there concern that the target condition as defined by the
reference standard does not match the review question?
CONCERN: Low/High/Unclear
“No” if the target condition is hyperbilirubinaemia in newborns
(Low)
“Yes” if the target condition is not hyperbilirubinaemia in new-
borns or it is not clearly stated (High)
“Unclear” if there is insufficient information available to answer
“yes”or “no” (Unclear)
Domain 4: Flow and timing Domain 4: Flow
A. Risk of bias
Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table
(refer to flow diagram):
Describe the time interval and any interventions between index test(s) and reference standard:
Describe any patients
or reference standar
(refer to flow diagram):
Describe the time
test(s) and reference
1.·Was there an appropriate interval between index test(s) and
reference standard?
Yes/No/Unclear
“Yes” if the time between the index test and the reference standard
is less than 30 minutes
“No” if the time between the index test and the reference stan-
dard is longer than 30 minutes for a significant proportion of the
patients
“Unclear” if insufficient information is available to answer “yes”
or “no”
·2. Did all patients receive a reference standard? Yes/No/Unclear
“Yes” if all the patients who received the index test received a
reference standard
“No” if not all the patients who received the index test received a
reference standard
“Unclear” if there is insufficient information to answer “yes” or
“no”
·3. Did patients receive the same reference standard? Yes/No/Unclear
“Yes” if the same reference standard was used for all patients
“No” if different reference standards were used.
“Unclear” if there is insufficient information to answer “yes” or
“no”
4.· Were all patients included in the analysis? Yes/No/Unclear
“Yes”if all patients were included in the analysis,or if any with-
drawals or exclusions are adequately explained with a flow chart
“No” if withdrawals or exclusions are not explained or accounted
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(Continued)
for. “Unclear” there is insufficient information to answer “yes” or
“no”
Could the patient flow have introduced bias? RISK: Low/High/Unclear
“No” if questions 1, 2, 3 and 4 are answered “yes” (Low risk)
“Yes” if any of the four questions is answered “no” (High risk)
“Unclear” if there is insufficient information to answer “yes” or
“no” (Unclear risk)
TcB: Transcutaneous bilirubin
TsB: Total serum bilirubin
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